2-pyridone based quinazoline compounds as dual EZH2 and EGFR inhibitors

2-Pyridone-based quinazoline compounds provide a dual-target approach to inhibit EZH2 and EGFR, addressing TNBC chemoresistance and metastasis by enhancing cancer cell inhibition while sparing normal cells, thus offering a safer and more effective treatment.

WO2026234695A1PCT designated stage Publication Date: 2026-11-12COUNCIL OF SCI & IND RES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IN2026/050763
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2026-05-04
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for triple-negative breast cancer (TNBC) face challenges due to chemoresistance, high metastasis risk, and drug resistance, with single-target inhibitors showing limited efficacy and dual-target therapies risking drug-drug interactions and toxicities.

Method used

Development of 2-Pyridone-based quinazoline compounds that act as dual inhibitors of EZH2 and EGFR, designed to selectively target both oncogenic sites while minimizing cytotoxicity in non-cancerous cells, synthesized through specific chemical processes.

Benefits of technology

The compounds demonstrate potent anticancer activity against TNBC cells with reduced toxicity to normal cells, inhibiting both EZH2 and EGFR effectively, offering a potential therapeutic strategy with improved efficacy and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000003_0001
    Figure IMGF000003_0001
  • Figure IMGF000004_0001
    Figure IMGF000004_0001
  • Figure IMGF000004_0002
    Figure IMGF000004_0002
Patent Text Reader

Abstract

The present invention relates to a 2-Pyridone-based quinazoline compound that functions as a dual EZH2 and EGFR inhibitor, offering potential therapeutic applications in cancer treatment. It further provides a process for synthesizing these compounds. The developed compounds demonstrate superior cytotoxic activity against TNBC cells compared to individual comparator drugs, namely Tazemetostat (EZH2 inhibitor) and Gefitinib (EGFR inhibitor). Among them, S-023-0996 (41a) exhibited significant efficacy in in vitro assays. Pharmacokinetic studies revealed that S-023-0996 (41a) is a dual inhibitor with 19.81% bioavailability. Moreover, subcutaneous administration of S-023-0996 (41a) at 100 mg / kg every other day led to a notable reduction in primary tumor burden, achieving 60% tumor growth inhibition, while ex vivo imaging confirmed its effectiveness in suppressing TNBC metastasis.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PT / 2026 / 12022

[0002] 2-PYRIDONE BASED QUINAZOLINE COMPOUNDS AS DUAL EZH2

[0003] AND EGFR INHIBITORS

[0004] FIELD OF THE INVENTION

[0005] The invention relates to a dual-target EZH2 (Enhancer of zeste homolog 2) and EGFR (Epidermal growth factor receptor) inhibitor in the field of cancer. The invention particularly relates to a 2-Pyridone -based quinazoline derivative as dual-targeted EZH2 and EGFR inhibitor and their use in the treatment of cancer.

[0006] BACKGROUND OF THE INVENTION

[0007] According to global cancer statistics, cancer is the second leading cause of death, with an estimated 19.3 million new cancer cases, and 10.0 million deaths in 2020 (CA Cancer J Clin. 2021, 77, 209-249). In cancer, due to genetic changes in DNA, abnormal cells divide uncontrollably, they go beyond their usual boundaries become invaded spread to other organs through metastasis leading to a major cause of death from cancer. (Cancer Res. 2022, 82, 3659-3661). Among four types of cancer (Carcinomas, sarcomas, leukemia, lymphomas), breast cancer comes under solid tumors (Carcinomas), because of heterogeneity, breast cancer has chemoresistance (Front Oncol. 2021, 11, 745052). Every year almost 2,00,000 breast cases, 70% of breast cancers are ER- / PR-positive, subsequently about 20-25 % are HER2 -positive. Aggressive Triple-negative breast cancer (TNBC), and more challenging breast cancers account for 10 to 20 %, in which both estrogen and progesterone receptors are negative. Subsequently, poor prognosis, resistance to chemotherapy because of genetic and transcriptomic evolution, faster growth rate, and higher risk of metastasis and recurrence risk are the problems with TNBC (a. Cancer, 2012, 118, 5463-5472; b. Cancer, 2011, 117, 3658-3669). The development of a validated drug for TNBC is one of the significant challenges for medicinal chemists.

[0008] The post-translational modifications (PTMs) of histones have a huge impact on the genetic expression of genes inside the eukaryotic cell. Unless permanent genetic alteration (mutation), because of reversible epigenetic alteration, it can be a fascinating target for the treatment of cancer. As the first discovered PTM, Lysine (K) acetylation of histones was well explored in the past few decades, but in addition to that, methylation, ubiquitination, crotonylation of lysine residues, methylation and ADP-ribosylation of arginine residues, and phosphorylation and glycosylation of serine and threonine residues are an interesting target nowadays (Nat. Struct. Mol. Biol. 2012, 19, 1218-1227).PT / 2026 / 12022

[0009] Enhancer of zeste Homologue 2 (EZH2) is a catalytic subunit of the polycomb repressive complex 2 (PRC2) which is an attractive target in the oncogene and therapeutic field. EZH2 -mediated methylation of lysine 27 of histone 3 (H3K27-monomethylation, demethylation, trimethylation) has a unique mechanism which conquers epigenetic gene silencing in cancer. Increased levels of trimethylated H3K27me3 have been associated with Triple Negative Breast Cancer (TNBC), Diffuse large B cell Lymphoma (DLBCL), and Follicular Lymphoma. Chemotherapy resistance is a major clinical challenge in TNBC, targeting hallmark H3K27me3 can be a possible route to overcome chemotherapy resistivity Nat Genet. 2022, 54, 459-468).

[0010] On the other, in the case of TNBC, EGFR was highly overexpressed compared with the human epidermal growth factor receptor 2 (HER-2) -positive in cell lines where phosphorylation is detected. However, the heterogeneity of TNBC cell lines was less sensitive to EGFR inhibition by the treatment of gefitinib. It has failed to show such significant efficacy although it can enhance the response to chemotherapy. Combination therapy can be a better way to resolve it. A combination of Gefitinib, carboplatin and docetaxel were tested for TNBC {Annals of Oncology, 2009, 20, 862-867,). For PI3K-mutated TNBC patients, the combination of EGFR (gefitinib) and mTOR (everolimus) resulted in a potential therapeutic opinion {Scientific Reports, 2020, 10, 6367). To inhibit TNBC cell proliferation and apoptosis, a triple combination of EGFR (gefitinib) + AKT(AT7867) + MEK(PD-0325901) was also a novel potential therapeutic strategy {Cancers 2021, 13, 1205). Another report regarding, the combination of SERMs (raloxifene) and gefitinib in clinical settings to improve the current management of TNBC.

[0011] Highly selective, more effective, and low toxicity single inhibitors can specifically inhibit a target molecule, but after repeated use, they became resistant to the cancer. As cancer is a complex disease, epigenetic modification of the target leads to lower survival of cancer patients. To overcome such treatment failure, combination therapy has been successfully introduced in cancer treatment. Although two or more drugs in a combination can beautifully elevate the drug efficacy, at the same time multiple drugs simultaneously provoke the risk factors that deal with drug-drug interactions and dose -limiting toxicities. At last dual -targeting inhibitors are the last answer where a single drug can bind two targets simultaneously becoming an effective strategy in the treatment of cancer {ACS Omega, 2023, 8, 16532— 16544).

[0012] In this regard, Triple Negative Breast cancer (TNBC), both EZH2 and EGFR signals are highly overexpressed. {Gland Surg, 2021, 10, 2535-2545). The single-target small molecules have several drawbacks like drug resistance and low efficiency. On the other hand, dual -targeting inhibitors simultaneously target two oncogenic targeted sites because of their high therapeutic value. The presentPT / 2026 / 12022

[0013] invention provides dual EZH2-EGFR inhibitors activity. The synthesized compounds are completely new. Herein, dual inhibitor molecules demonstrate lower cytotoxic activity against non-cancerous cells.

[0014] OBJECTIVE OF THE INVENTION

[0015] The main objective of the present invention is to provide chimeric EZH2 and EGFR inhibitor.

[0016] The objective of the invention is to provide 2-Pyridone-based quinazoline derivatives as dual-target EZH2 (Enhancer of zeste homolog 2) and EGFR (Epidermal growth factor receptor) inhibitor for treatment of cancer.

[0017] Another objective of the invention is to provide 2-Pyridone-based quinazoline compound acting as dual target inhibitor molecules that demonstrates lower cytotoxic activity against non-cancerous cells.

[0018] Another objective of the invention is to synthesize these 2-Pyridone-based quinazoline derivatives.

[0019] Yet another objective of the invention is to provide a pharmaceutical composition comprising 2-Pyridone -based quinazoline derivatives showing dual EZH2-EGFR inhibitory activity.

[0020] SUMMARY OF THE INVENTION

[0021] Accordingly, the invention provides 2-Pyridone-based quinazoline compounds as dual-target EZH2(Enhancer of zeste homolog 2) and EGFR (Epidermal growth factor receptor) inhibitor for treatment of cancer. The present invention provides a 2-Pyridone-based quinazoline compound general formula I,

[0022]

[0023] wherein, R is a substituted phenyl, wherein the substituent is selected from the group consisting of Cl, F, Br, -CF3, and alkyne;

[0024] Zis H or OMe;

[0025] A is a substituted or unsubstituted phenyl or biphenyl group; and

[0026] L is a linker of one or more Oxygen containing aliphatic chain with a N containing heterocyclic group, comprising an ester or unsaturated amide or combination thereof.PT / 2026 / 12022

[0027] In a preferred embodiment of the present invention, the N containing heterocyclic group is selected form the group consisting of piperazine, piperidine, pyrrolidine, and azetidine.

[0028] In a preferred embodiment of the present invention, the substituent at the ortho position of phenyl of R is F, substituent at the meta position of phenyl of R is Br, CF3, Cl or alkyne or the substituent at the para position of phenyl of R is Cl or F.

[0029] In a preferred embodiment, the present invention provides a compound F-I,

[0030]

[0031] F I

[0032] wherein, Z is selected from H or OMe;

[0033] L is a linker of one or more Oxygen containing aliphatic chain with a N containing heterocyclic group, comprising an ester or unsaturated amide or combination thereof, wherein the heterocyclic group is selected from the group consisting of piperazine, piperidine, pyrrolidine, and azetidine.

[0034] In a preferred embodiment, the present invention provides a compound F-II,

[0035]

[0036] FII

[0037] L is a linker of one or more Oxygen containing aliphatic chain with a N containing heterocyclic group, comprising an ester or unsaturated amide or combination thereof, wherein the heterocyclic group is selected from the group consisting of piperazine, piperidine, pyrrolidine, and azetidine.

[0038] In a preferred embodiment, the present invention provides a compound F-III,

[0039]

[0040] PT / 2026 / 12022

[0041] wherein, R is a substituted phenyl, wherein the substituent is selected from the group consisting of Cl, F, Br, -CF3, and alkyne;

[0042] A is a substituted or unsubstituted phenyl or biphenyl group.

[0043] In an embodiment of the present invention, the compound is a dual-target EZH2 (Enhancer of zeste homolog 2) and EGFR (Epidermal growth factor receptor) inhibitor for treatment of cancer.

[0044] In an embodiment of the present invention, the compound selectively induce cytotoxicity in cancer cells while sparing non-cancerous cells.

[0045] In an embodiment of the present invention, the compound is selected form the group consisting of: 4'-((4-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-I,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-023-0983, 30a):

[0046] 4'-((4-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-I,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-023-0986, 30b):

[0047] 4'-((4-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-I,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-023-0984, 30c):

[0048] 4'-((4-(((4-((3 -chloro-4-fluorophenyl)amino)-7 -methoxyquinazolin-6-yl)oxy)methyl)piperidin- 1 -yl)methyl)-N-((4,6-dimethyl-2-oxo-I,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-023-0985, 30d):

[0049] 4'-((3 -(((4-((3 -chloro-4-fluorophenyl)amino)-7 -methoxyquinazolin-6-yl)oxy)methyl)piperidin- 1 -yl)methyl)-N-((4,6-dimethyl-2-oxo-I,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-023-0987, 30e):

[0050] 4'-((3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-I,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-024-0560, 30f):

[0051] 4'-((4-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethyl)piperidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-I,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-024-0562, 30g):

[0052] 4'-((4-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)piperidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-I,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-024-0564, 30h):

[0053] 4'-((3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pyrrolidin-l-yl)methyl)-N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-024-0566 30i):PT / 2026 / 12022

[0054] 4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl4-((3'-(((4,6-dimethyl-2-oxo-l,2-dihydropyri din-3 -yl)methyl)carbamoyl)-5'-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4'-methyl-[ 1,1'-biphenyl]-4-yl)methyl)piperazine-l-carboxylate (S-023-0982, 30j):

[0055] 4'-((4-(2-((4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)amino)-2-oxoethylidene)piperidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,r-biphenyl]-3-carboxamide(S-023-0989, 30k):

[0056] {4'-((4-(5-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pentyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,r-biphenyl]-3-carboxamide (S-023-0995, 301):

[0057] 4'-((4-(6-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)hexyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,r-biphenyl]-3-carboxamide(S-023-0990, 30m):

[0058] 4'-((4-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)- 5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[ 1, 1 '-biphenyl] -3 -carboxamide(S-023-0988, 30n):

[0059] 4'-((4-(2-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethoxy)ethyl)piperazin- 1 -yl)methyl)-N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3 -yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide(S-023-0992, 30o):

[0060] 5-((3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide (S-024-0561, 33a):

[0061] 5-((4-(2-((4-((3 -chloro-4-fluorophenyl)amino)-7 -methoxyquinazolin-6-yl)oxy)ethyl)piperidin- 1 -yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methylbenzamide (EG-30, 33b):

[0062] 5-((4-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)piperidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methylbenzamide (S-024-0565, 33c):

[0063] 5-((3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pyrrolidin-l-yl)methyl)-N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methylbenzamide (S-024-0567, 33d):

[0064] 5-((2-(((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)methyl)morpholino)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methylbenzamide (S-024-0563, 33e):PT / 2026 / 12022

[0065] 5-((4-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methylbenzamide (S-023-0991, 33f):

[0066] 5-((4-(2-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethoxy)ethyl)piperazin- 1 -yl)methyl)-N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3 -yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methylbenzamide (S-023-0993, 33g):

[0067] 5-((4-(2-(2-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethoxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methylbenzamide (S-023-0994, 33h):

[0068] N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)- 2-methyl-5-((4-methylpiperazin-l-yl)methyl)benzamide (S-024-0568, 33i):

[0069] N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)- 5-((4-(2-(2-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-2-methylbenzamide(S-023-0996, 41a):

[0070] 5-((4-(2-(2-((4-((3,4-dichlorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l- yl)methyl)-N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide(S-023-0997, 41b):

[0071] 5-((4-(2-(2-((4-((3-chlorophenyl)amino)-7-methoxyqiunazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide(S-023-0998, 41c):

[0072] N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)- 5-((4-(2-(2-((4-((4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-2-methylbenzamide(S-023-0999, 41d):

[0073] 5-((4-(2-(2-((4-((2,4-difluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l- yl)methyl)-N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide(S-023-1000, 41e):

[0074] 5-((4-(2-(2-((4-((3-bromophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide(S-023-l 001, 41 f):

[0075] N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-5-((4-(2-(2-((7-methoxy-4-((3-(trifluoromethyl)phenyl)amino)quinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-2-methylbenzamide(S-023-1002, 41g):

[0076] 5-((4-(2-(2-((4-((3-bromo-4-fluorophenyl)amino)-7-methoxyquinazolin-6- yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)- 3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide(S-023-1003, 41h): andPT / 2026 / 12022

[0077] 5-((4-(2-(2-((4-((3-chloro-2,4-difluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide(S-023-1004, 41i).

[0078] The present invention provides a process for the preparation of the compound of general formula I selected form F-I, F-II and F-III,

[0079]

[0080] comprising the steps of:

[0081] a. Suzuki coupling of intermediate 9 with 4- formyl phenyl boronic acid to prepare compound 11;

[0082]

[0083] b. reacting compound 11 with amine of formula A by reductive amination process to obtain compound F-I compounds in the presence of sodium tri acetoxy borohydride;

[0084]

[0085] alternativelyPT / 2026 / 12022

[0086] c. Suzuki Molarder coupling of compound 9 with Potassium vinyltrifluoroborate in presence of Pd(PPh3)4 to prepare compound 32 and

[0087]

[0088] d. reacting compound 32 with amine B by reductive amination process to obtain the compound F-II in the presence of sodium tri acetoxy borohydride

[0089]

[0090] e. alternatively reacting with compound 32 with amine C in the presence of sodium tri acetoxy borohydride to obtain F-III

[0091]

[0092] The invention also relates to a process for the preparation of 2-Pyridone-based new quinazoline derivatives as dual-targeted EZH2(Enhancer of zeste homolog 2) and EGFR (Epidermal growth factor receptor) inhibitor in the field of cancer.

[0093] Herein, 5-bromo-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methylbenzamide (9) is the main intermediate, which will diverted into another two intermediate compound 11 and 32.

[0094] (i) Compound 9 underwent to Suzuki coupling with 4- formyl phenyl boronic acid in presence of Pd(PPh3)4 at 100°C for 4h to give compound 11. To prepare F-I compounds, the compound 11 reacted with (reductive amination process) previously synthesised amine 15a-j, 19, 25, 29c-e, after 30 min sodium tri acetoxy borohydride added at 0 °C. After completion, quenched with aqueous sodiumPT / 2026 / 12022

[0095] bicarbonate, workup with DCM. Finally, F-I compounds are purified by column chromatography over silica gel with MeOH / DCM (7-9%) as an off-white solid.

[0096] (ii)Another way, Compound 9 underwent to Suzuki Molarder coupling with Potassium vinyltrifluoroborate in presence of Pd(PPh3)4 at 100°c for 5h to give compound 32. To prepare F-II compounds, the compound 32 reacted with (reductive amination process) previously synthesised amine 15f-j / 29c-f, after 30 min sodium tri acetoxy borohydride added at 0 °C. After completion, quenched with aqueous sodium bicarbonate, workup with DCM. Finally, F-II compounds are purified by column chromatography over silica gel with MeOH / DCM (7-9%) as an off-white solid.

[0097] (iii)To prepare F-III compounds, previously synthesized amine {(40a-i) by various -R [various benzene derivatives, ortho (-F), meta (-Br,-CF3,-Cl, alkyne ),para (-C1, -F) substituted]} reacted with compound 32 after 30 min sodium tri acetoxy borohydride added at 0 °C. After completion, quenched with aqueous sodium bicarbonate, workup with DCM. Finally, F-III compounds are purified by column chromatography over silica gel with MeOH / DCM (7-9%) as an off-white solid.

[0098] Quinazoline derivatives F-I to F-III are useful as anti -cancer agents with dual EZH2-EGFR inhibitory activity. The compounds inhibit both the targets with similar or better potency than the two comparator drugs at 10 pM concentration. Dual inhibitor molecules show better cytotoxic activity in cancer cells as compared to the individual comparator drug. On the contrary, dual inhibitor molecules demonstrate lower cytotoxic activity against non-cancerous cells.

[0099] BRIEF DESCRIPTION OF DRAWINGS

[0100] Fig. 1. Both EZH2 and EGFR are over-expressed in TNBC cohort compared to non-TNBC. Box and whisker plot for the relative EZH2 (a) and EGFR (b) mRNA expression between non-TNBC and TNBC tumors according to the TCGA dataset.

[0101] Fig. 2. S-023-0996 impedes TNBC cell migration and invasion more efficiently than the rest two hit molecules in vitro. (A) Representative images of the wound healing assay in HCC-1806 cells indicating inhibition of TNBC cell migration at 2.5 pM concentration of S-023-0996, S-023-1001 and S-023-1003, magnification lOx [Scale bar, 50 pm]; (B) Representative images of the transwell chamber invasion assay in MDA-MB-231 cells demonstrating inhibition of TNBC cell invasion by lead molecule, S-023-0996, at 10 pM concentration, magnification lOx [Scale bar, 50 pm].

[0102] Fig. 3. S-023-0996 binds to both the targets EZH2 and EGFR in vitro. (A) Immunoblot analysis of cellular thermal shift assay (CETSA) of EZH2 and EGFR with S-023-0996 at 10 pM for 2 h; (B & C)PT / 2026 / 12022

[0103] Quantitative results of CETSA for S-023-0996 binding to EZH2 and EGFR, respectively, in panel B & C. Bands from immunoblotting were quantified by densitometry analysis using ImageJ.

[0104] Fig. 4. (A) In vitro stability of compound S-023-0996 in (a) Simulated Intestinal Fluid, (b) TRIS buffer, (c) simulated gastric fluid. (B) In vitro stability of compound S-023-0996 in mice blood plasma. (C) Overlaid pharmacokinetic profile of S-023-0996 post subcutaneous administration at 100 mg / kg (n=3) and intravenous administration at 10 mg / kg dose (n=3) in BALB / c mice.

[0105] Fig. 5. S-023-0996 treatment impairs TNBC growth and metastasis in vivo. (A) In vivo bioluminescence images of 4T-1 tumor-bearing nude mice (n = 3 per group), treated with either vehicle or S-023-0996 (100 mg / kg / every other day). The color scale indicates the bioluminescence intensity (counts / sec) emitted from each group. (B) Representative bioluminescence images of the lungs harvested from control and S-023-0996-treated tumor-bearing mice. (C) Representative picture of tumors excised from the animals after treatment (n = 3 per group). (D) Tumor volume of mice with orthotopic allograft of 4T-1 cells. Each bar represents mean ± SEM. ****p < 0.0001. For panel D, two-way ANOVA Sidak’s multiple comparisons test was applied

[0106] DETAILED DESCRIPTION OF THE INVENTION

[0107] The present invention provides 2-Pyridone-based new quinazoline compounds of formula I and a process for the preparation of the said compounds useful in anticancer activity through inhibition of EZH2 and EGFR.

[0108]

[0109] wherein, R is a substituted benzene, wherein the substituent is selected from the group consisting of Cl, F, Br,-CF3, and alkyne;

[0110] Zis selected from H or OMe;

[0111] A is a substituted oor unsubstituted phenyl or biphenyl; and

[0112] L is a linker of aliphatic chain with a N containing heterocyclic group.

[0113] The present invention depicts 2-Pyridone-based new quinazoline compounds and a process for the preparation of the said compounds of F-I to F-III useful in anticancer activity wherein Z designated H, -OMe and L designated as linkers contain piperazine, piperidine and cyclic skeleton with various linearPT / 2026 / 12022

[0114] chain moieties. In case of F-I, Li linker part was varied ranging from piperazine, piperidine and cyclic skeleton with various linear chain moieties. In F-II, the phenylic B ring was removed and L2 linear linkers were varied from piperazine skeleton with poly ethylene glycol linker. In the final modification F-III, -R indicates various benzene derivatives, ortho (-F), meta (-Br,-CF3,-Cl, alkyne ). pa a (-C1, -F) substituted.

[0115] The compounds of general formula (F-I to F-III) are new chemical entities and they have not been prepared earlier.

[0116] The compounds synthesized were tested for anticancer activities. A number of these compounds showed inhibition of EZH2 and EGFR inhibitor. The compounds of F-I to F-III were synthesized from various synthetic intermediates.

[0117] Experimental Procedures:

[0118] General Experimental

[0119] All the starting materials were obtained from commercial sources and used as such. NMR spectrum were recorded on 300, 400 or 500 MHz spectrometer for1H NMR, 100 or 125 MHz for13C NMR, 376 MHz19F NMR spectroscopy. Chemical shifts are reported relative to the residual signals of either tetramethylsilane in CDCE or deuterated DMSO for ’H and13C NMR spectroscopy. Multiplicities are reported as follows: singlet (s), broad singlet (bs), doublet (d), doublet of doublets (dd), doublet of triplets (dt), triplet (t), quartet (q), multiplet (m). HRMS were recorded by using Q-TOF mass spectrometer. Column chromatography was performed with silica gel (100-200 mesh) as the stationary phase. All reactions were monitored by using TLC. The purity and characterization of compounds were further established by using HRMS. HRMS were recorded by using Q-Tof mass spectrometer.

[0120]

[0121] Scheme la. Synthesis of compound 11 as intermediate for preparation of general formula.PT / 2026 / 12022

[0122] Procedures for Scheme la.

[0123] Preparation of 3-(aminomethyl)-4,6-dimethylpyridin-2(lH)-one (3): A mixture of 1,3 -diketone (la, 1 mmol), cyanoacetamide (lb, 1 mmol), and DABCO in ethanol (5 mL) was refluxed in a single neck round bottom flask under N2 condition at 80°C for 1 — 1.5 h. The completion of the reaction was monitored by TLC. After that, the reaction mixture was cooled down to room temperature, and the precipitate was filtered off and recrystallized from ethanol to give the pure product 2 (90% yield).

[0124] 3-Cyano-2,4-dimethyl-2- hydroxypyridine 2 (0.3 g, 2.0 mmol) was dissolved in MeOH (5 mL). The catalytic amount of Raney Ni and aqueous NH3 (0.3 mL) was added to the stirred reaction mixture under hydrogen pressure (bladder pressure) for 3-4 h at room temperature. After completion of the reaction, the catalyst was filtered off and the filtrate was concentrated under reduced pressure. The residue was thoroughly dried to provide the desired product 3 (0.3 g), quantitative yield.

[0125] Preparation of methyl 5-bromo-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzoate (7): Tetrahydro-4H-pyran-4-one 5 (2.46 mL, 26.67 mmol) and AcOH (6.10 mL, 106.68 mmol) were added to a stirred solution of 4 (4.34 g, 17.78 mmol) in 1,2-dichloroethane (50 mL). The reaction mixture was stirred at r.t. for 0.5 h under N2 aatmosphere, after that Na(AcO)3BH ( 11.31 g, 53.34 mmol) was added at 0 °C into the reaction mixture. The reaction mixture was warmed to room temperature and allow the mixture to stir for 24 h. After the completion of the reaction, DCE was evaporated under reduced pressure. NaHCO3 was added and worked up with DCM (3 x 100 ml). The compound 6 was recrystallized with chilled hexane three times to a yellow solid 6. A yellow solid 6 (5.34 g, 91.5% yield). Thereafter acetaldehyde (2.76 mL, 48.81 mmol) and AcOH (5.58 mL, 97.62 mmol) were added to a stirred solution of product 6 (5.34 g, 16.27 mmol) in 1,2-dichloroethane (50 mL). The mixture was stirred at r.t. for 0.5 h under N2 aatmosphere, after that Na(AcO)3BH (10.35 g, 48.81 mmol) was added into the reaction mixture at 0 °C. The reaction mixture was warmed to room temperature and allow the mixture to stir for 24 h. After the completion of the reaction, DCE was evaporated under reduced pressure. NaHCO3 was added and worked up with DCM (3 x 100 ml). This material proceeded to the next step without further purification. ESMS (ESI) [M + H]+found, 356.3 calculated for C16H22BrNO3, 356.1.

[0126] Preparation of 5-bromo-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide (9): To a solution of 7 (300 mg, 0.842 mmol) in MeOH (6 ml) cooled in an ice / water bath was added LiOH aqueous solution (IM, 2 ml) dropwise under ice cold condition, and the reaction was stirred at room temperature for overnight. After the reaction was complete, MeOH was removed under reduced pressure, and the residue was acidified with 3M HC1 to pH 5. The aqueous layer was extracted with EtOAc (3 x 25 mL). The combined organicPT / 2026 / 12022

[0127] phases were dried over Na2SO4, filtered, and concentrated under reduced pressure to afford 8 which further (260 mg, 81%). To a solution of 8 (524 mg, 1equiv.) and 3 (233 mg, 1equiv.) in DMSO (7 mL), were added HOAt (208 mg, 1equiv.), EDCI (293.3 mg, 1equiv.), and NMM (0.4 mL, 1.2 equiv.) at ice-cooled condition. The mixture was stirred at room temperature overnight before EtOAc (150 mL) and water (100 mL) were added. The aqueous NaHCO’, phase was extracted with DCM (2 x 100 mL). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. This material proceeded to the next step without further purification. ESMS (ESI) [M + H]+found, 424.6 calculated for C25H33ClFN3O3, 424.2.

[0128] Preparation of N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4'-formyl-4-methyl-[l,l'-biphenyl]-3-carboxamide (11): Water (2 ml) and Na2CO3 (208.1 mg, 1.9635 mmol) were added to a stirred solution of 5-bromo-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methyl benzoate (7, 200mg, 0.561 mmol), 4- formyl phenylboronic acid (8, 101 mg, 0.6736 mmol) in Dioxane (6 ml) under N2 aatmosphere at room temperature. The reaction mixture was purged for 30 minutes. Thereafter Pd(PPh3)4 (65 mg, 0.0561 mmol)was added and again purged the reaction mixture for another 15 minutes. The reaction mixture was heated at 100°C for 4h under N2 aatmosphere. After completion of the reaction, the reaction mixture was passed through celite bead followed by the aqueous layer was extracted with EtOAc (2 x 150 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography with EtOAc / PE (15-20%) to furnish methyl 5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4'-formyl-4-methyl-[1,1'-biphenyl]-3-carboxylate 11 as a white solid (151 mg, 71% yield). 'H NMR (400MHZ, DMSO-d6): 11.5 (brs, 1H), 10.05 (s, 1H), 8.25 (t, J= 5.04Hz, 1H), 7.98(d, J=8.34 Hz, 2H), 7.89 (d, J= 8.18 Hz, 2H), 7.52 (d, J= 1.73 Hz, 2H),7.34 ( d, J= 1.73 Hz, 1H), 5.87 (s, 1H), 4.30 (d, J=4.91 Hz, 2H), 3.86-3.82 (m, 2H), 3.29-3.23 (m, 2H), 3.28-2.99 (m, 3H), 2.27 (s, 3H), 2.22 (s, 3H), 2.11 (s, 3H), 1.68-1.65 (m, 2H), 1.58-1.48 (m, 2H), 0.84 (t, J= 6.9 Hz, 3H);13C NMR (100 MHz, DMSO-de): 193.2, 169.3, 163.5, 150.1, 149.7, 146.0, 143.3, 140.3, 136.3, 135.5, 134.6, 130.6, 127.7, 123.8, 122.0, 121.7, 107.9, 66.8, 58.3, 41.6, 35.4, 30.8, 19.4, 18.7, 15.2, 13.2; ESMS (ESI) [M + H]+found, 502.8 calculated for C30H35N3O4, 502.3.

[0129]

[0130] Scheme lb. Synthesis of compound 15a-j as intermediate.PT / 2026 / 12022

[0131] Procedures for Scheme lb

[0132] General procedure for the preparation of 13a-b: To a stirred solution of tert-Butyl piperazine-1-carboxylate (1 equiv.) K2CO3 (3 equiv.) in dioxane (5 ml), dibromide alkane (10 equiv.) was added dropwisely and the reaction mixture was heated at 65°C overnight. After the completion, the reaction mixture was cooled to room temperature, water was added to the reaction mixture, The aqueous layer was extracted with EtOAc (3 x 25 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography with EtOAc / hexane (20-25%) to afford 13a-b as a white solid (60% yield).

[0133] tert-butyl 4-(3-bromopropyl)piperazine-l-carboxylate (13a): It was already reported in the previous method.

[0134] tert-butyl 4-(2-bromoethyl)piperazine-1-carboxylate (13b) White solid, Yield 64%,1H NMR (400MHZ, CDCl3): 3.44-3.39 (m, 6H), 2.81-2.77 (m, 2H), 2.46-2.44 (m, 4H), 1.45 (s, 6H);13C NMR (125 MHz, CDCl3): 154.7, 79.7, 59.8, 52.8, 28.6, 28.4.

[0135] Preparation of N-Boc-piperidine-4-p-tosylate (13c): Add tert-butanol (1.41 mL, 15 mmol), piperidin-4-ol (1 g, 30 mmol) and BOC2O (7.93 mL, 34 mmol) to a solution of sodium hydroxide (593 mg, 15 mmol) in water (12 mL). The reaction mixture was stirred at room temperature overnight. After the completion of the reaction, dilute the reaction mixture with 0.2 M HC1. The reaction mixture was extracted with EtOAc (3 x 100 mL) followed by washing the combined organic layers with brine, drying the organic layers overNa2SO4. The organic layer was concentrated under reduced pressure. The crude product was purified by flash chromatography EtOAc / hexane (50%) to obtain tertbutyl 4-hydroxypiperidine-1 -carboxylate 13c' (White solid, 65% yield), ter / butyl 4-hydroxypiperidine-l-carboxylate (13c') 'H NMR (400MHZ, DMSO-d6): 4.68-4.67 (d, J= 4.20 Hz, 1H), 3.68-3.66 (m, 1H), 3.65-3.58 (m, 2H), 3.52-3.41 (m, 1H), 2.97-2.92 (m, 1H), 1.69-1.65 (m, 2H);13C NMR (100 MHz, CDCI3): 154.9, 79.6, 67.5, 34.1, 28.4.

[0136] T’-toluenesulfonyl chloride (1.5 g, 6.0 mmol) was added to a solution of N-Boc-4-hydroxypiperidine 13c' (800 mg, 4.0 mmol) in pyridine (7 mL). The reaction mixture was stirred overnight at room temperature. After the completion, the reaction mixture was poured into EtOAc (50 mL) and subsequently washed with dilute HC1, water, 5% NaOH solution followed by brine solution, dried over anhydrous Na2SO4. The filtrated was concentrated under reduced pressure. The crude product was purified by column chromatography EtOAc / hexane (30%) to get N-Boc-piperidine-4-p-tosylate 13c (White solid, 72% yield). N-Boc-piperidine-4-p-tosylate (13c) 'H NMR (400MHZ, CDCI3): 7.79 (d, J= 8.34 Hz, 2H), 7.34 (d, J= 8.12 Hz, 2H), 4.70-4.65 (m, 1H), 3.62-3.55 (m, 2H), 3.28-3.21 (m, 2H),PT / 2026 / 12022

[0137] 2.45 (s, 3H), 1.80-1.73 (m, 2H), 1.72-1.64 (m, 2H), 1.43 (s, 9H);13C NMR (100 MHz, CDC13): 154.6, 144.7, 134.4, 129.9, 127.6, 79.9, 78.0, 40.4, 31.3, 28.4, 21.6.

[0138] General procedure for preparation of 13d '-e': To a solution of piperidin-methanol (1 equiv) and DCM (20 mL), BOC2O (1.1 equiv) was added drop wisely at 0°C. Thereafter, the reaction mixture was allowed to stir at room temperature for 2.30-3h. The reaction mixture was then diluted with H2O and extracted with DCM (3 x 50 ml). The combined organic phases were dried over anhydrous Na2SO4 and concentrated under reduced pressure. The crude product was purified by column chromatography EtOAc / hexane (40-45%) to get 13d'-e' as white solid (98% yield).

[0139] tert-butyl 4-(hydroxymethyl)piperidine-l-carboxylate (13d') (White solid, 85% yield); 'H NMR (400MHZ, DMSO-d6): 4.45 (t, J= 5.3 Hz, 1H), 3.94 (d, 7=12.63 Hz, 2H), 3.24 (t, J= 5.76 Hz, 2H), 2.66 (brs, 2H), 1.63-1.60 (m, 2H), 1.55-1.46 (m, 1H), 1.39 (s, 9H), 1.02-0.91 (m, 2H); Spectral data by literature.

[0140] tert-butyl 3-(hydroxymethyl)piperidine-l-carboxylate ( 13e') White solid, Yield 80%, 'H NMR (400MHZ, DMSO-d6): 4.50-4.47 (m, 1H), 3.94 (brs, 1H), 3.82-3.77 (m, 1H), 3.30-3.26 (m, 1H), 3.24-3.16 (m, 1H), 2.73-2.67 (m, 1H), 1.68-1.64 (m, 1H), 1.61-1.54 (m, 1H), 1.51-1.43 (m, 1H), 1.39 (s, 9H), 1.34-1.23 (m, 2H), 1.13-1.03(m, 1H);13C NMR (100 MHz, DMSO-d6): 154.4, 79.8, 64.0, 47.7, 44.9, 58.6, 27.3, 24.8.

[0141] Preparation of tert-butyl 4-(bromomethyl)piperidine-l-carboxylate (13d): To a stirred solution of tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate (600 mg, 2.79 mmol) in DCM (20 ml) was added CBr4 (1.02 g, 3.07 mmol) and PPh3 (0.800 g, 3.07 mmol) at 0°C. The reaction mixture was stirred at room temperature overnight. After monitoring by TLC, the crude product was directly packed for column chromatography EtOAc / hexane (4%) to get 13d as liquid (80% yield). 'H NMR (400MHZ, CDCI3); 4.12 (brs, 2H), 3.29 (d, J= 6.04 Hz, 2H), 2.72-2.66 (m, 2H), 1.84-1.80 (m, 2H), 1.78-1.73 (m, 1H), 1.45 (s, 9H), 1.13-1.123 (m, 2H);13C NMR (100 MHz, CDCI3): 154.7, 79.5, 43.5, 38.8, 30.8, 28.4.

[0142] Preparation of tert-butyl 3-((tosyloxy)methyl)piperidine-1-carboxylate (13e): Et3N (0.81 mL, 5.80 mmol) and DMAP (52.0 mg, 0.426 mmol) was added to a solution of (±)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate (1.0 g, 4.65 mmol) in DCM (20 mL) followed by addition of TsCl (0.883 g, 4.65 mmol) at 0°C. The resulting solution was stirred for 16 h at room temperature. The reaction mixture was diluted with saturated aqueous NaOH solution (50 mL) and extract with EtOAc (3x100 mL). Wash the combined organic extracts with H2O (100 mL) and brine (100 mL). Dried over Na2SO4. The resultingPT / 2026 / 12022

[0143] mixture was concentrated under reduced pressure and purified by Column chromatography EtOAc / hexane (30%) to get 13d as liquid (85% yield).

[0144] tert-butyl 4-(3-hydroxypropyl)piperidine-1-carboxylate(13h') A 100 mL Round bottom flask was charged with 1 g of 3-(piperidin-4-yl)propan-1-ol (7.00mmol, 1 equiv), 14 mL of 2 M NaOH solution (28 mmol, 4 equiv) and 33.5 mL of dioxane and then it was cooled to 0°C and was added 1.92 g of BOC2O (7.68 mmol, 1. lequiv). The solution was stirred at room temperature for 12 h. After completion, it was concentrated and acidifed by addition of 2 M HC1 solution till the pH reached 6. The product was extracted with DCM (3x50 ml) and dried over Na2SO4. The crude product was purified on a silica gel column using 30% of EA in hexane. White solid, Yield 82%, 'H NMR (400MHZ, DMSO-de): 4.33 (t, J= 5.15 Hz, 1H), 3.92 (d, J= 12.36 Hz, 2H), 3.51-3.40 (m, 1H), 3.69-3.34 (m, 2H), 2.65 (brs, 1H), 1.63- 1.59 (m, 2H), 1.45-1.30 (m, 12H), 1.23-1.17 (m, 2H), 0.98-0.87 (m, 2H).

[0145] tert-butyl 3-hydroxypyrrolidine-l-carboxylate (13i'): This procedure is similar as 13c'. White solid, Yield 57%, 'H NMR (400MHZ, DMSO-d6): 4.87 (d, J= 3.42 Hz, 1H), 4.21 (brs, 1H), 3.52-3.41 (m, 1H), 3.29-3.26 (m, 2H), 3.10 (d, J= 11.19 Hz, 1H), 1.89-1.78 (m, 1H), 1.73 (brs, 1H), 1.39 (s, 9H).

[0146] General procedure for the preparation of compound (13e-13j): Et3N (0.81 mL, 5.80 mmol) and DMAP (52.0 mg, 0.426 mmol) was added to a solution of (±)-tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate (1.0 g, 4.65 mmol) in DCM (20 mL) followed by addition of TsCl (0.883 g, 4.65 mmol) at 0°C. The resulting solution was stirred for 16 h at room temperature. The reaction mixture was diluted with saturated aqueous NaOH solution (50 mL) and extracted with EtOAc (3x100 mL). The combined organic extract was washed with H2O (100 mL) and brine (100 mL). It was dried over Na2SO4. The resulting mixture was concentrated under reduced pressure and purified by Column chromatography using EtOAc / hexane (30%) to get (+) tert-butyl 3-( (tosyloxy )methyl)piperidine-l -carboxylate 13e as pale yellow liquid (85% yield). 'H NMR (400MHZ, CDCI3): 7.78 (d, J= 8.28 Hz, 2H), 7.34 (d, J= 8.01 Hz, 2H), 3.92-3.77 (m, 4H), 2.84-2.79 (m, 1H), 2.45 (s, 3H), 1.89-1.79 (m, 1H), 1.75-1.73 (m, 1H), 1.66-1.55 (m, 2H), 1.43-1.35 (m, 10H), 1.28-1.19 (m, 1H);13C NMR (100 MHz, CDCI3):

[0147] 154.7.144.9, 132.9, 129.0, 127.1, 79.7, 71.7, 46.2, 44.0, 35.3, 28.4, 26.7, 23.9, 21.6.

[0148] tert-butyl 3-(tosyloxy)azetidine-l-carboxylate(13f): Pale yellow liquid, Yield 66%, 'H NMR (400MHZ, CDCI3): 7.79-7.76 (m, 2H), 7.36 (d, J= 7.92 Hz, 2H), 5.03-4.97 (m, 1H), 4.12-4.07 (s, 2H), 3.93-3.91 (m, 2H), 2.45 (s, 3H), 1.40 (s, 9H);13C NMR (100MHZ, CDCI3): 155.8, 145.5, 133.0, 130.1, 127.9, 80.2, 67.8, 56.3, 28.3, 21.7.

[0149] tert-butyl 4-(2-(tosyloxy)ethyl)piperidine-l-carboxylate (13g): Yellow liquid, Yield 65%,JH NMR (400MHZ, CDCI3): 7.77 (d, J= 8.32 Hz, 2H), 7.34 (d, J= 8.02 Hz, 2H), 4.07-4.00 (m, 4H), 2.63-2.57PT / 2026 / 12022

[0150] (m, 2H), 2.44 (s, 3H), 1.58-1.50 (m, 5H), 1.42 (s, 9H), 1.06-0.96 (m, 2H);13C NMR (100MHZ, CDC13):

[0151] 154.8, 144.8, 133.0, 129.9, 127.9, 79.3, 68.0, 43.6, 35.2, 32.2, 31.6, 28.4, 21.6.

[0152] tert-butyl 4-(3-(tosyloxy)propyl)piperidine-l-carboxylate.(13h): Yellow liquid, Yield 63%,XH NMR (400MHZ, CDC13): 7.77 (d, J= 8.31 Hz, 2H), 7.33 (d, J= 8.00 Hz, 2H), 4.02-3.99 (m, 4H), 2.64-2.58 (m, 2H), 2.44 (s, 3H), 1.70-1.61 (m, 2H), 1.57-1.54 (s, 2H), 1.43 (s, 9H), 1.32-1.20 (m, 3H), 1.06-0.96 (m, 2H);13C NMR (400MHZ, CDC13): 154.8, 144.7, 133.2, 129.8, 127.9, 79.3, 70.6, 44.1, 35.4, 32.1, 31.9, 28.5, 26.0, 21.6.

[0153] tert-butyl 3-(tosyloxy)pyrrolidine-1-carboxylate(13i): Pale Yellow liquid, Yield 82%,1H NMR (400MHZ, CDCl3): 7.78 (d, J= 8.18 Hz, 2H), 7.36 (d, J= 7.85 Hz, 2H), 5.03 (brs, 1H), 3.48-3.36 (m, 4H), 2.44 (s, 3H), 2.16-1.98 (m, 2H), 1.42 (s, 9H);13C NMR (100MHZ, CDCl3): 154.1, 145.0, 134.0, 133.8, 130.0, 127.7, 80.8, 80.0, 79.8, 51.9, 51.4, 43.6, 43.2, 32.4, 31.3, 28.4, 21.7.

[0154] tert-butyl 2-((tosyloxy)methyl)morpholine-4-carboxylate (13j): Yellow liquid, Yield 70%,1H NMR (400MHZ, CDCI3): 7.78 (d, J= 8.38 Hz, 2H), 7.34 (d, J= 8.06 Hz, 2H), 4.05-3.97 (m, 2H), 3.83-3.80 (m, 3H), 3.62-3.56 (s, 1H), 3.48-3.42 (m, 1H), 2.91-2.88 (m, 1H), 2.66 (brs, 1H), 2.44 (s, 3H), 1.45 (s, 9H);13C NMR (100MHZ, CDCk): 154.6, 145.0, 132.7, 129.9, 128.0, 80.4, 72.6, 69.5, 66.3, 44.4, 28.3, 21.7.

[0155] General procedure for preparation of 14a-j: Compound 13a-j (1.8 equiv) was added to a suspension of commercially available 4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-ol 12 (1 equiv.) and potassium carbonate (3 equiv) in DMF (10 mL). The reaction mixture was stirred overnight at 80 °C, After the completion, the reaction mixture was cooled to room temperature, water was added to the reaction mixture, The aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by flash column chromatography with MeOH / DCM (4-6%) to afford 14a-j as a white solid (60-85% yield).

[0156] tert-butyl 4-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)piperazine-1-carboxylate (14a): White solid, Yield 75%,1H NMR (400MHZ, DMSO-d6): 9.57 (brs, 1H), 8.49 (s, 1H), 8.12 (dd, J= 2.64, 6.88 Hz, 1H), 7.81-7.77(m, 2H), 7.43 (t, J= 9.12 Hz, 1H), 7.19 (s, 1H), 4.17 (t, J= 6.3Hz, 2H), 3.93 (s, 3H), 3.32-3.29 (m, 4H), 2.83-2.79 (m, 1H), 2.34 (t, J=4.9Hz, 4H), 2.04-1.95 (m, 3H), 1.38 (s, 9H);13C NMR (100 MHz, DMSO-de): 156.5, 154.9, 154.3, 153.1, 148.8, 147.5, 137.3, 123.9, 122.8 (d, J= 6.68 Hz), 119.2 (d, J= 18.63 Hz), 117.0 (d, J= 21.26 Hz), 109.3, 107.8, 103.1, 79.2, 67.6, 56.3, 54.9, 53.1, 46.2, 31.1, 28.5;19F NMR (376 MHz, DMSO-d6): -123.33; ESMS (ESI) [M + H]+found, 546.3 calculated for C27H33ClFN5O4, 546.2.PT / 2026 / 12022

[0157] tert-butyl 4-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethyl)piperazine-1-carboxylate (14b): White solid, Yield 78%,1H NMR (400MHZ, DMSO-d6): 9.56 (brs, 1H), 8.48 (s, 1H), 8.12 (dd, J= 2.61, 6.86 Hz, 1H), 7.85 (s, 1H), 7.82-7.78 (m, 1H), 7.42 (t, J= 9.0 Hz, 1H), 7.18 (s, 1H), 4.24 (t, J= 6.0 Hz, 2H), 3.92 (s, 3H), 3.31 (brs, 8H), 2.82 (t, 7=6.0 Hz, 4H), 1.38 (s, 9H);13C NMR (125 MHz, DMSO-d6): 170.6, 156.5, 155.0, 154.3, 153.1, 148.6, 137.4, 129.1, 123.9, 122.8 (d, J= 6.07 Hz), 119.2 (d, J= 23.61 Hz), 117.0 (d, J= 22.22 Hz), 107.8, 103.3, 79.2, 67.2, 56.9, 56.4, 53.4, 28.5;19F NMR (376 MHz, DMSO-d6): -123.32; ESMS (ESI) [M + H]+found, 532.5 calculated for C26H31CIFN5O4, 532.2.

[0158] tert-butyl-4-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidine-1-carboxylate (14c): White solid, Yield 70%,1H NMR (400MHZ, DMSO-d6): 9.51 (brs, 1H), 8.51 (s, 1H), 8.11 (dd, 7= 2.51, 6.80 Hz, 1H), 7.92 (s, 1H), 7.80-7.77 (m, 1H), 7.45 (t, 7= 9.07 Hz, 1H), 7.24 (s, 1H), 4.75-4.71 (m, 1H), 3.95 (s, 3H), 3.71-3.66 (m, 2H), 3.29-3.26 (m, 2H), 2.00-1.97 (m, 2H), 1.69-1.61 (m, 2H), 1.42 (s, 9H);13C NMR (100 MHz, DMSO-d6): 172.4, 156.6, 156.2, 154.9, 154.4, 153.4, 153.5, 147.7, 146.7, 137.1, 124.2, 123.1 (d, 7= 6.59 Hz), 119.40 (d,7= 18.25 Hz), 117.10 (d, 7= 21.80 Hz), 109.2, 108.2, 107.0, 79.2, 74.1, 56.5, 30.6, 28.5, 21.5;19F NMR (376 MHz, DMSO-d6): -123.04;

[0159] HRMS (ESI) [M + H]+found, 503.1853 calculated for C25H28C1FN4O4, 503.1856.

[0160] tert-butyl 4-(((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)methyl)piperidine-1-carboxylate (14d): White solid, Yield 80%,1H NMR (400MHZ, DMSO-d6): 9.52 (brs, 1H), 8.50 (s, 1H), 8.11 (dd, 7= 2.57, 6.85 Hz, 1H), 7.82-7.79 (m, 2H), 7.44 (t, 7= 9.13 Hz, 1H), 7.21 (s, 1H), 4.00 (d, 7= 6.28 Hz, 2H), 3.95 (s, 3H), 2.79 (brs, 2H), 2.09-2.02 (m, 2H), 1.84 (d, 7= 12.48 Hz, 2H), 1.42 (s, 9H), 1.29-1.19 (m, 3H);13C NMR (125 MHz, DMSO-d6): 172.4, 156.5, 155.0, 154.6, 154.5, 153.1, 152.7, 148.8, 147.4, 137.3, 124.0, 122.8 (d, 7= 6.70 Hz), 119.2 (d,7= 18.01 Hz), 117.0 (d, 7= 20.59 Hz), 109.2, 107.8, 103.0, 79.0, 73.5, 56.4, 35.9, 31.1, 28.6, 21.5;19F NMR (376 MHz, DMSO-de): -123.28; HRMS (ESI) [M + H]+found, 517.2004 calculated for C26H30CIFN4O4, 517.2012.

[0161] tert-butyl 3-(((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)methyl)piperidine-1-carboxylate (14e): White solid, Yield 85%,1H NMR (400MHZ, DMSO-d6): 9.52 (brs, 1H), 8.48 (s, 1H), 8.11 (dd, 7= 2.62, 6.86 Hz, 1H), 7.83-7.77 (m, 2H), 7.41 (t, 7= 9.00 Hz, 1H), 7.18 (s, 1H), 4.04-3.99 (m, 1H), 3.93 (s, 3H), 3.80-3.76 (m, 2H), 2.86 (brs, 1H), 1.99-1.98 (m, 1H), 1.90-1.88 (d, 2H), 1.69-1.65 (m, 1H), 1.37 (s, 12H);13C NMR(100 MHz, DMSO-d6): 156.5, 154.9, 154.8, 154.4, 153.0, 152.4, 148.7, 147.5, 137.3, 123.9, 122.8 (d, 7= 7.15 Hz), 119.2 (d, 7= 18.24 Hz), 117.0 (d, 7= 21.81 Hz), 109.2, 107.8, 79.0, 63.3, 56.3, 40.9, 36.1, 28.5, 27.2;19F NMR (376 MHz, DMSO-d6): -123.34; HRMS (ESI) [M + H]+found, 517.2021 calculated for C26H30CIFN4O4, 517.2012.PT / 2026 / 12022

[0162] tert-butyl 3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidine-1-carboxylate (14f): Pale yellow solid, Yield 60%, mp 210°C;1H NMR (400MHZ, DMSO-d6): 9.47 (s, 1H), 8.48 (s, 1H), 8.11 (dd, J= 2.57, 6.86 Hz, 1H), 7.77-7.73 (m, 1H), 7.46 (s, 1H), 7.42 (t, J= 9.09 Hz, 1H), 7.21 (s, 1H), 5.16-5.11 (m, 1H), 4.47-4.43 (m, 2H), 3.94 (s, 3H), 3.92-3.88 (m, 2H), 1.40 (s, 9H);

[0163] 13C NMR (100 MHz, DMSO-d6): 156.6, 156.1, 155.0, 154.9, 153.5, 152.6, 148.0, 146.2, 137.5 (d, J= 2.97 Hz), 124.4, 123.2 (d, J= 6.95 Hz), 119.2 (d, J= 18.55 Hz), 117.0 (d, J= 21.43 Hz), 109.0, 108.3, 103.8, 79.5, 67.2, 56.4, 28.5;19F NMR (376 MHz, DMSO-d6): -122.96; ESMS (ESI) [M + H]+found, 475.4 calculated for C23H24CIFN4O4, 475.2.

[0164] tert-butyl 4-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethyl)piperidine-1-carboxylate (14g): White solid, Yield 77%, mp 166°C;1H NMR (400MHZ, DMSO-d6): 9.62 (brs, 1H), 8.48 (s, 1H), 8.13 (dd, J= 2.63, 6.86 Hz, 1H), 7.83-7.80 (m, 2H), 7.41 (t, J= 9.09 Hz, 1H), 7.18 (s, 1H), 4.18-4.15 (m, 2H), 3.97-3.88 (m, 5H),) 2.73-2.67 (m, 2H), 1.80-1.66 (m, 5H), 1.39 (s, 9H), 1.19-1.04 (m, 3H);13C NMR (100 MHz, DMSO-d6): 156.5, 154.9, 154.8, 154.3, 153.0, 152.4, 148.8, 147.4, 137.3, 123.9, 122.7 (d, J= 6.65 Hz), 119.2 (d, J= 18.28 Hz), 117.0 (d, J=21.60 Hz), 109.3, 107.7, 103.1, 78.9, 67.0, 56.3, 43.6, 35.6, 32.8, 32.1, 28.6;19F NMR (376 MHz, DMSO-d6): -123.39; ESMS (ESI) [M + H]+found, 531.5 calculated for C27H32CIFN4O4, 531.2.

[0165] tert-butyl 4-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)piperidine-1-carboxylate (14h): White solid, Yield 79%,1H NMR (400MHZ, DMSO-d6): 9.46 (s, 1H), 8.48 (s, 1H), 8.11 (dd, J= 2.62, 6.84 Hz, 1H), 7.82-7.78 (m, 1H), 7.75 (s, 1H), 7.44-7.40 (m, 1H), 7.18 (s, 1H), 4.12-4.08 (m, 2H), 3.92 (s, 5H), 2.67 (brs, 2H), 1.87-1.78 (m, 2H), 1.54-1.43 (m, 3H), 1.38 (s, 9H), 1.04-0.94 (m, 2H);13C NMR (125 MHz, DMSO-d6): 172.5, 162.8, 156.4, 155.0, 154.3, 153.0, 152.6, 148.8, 147.4, 137.3, 123.9, 122.7 (d, J= 6.72 Hz), 119.3 (d, J= 17.74 Hz), 117.0 (d, J= 21.70 Hz), 109.2, 107.7, 102.9, 78.8, 69.5, 56.3, 44.2, 35.4, 33.0, 32.2, 28.6, 26.2, 21.5;19F NMR (376 MHz, DMSO-d6): -123.38; ESMS (ESI) [M + H]+found, 545.3 calculated for C28H34ClFN4O4, 545.2.

[0166] tert-butyl 3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pyrrolidine-1-carboxylate (14i): Off White solid, Yield 72%, mp 108°C;1H NMR (400MHZ, DMSO-d6): 9.54 (s, 1H), 8.50 (s, 1H), 8.10 (dd, J= 2.57, 6.83 Hz, 1H), 7.83 ( s, 1H), 7.80-7.76 (m, 1H), 7.47-7.43 (m, 1H), 7.23 (s, 1H), 5.19-5.16 (m, 1H), 3.94 (s, 3H), 3.71-3.67 (m, 1H), 3.51-3.47 (m, 1H), 3.44-3.39 (m, 1H), 2.23-2.16 (m, 2H), 1.43-1.41 (m, 9H);13C NMR (100 MHz, DMSO-d6): 172.5, 162.8, 156.6, 155.6, 153.4, 152.8, 147.7, 146.8, 137.1, 124.3, 123.1 (d, J= 8.32 Hz), 119.3 (d, J= 18.20 Hz), 117.1 (d, J= 21.84 Hz), 109.1, 108.3, 105.6, 79.1, 56.4, 36.2, 31.2, 28.6;19F NMR (376 MHz, DMSO-d6): -123.04;

[0167] ESMS (ESI) [M + H]+found, 489.2 calculated for C24H26CIFN4O4, 489.2.PT / 2026 / 12022

[0168] / e / 7-butyl2-(((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)methyl)morpholine-4-carboxylate(14j): Off white solid, Yield 70%, mp 209°C;XH NMR (400MHZ, DMSO-de): 8.49 (s, 1H), 8.13 (dd, J= 2.44, 6.81 Hz, 1H), 7.81-7.78 (m, 2H), 7.49-7.40 (m, 1H), 7.20 (s, 1H), 4.21-4.18 (m, 1H), 4.17-4.09 (m, 1H), 4.07-3.98 (m, 2H), 3.94-3.88 (m, 3H), 3.84-3.74 (m, 3H), 3.70-3.63 (m, 1H), 3.54-3.48 (m, 1H), 1.42-1.38 (m, 9H);13C NMR (100 MHz, DMSO-de): 156.5, 154.8, 154.4, 154.3, 153.3, 152.4, 148.3, 147.6, 145.5,137.4, 132.6, 130.6, 128.1, 123.9, 122.8 (d, J= 6.83 Hz), 119.3 (d, J= 18.14 Hz), 117.0 (d, J= 21.44 Hz), 109.2, 107.9, 103.3, 79.7, 79.6, 73.6, 70.6, 66.2, 65.9, 56.4, 28.5;19F NMR (376 MHz, DMSO-d6): -123.36; ESMS (ESI) [M + H]+found, 519.5 calculated for C25H28CIFN4O5, 519.2.

[0169] General procedure for preparation of 15a-b, 15g-h: Compound 14a-b or 14g-h was dissolved in 5 mL DCM. Then 1.5 mL of trifluoroacetic acid was added dropwise at 0 °C under N2 aatmosphere. The reaction mixture was stirred for 2 hours at ambient temperature. The reaction mixture is concentrated under reduced pressure and combined with 2N NaOH solution followed by workup with 10% MeOH / DCMto get 15a-b or 15g-h as a white solid (70-85% yield).

[0170] N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(piperazin-l-yl)propoxy)quinazolin-4-amine (15a):

[0171] White semisolid, Yield 85%, ESMS (ESI) [M + H]+found, 446.3 calculated for C22H25CIFN5O2, 446.2.

[0172] N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(2-(piperazin-l-yl)ethoxy)quinazolin-4-amine (15b):

[0173] White semisolid, Yield 80%, ESMS (ESI) [M + H]+found, 432.4 calculated for C21H23CIFN5O2, 432.2.

[0174] N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(2-(piperidin-4-yl)ethoxy)quinazolin-4-amine (15g):

[0175] White semisolid, Yield 84%, ESMS (ESI) [M + H]+found, 431.1 calculated for C22H24CIFN4O2, 431.2.

[0176] N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(piperidin-4-yl)propoxy)quinazolin-4-amine (15h):

[0177] White semisolid, Yield 70%, ESMS (ESI) [M + H]+found, 445.2 calculated for C22H24CIFN4O2, 445.9.

[0178] General procedure for preparation of 15c-f and 15i-j: This compound 14c-f or 14i-j was stirred in a mixture of DCM-TFA ( 1: 1) at 0 °C under N2 atmosphere. The mixture was stirred at room temperature for 1 h. After evaporation of the solvents, the residue was diluted with dichloromethane and washed with aqueous ammonia. The organic layer was dried over magnesium sulfate and the solvents evaporated to afford 15c-f, or 15i-j (73-99%).

[0179] N-(3-chloro-4-fluorophenyI)-7-methoxy-6-(piperidin-4-yloxy)quinazoIin~4-amine (15c): White semisolid, Yield 90%, ESMS (ESI) [M + H]+found, 403.4 calculated for C20H20CIFN5O2, 403.1.PT / 2026 / 12022

[0180] N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(piperidin-4-yImethoxy)quinazoIin-4-amine (15d): White semisolid, Yield 73%, ESMS (ESI) [M + H]+found, 417.4 calculated for C21H22ClFN4O2, 417.1.

[0181] N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(piperidin-3-ylmethoxy)quinazolin-4-amine (15e): Pale yellow solid, Yield 82%, mp 134°C; ESMS (ESI) [M + H]+found, 417.4 calculated for C21H22ClFN4O2, 417.1.

[0182] 6-(azetidin-3-yloxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine (15f): White semisolid, Yield 88%, ESMS (ESI) [M + H]+found, 375.1 calculated for C18H16ClFN4O2, 375.1.

[0183] N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(pyrrolidin-3-yloxy)quinazolin-4-amine(15i)): White semisolid, Yield 80%, ESMS (ESI) [M + 3] found, 391.2 calculated for C19H18ClFN4O2, 391.1.

[0184] N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(morpholin-2-ylmethoxy)quinazolin-4-amine (15j):

[0185] Brown solid, Yield 99%, mp 83°C; ESMS (ESI) [M + H]+found, 419.1 calculated for C20H20CIFN4O3, 419.1.

[0186]

[0187] Scheme 1c. Synthesis of compound 19 as intermediate.

[0188] Procedures for Scheme 1c

[0189] Preparation of 4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl piperazine-1-carboxylate (19) A 100 mL two-necked flask with a magnetic stirring bar was evacuated and backfilled N2 aatmosphere for three times. Triphosgene (5.0 mmol) and DCM (30 mL) were added to the flask. The mixture was cooled at 0 °C and dehydrated pyridine (3.0 mL) was slowly added to the flask. After stirring for 15 min at 0 °C, tert-butyl piperazine -1 -carboxylate 16 (10 mmol) was slowly added to the mixture. Thereafter the mixture was warmed to room temperature and stirred for 6 h at room temperature. The reaction mixture was carefully quenched with 1 M HC1 (10 mL) and was extracted with DCM (50 mL x 3). The organic layer was washed with water, and brine and then dried over Na2SO4. After the filtration, the solution was concentrated under reduced pressure. This material 17 (tert-butyl 4-(chlorocarbonyl)piperazine-l-carboxylate) proceeded to the next step without further purification.PT / 2026 / 12022

[0190] l-(tert-butyl) 4-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl) piper azine- 1,4-dicarboxylate (18) A mixture of 12 (309 mg, 0.9677 mmol), 17 (240 mg, 0.9677 mmol), and potassium carbonate (268 mg, 1.94 mmol) in dry N, N-dimethylformamide (5 mL) was stirred overnight at room temperature under Nz aatmosphere. After completion of the reaction, crushed ice was added to the reaction mixture. The filtration cake was dried under a vacuum to afford crude 18 (345 mg) as a yellow solid, which was again used for the next step without further purification. MP 207°C;1H NMR (400MHZ, DMSO-d6): 8.58 (s, 1H), 8.30 (s, 1H), 8.22-8.21 (m, 1H), 7.96 (s, 1H), 7.83-7.81 (m, 1H), 7.41 (t, J= 9.0 Hz, 1H), 7.32 (s, 1H), 3.94 (s, 3H), 3.44 (brs, 8H), 1.44 (s, 9H),13C NMR (125 MHz, DMSO-d6): 157.3, 156.5, 154.9, 154.6, 154.3, 152.9, 150.4, 140.3, 123.6, 122.4 (d, J= 7.18 Hz), 119.2 (d, J= 20.12 Hz), 117.1 (d, J= 22.13 Hz), 116.7, 109.1, 108.7, 79.8, 56.9, 44.8, 44.1, 28.5;19F NMR (376 MHz, DMSO-d6): -123.13; HRMS (ESI) [M + H]+found, 532.1760 calculated for C25H27ClFN5O5, 532.1758.

[0191] HC1 in dioxane (4M, 1.5 mL) was added to a solution of 18 (345 mg, crude) in methanol (3 mL) at 0 °C under Nz aatmosphere. The mixture was allowed to stir at room temperature for 3 h and concentrated. Then diluted with water till all salts are soluble in water. Thereafter extracted with EtOAc to remove impurities. The aqueous layer was basified with solid NaHCCh and extracted with DCM (3 x 25 mL). Crude solution was concentrated under reduced pressure, and compound 19 (210 mg, yellow solid) was used for the next reaction without further purification. HRMS (ESI) [M + H]+found, 432.1231 calculated for C20H19CIFN5O3, 432.1233.

[0192]

[0193] Scheme Id. Synthesis of compound 25 as intermediate

[0194] Procedures for Scheme Id

[0195] Preparation of N-(4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide (25): Potassium carbonate (80 mg, 0.582 mmol) and Triethyl phosphonoacetate (0.09 ml, 0.582 mmol) was added to a solution of compound 20 (58 mg, 0.29 mmol) in DMF (1.5 mL). Then the reaction mixture was refluxed at 90°C for 2.30h. After completion of the reaction, crushed ice was added to the reaction mixture. The aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic phase was dried over Na2SO4. filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography using hexane / EtOAc (10%) to obtain tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-l -carboxylate 21 (Pale yellow semisolid, 50% yield).XHPT / 2026 / 12022

[0196] NMR (400MHZ, CDCI3): 5.71 (s, 1H), 4.15 (q, J= 7.28 Hz, 1H), 3.51-3.46 (m, 4H), 2.93 (t, J= 5.50 Hz, 2H), 2.27 (t, J= 5.50 Hz, 2H), 1.47 (s, 9H), 1.29-1.27 (m, 3H);13C NMR (125 MHz, CDCI3):

[0197] 166.3, 157.8, 115.3, 79.8, 59.8, 44.6, 36.4, 29.6, 28.4, 14.3.

[0198] LiOH.solution was added to 21 (300 mg) in THF, ETOH. The reaction mixture was stirred at 50 °C for 16h. After completion, the mixture was neutralized with AcOH to PH= 5 and the aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic phases were dried over Na2SO4 and concentrated under reduced pressure, 2-( 1 -(tert-butoxy carbonyl )piperidin-4-ylidene)acetic acid 22 (200 mg, yellow solid) was used for the next reaction without further purification

[0199] 2-(l-(tert-butyloxycarbonyl)piperidine-4-ylidene)acetic acid (200 mg) was added to 4 mL of anhydrous THF in a one-neck flask (50 mL). The solution was stirred and cooled on salt -ice bath. Then, 0.6 mL of isobutyl chloroformate and 0.1 mL of N-methylmorpholine were added, and the reaction mixture was stirred for 20 min 1.046 g of N -(3-ethynylphenyl)quinazoline-4,6- diamine (200 mg) was dissolved in 2 mL of pyridine (dried over molecular sieves) and 0.1 mL of N-methylmorpholine were added to the reaction mixture on an ice bath with stirring for 45 minutes. After reaction completion, the solvent was evaporated in vacuo and the remaining residue was partitioned with chloroform and water. The chloroform layer was washed once with brine, dried over anhydrous Na2SO4and evaporated in vacuo to give a crude product. The crude product was purified by flash column chromatography using hexane / EtOAc (70%) to obtain tert-butyl4-((4-(3-chloro-4-fluorophenylamino)quinazolin-6-ylcarbamoyl)methylene)piperidine-l -carboxylate 24 (White semisolid, Yield 60 %).

[0200] ter / -butyl4-(2-((4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)amino)-2-oxoethylidene)piperidine-l-carboxylate (24): 'H NMR (400MHZ, CDCL): 8.82-8.78 (m, 2H),8.63 (s, 1H), 7.86 (dd, J= 2.63, 6.58 Hz,lH), 7.75 (d, J=8.87 Hz, 1H), 7.55-7.51 (m, 1H), 7.43 (d, J= 8.52 Hz, 1H), 7.07 (t, J= 8.78 Hz, 1H), 5.62 (brs, 1H), 3.91 (brs, 2H), 3.50 (t, J= 5.61 Hz, 2H), 3.15 (brs, 2H), 2.17-2.16 (m, 2H), 1.46 (s, 9H);13C NMR (100 MHz, CDCI3): 169.6, 157.5, 156.0, 155.0, 153.8, 146.6, 136.03, 135.1 (d, J= 3.21 Hz), 130.8, 128.9, 126.0, 124.3, 121.9 (d, J= 6.67 Hz), 120.8 (d, J= 18.41 Hz), 116.4 (d, J= 21.88 Hz), 115.3, 110.4, 80.1, 60.4, 46.0, 43.3, 28.5; ESMS (ESI) [M + H]+found, 532.5 calculated for C25H27CIFN5O5, 532.2.

[0201] General procedure for preparation of 25 as similar preparation of 15c-f

[0202] N-(4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)-2-(piperidin-4-ylidene)acetamide (25):

[0203] White semisolid, Yield 90%, ESMS (ESI) [M + H]+found, 412.4 calculated for C21H19CIFN5O, 412.1.PT / 2026 / 12022

[0204]

[0205] Scheme le. Synthesis of compound 29a-e as intermediate.

[0206] Procedures for Scheme le

[0207] General procedure for preparation of 29a-e:

[0208] The precursor compound 7-methoxyl 6-hydroxyl-4-(4 -fluoro-3 -chloro)quinazoline 12 (1 equiv.) and potassium carbonate (5 equiv.) were mixed in DMF (5 mL). Then dihalo alkane 26a-e (2 eqiv.) was added dropwise and the mixture was heated at 80 °C for (8 mins-2h). After completion of the reaction, crushed ice was added to the reaction mixture. The aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic phase was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography using hexane / EtOAc (55-80%) to obtain (27a-e) (54-93% yield) [KI was added for dichloro compound and time also increased more than 2h],

[0209] 6-((5-bromopentyl)oxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine (27a): Off white solid, Yield 93%, mp 130°C; 'H NMR (400MHZ, CDC13): 8.46 (s, 1H), 7.89 (dd, J= 2.60, 6.4 Hz, 1H), 7.60-7.56 (m, 1H), 7.16 (d, J=8.86 Hz, 1H), 7.12 (s, 1H), 7.08 (s, 1H), 5.01 (s, 1H), 4.09-4.06 (m, 2H), 3.89 (s, 3H), 3.49-3.44 (m, 2H), 2.00-1.89 (m, 4H), 1.70-1.62 (m, 2H);13C NMR (100 MHz, CDC13): 176.1, 156.3, 156.1, 155.4, 153.6, 152.1, 149.1, 145.1, 135.2 (d, J= 3.29 Hz), 124.2, 121.8 (d, J= 6.53 Hz), 121.1 d, J= 18.72 Hz), 116.5 (d, J= 21.77 Hz), 108.4, 106.0, 101.1, 69.0, 56.1, 33.6, 32.3, 28.2, 24.8;19F NMR (376 MHz, CDCI3): -120.58; ESMS (ESI) [M + H]+found, 468.3 calculated for C20H20BrClFN3O2, 468.0.

[0210] 6-((6-bromohexyl)oxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine (27b): White semisolid, Yield 44%, mp

[0211]

[0212] NMR (400MHZ, DMSO-d6): 9.51 (brs, 1H), 8.49 (s, 1H), 8.11 (dd, J= 2.60, 6.8 Hz, 1H), 7.82-7.77 (m, 2H), 7.43 (t, J=9.2 Hz, 1H), 7.19 (s, 1H), 4.13 (t, J= 6.45 Hz, 2H), 3.94 (s, 3H), 3.55 (t, J= 6.70 Hz, 2H), 1.87-1.80 (m, 4H), 1.50-1.49 (m, 4H);13C NMR (100 MHz, DMSO-d6): 172.5, 156.7, 155.2, 155.1, 152.6 (d, J= 4.57 Hz), 149.0, 146.1, 136.9 (d, J= 3.40 Hz), 124.3, 123.1 (d, J= 7.50 Hz), 119.4 (d, J= 18.33 Hz), 116.9 (d, J= 21.66 Hz), 109.0, 106.9, 103.1, 69.2,PT / 2026 / 12022

[0213] 56.4, 35.6, 32.7, 28.9, 27.8, 25.3;19F NMR (376 MHz, DMSO-d6): -122.15; ESMS (ESI) [M + H] found, 482.4 calculated for C21H22BrClFN3O2, 482.1.

[0214] 6-(2-(2-bromoethoxy)ethoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine (27c):

[0215] White solid, Yield 70%, mp 109°C;1H NMR (400MHZ, DMSO-d6): 9.49 (brs. 1H), 8.52 (s, 1H), 8.14 (dd, J= 2.64, 6.87 Hz, 1H), 7.85-7.81 (m, 2H), 7.42 (t, J= 9.10 Hz, 1H), 7.19 (s, 1H), 4.31-4.29 (m, 2H), 3.96-3.93 (m, 5H), 3.89 (t, J= 5.57 Hz, 2H), 3.67 (t, J= 5.57 Hz, 2H);13C NMR (100 MHz, DMSO-d6): 162.7, 156.4, 154.8, 153.1, 152.3, 148.4, 147.5, 137.3 (d, J= 2.90 Hz), 123.7, 122.4 (d, J= 5.68 Hz), 119.2 (d, J= 16.71 Hz), 116.8 (d, J= 21.74 Hz), 109.2, 107.7, 103.1, 71.1, 68.9, 68.8, 56.2, 32.6;

[0216] 19F NMR (376 MHz, DMSO-d6): -123.43; ESMS (ESI) [M + H]+found, 470.0 calculated for C19H18BrClFN3O3, 470.3.

[0217] N-(3-chloro-4-fluorophenyl)-6-(2-(2-(2-chloroethoxy)ethoxy)ethoxy)-7-methoxyquinazolin-4-amine (27d): White solid, Yield 80%, mp 120°C; 'H NMR (400MHZ, CDC13): 8.58 (brs, 1H), 7.91-7.89 (m, 1H), 7.59-7.57 (m, 1H), 7.38 (brs, 1H), 7.13 (t, J= 8.74 Hz, 3H), 4.32-4.30 (m, 2H), 3.94-3.92 (m, 2H), 3.90 (s, 3H), 3.76-3.74 (m, 2H), 3.72-3.70 (m, 4H), 3.58-3.55 (m, 2H);13C NMR (100 MHz, CDC13): 155.4, 154.9, 154.3, 152.5, 152.1, 147.7, 134.4 (d, J= 3.42 Hz), 123.2, 120.9 (d, J= 6.83 Hz), 119.9 (d, J= 16.71 Hz), 115.5 (d, J= 21.88 Hz), 106.2, 101.6, 70.2, 69.6, 69.5, 68.8, 68.0, 55.1, 41.8;

[0218] 19F NMR (376 MHz, CDCk): -121.0; ESMS (ESI) [M + H]+found, 470.0 calculated for C21H22Cl2FN3O4, 470.1.

[0219] N-(3-chloro-4-fluorophenyl)-6-(2-(2-(2-(2-chloroethoxy)ethoxy)ethoxy)ethoxy)-7-methoxyquinazolin-4-amine (27e / GF-55): White solid, Yield 54%, mp 135°C; 'H NMR (400MHZ, CDCI3): 8.66 (brs, 1H), 8.55 (s, 1H), 7.93 (dd, J= 2.56, 6.6 Hz, 1H), 7.64-7.61 (m, 1H), 7.55 (s, 1H), 7.15-7.11 (m, 2H), 4.33-4.31 (m, 2H), 3.92-3.89 (m, 5H), 3.73-3.72 (m, 2H), 3.70-3.68 (m, 2H), 3.66-3.60 (m, 6H), 3.54-3.51 (m, 2H);13C NMR (100 MHz, CDCI3): 156.7, 156.0, 155.4, 153.5, 152.3, 148.7, 135.5 (d, J= 3.34 Hz), 124.5, 122.2 (d, J= 6.95 Hz), 120.7 (d, J= 18.67 Hz), 116.4 (d, J= 22.15 Hz), 108.8, 106.3, 103.5, 71.3, 70.6, 70.5, 70.4, 70.2, 69.8, 69.1, 56.2, 42.7;19F NMR (376 MHz, CDCk): -121.0; ESMS (ESI) [M + H]+found, 514.5 calculated for C23H26Cl2FN3O5, 514.1.

[0220] General procedure for preparation of 28a-e:

[0221] 1-Boc-piperazine (1.15 equiv), DIPEA (2.0 equiv), and KI (catalytic amount) were added to a stirred solution of 27a-e (1.0 equiv) in NMP. The reaction mixture was heated at 70 °C for overnight. The reaction mixture was cooled down to room temperature, water was added to the reaction mixture. The aqueous layer was extracted with EtOAc (3 x 50 mL). The combined organic phases were dried overPT / 2026 / 12022

[0222] Na2SO4and concentrated under reduced pressure. The residue was purified by flash column chromatography with MeOH / DCM (4-6%) to afford 28a-e as a white solid (64-93% yield).

[0223] ter / -butyl4-(5-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pentyl)piperazine-l-carboxylate (28a): Pale yellow Liquid, Yield 93%,1H NMR (400MHZ, DMSO-d6): 9.52 (brs, 1H), 8.48 (s, 1H), 8.11 (dd, J= 2.64, 6.85 Hz, 1H), 7.82-7.78 (m, 2H), 7.16 (t, 7=9.10 Hz, 1H), 7.18 (s, 1H), 4.13 (t, 7=6.46 Hz, 1H), 3.92 (s, 3H), 3.30 (brs, 4H), 2.35 (brs, 6H), 1.87- 1.80 (m, 2H), 1.57-1.43 (m, 4H), 1.38 (s, 9H);13C NMR (100 MHz, DMSO-d6): 172.5, 156.5, 155.0, 154.2, 153.0, 152.4, 148.9, 147.4, 137.3, 124.0, 122.8 (d, 7= 6.68 Hz), 119.2 (d, 7= 18.45 Hz), 117.0 (d, 7= 21.82 Hz), 109.3, 107.7, 102.9, 79.4, 69.2, 57.8, 56.3, 52.7, 28.9, 28.5, 23.9;19F NMR (376 MHz, DMSO-d6): -123.27; ESMS (ESI) [M + H]+found, 574.6 calculated for C29H37CIFN5O4, 574.3.

[0224] te / 7-butyl4-(6-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)hexyl)piperazine-l-carboxylate (28b): Pale yellow Liquid, Yield 64%, 'H NMR (400MHZ, DMSO-d6): 9.51 (brs, 1H), 8.49 (s, 1H), 8.11 (dd, 7= 2.63, 6.87 Hz, 1H), 7.82-7.78 (m, 2H), 7.44 (t, 7=9.19 Hz, 1H), 7.20 (s, 1H), 4.15-4.11 (m, 2H), 3.93 (s, 3H), 3.29 (brs, 6H), 2.32-2.28 (m, 4H), 1.86- 1.79 (m, 2H), 1.50-1.47 (m, 6H), 1.38 (s, 9H);13C NMR (100 MHz, DMSO-d6): 173.8, 156.5, 155.0, 154.2, 153.0, 148.9, 147.4, 137.3 (d, 7= 3.76 Hz), 123.9, 122.8 (d, 7= 7.00 Hz), 119.3, 117.0 (d, 7= 21.55 Hz), 109.3, 107.7, 102.9, 83.8, 79.2, 69.2, 56.3, 52.9, 29.0, 28.5, 28.0, 27.1, 26.0;19F NMR (376 MHz, DMSO-d6): -123.31; ESMS (ESI) [M + H]+found, 588.6 calculated for C30H39CIFN5O4, 588.3.

[0225] te / 7-butyl4-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazine-l-carboxylate (28c): Off white semisolid, Yield 86%, 'H NMR (400MHZ, DMSO-d6): 9.68 (brs. 1H), 8.50 (s, 1H), 8.14 (dd, 7= 2.62, 6.87 Hz, lH), 7.86 (s, 1H), 7.84- 7.80 (m, 1H), 7.42 (t, 7= 9.10 Hz, 1H), 7.20 (s, 1H), 4.29-4.27 (m, 2H), 3.94 (s, 3H), 3.83 (t, 7= 4.60 Hz, 2H), 3.63 (t, 7= 5.71 Hz, 2H), 3.28-3.25 (m, 4H), 3.67 (s, 1H), 2.52 (brs, 1H), 2.37 (t, 7=4.98 Hz, 4H), 1.38 (s, 9H);13C NMR (100 MHz, DMSO-d6): 156.5, 154.9, 154.3, 153.1, 152.3, 148.6, 147.5, 137.4 (d, 7= 2.96 Hz), 123.8, 122.7 (d, 7= 6.57 Hz), 119.2 (d, 7= 18.19 Hz), 116.9 (d, 7= 21.72 Hz), 109.2, 107.8, 103.2, 79.2, 69.0, 68.9, 68.7, 57.6, 56.3, 53.3, 28.5;19F NMR (376 MHz, DMSO-d6): - 123.43; ESMS (ESI) [M + H]+found, 576.6 calculated for C28H35ClFN5O5, 576.2.

[0226] ter / -butyl4-(2-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethoxy)ethyl)piperazine-l-carboxylate (28d): Pale yellow Liquid, Yield 74%, 'H NMR (400MHZ, CDCI3): 8.90 (brs, 1H), 8.51 (brs, 1H), 7.87 (t, 7=2.59, 6.66 Hz, 1H), 7.65-7.61 (m, 1H), 7.56 (s, 1H), 7.09 (t, 7= 8.78 Hz, 1H), 6.99 (brs, 1H), 4.29-4.26 (m, 2H), 3.91-3.89 (m, 2H), 3.79 (s, 3H), 3.73-3.71 (m, 2H), 3.61-3.59 (m, 2H), 3.53 (t,7= 5.08 Hz, 2H), 3.30 (brs, 4H), 2.50 (t,7= 5.08 Hz, 2H), 2.34 (brs, 4H), 1.36 (s, 9H);13C NMR (100 MHz, CDCI3): 156.7, 155.8, 154.7, 154.6, 153.3PT / 2026 / 12022

[0227] (d, J= 7.95 Hz), 148.2, 147.0, 136.9 (d, J= 3.34 Hz), 124.7, 122.6 (d, J= 6.65 Hz), 120.5 (d, J= 18.44 Hz), 116.2 (d, J= 21.96 Hz), 109.0, 107.0, 102.9, 79.9, 70.6, 69.9, 69.6, 68.6, 67.5, 57.7, 55.9, 52.8, 43.0, 28.3;19F NMR (376 MHz, CDCh): -121.51; ESMS (ESI) [M + H]+found, 620.7 calculated for C23H26Cl2FN3O5, 620.3.

[0228] ter / -butyl4-(2-(2-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethoxy)ethoxy)ethyl)piperazine-l-carboxylate (28e): Pale yellow Liquid, Yield 82%, 'H NMR (400MHZ, CDC13): 9.01 (brs, 1H), 8.56 (s, 1H), 7.90 (dd, J= 2.59, 6.63 Hz, 1H), 7.74-7.70 (m, 2H), 7.13-7.08 (m, 2H), 4.36 (t, J=5.0 Hz, 2H), 3.90 (s, 3H), 3.86 (t, J=5.0 Hz, 2H), 3.69-3.67 (m, 2H), 3.63-3.56 (m, 6H), 3.51 (t, J= 5.4 Hz, 2H), 3.34-3.32 (m, 4H), 2.48 (t, J= 5.37 Hz, 2H), 2.32 (brs, 4H), 1.38 (s, 9H);13C NMR (100 MHz, CDC13): 156.8, 155.6, 155.0, 154.7, 153.3 (d, J= 17.31 Hz), 148.4, 147.2, 136.2 (d, J= 3.39 Hz), 124.2, 122.2 (d, J= 6.69 Hz), 120.5 (d, J= 18.36 Hz), 116.2 (d, J= 21.92 Hz), 109.3, 107.3, 103.5, 79.8, 70.5, 70.4, 70.3, 70.2, 69.8, 68.6, 67.9, 57.7, 56.1, 53.1, 42.9, 28.4;

[0229] 19F NMR (376 MHz, CDC13):-121.77; ESMS (ESI) [M + H]+found, 664.7 calculated for C32H43CIFN5O7, 664.3.

[0230] The procedure for the preparation of 29a-e is similar as 16a-b.

[0231] N-(3-chloro-4-fluorophenyl)-7-methoxy-6-((5-(piperazin-l-yl)pentyl)oxy)quinazolin-4- amine (29a): White semisolid, Yield 85%, ESMS (ESI) [M + H]+found, 474.5 calculated for C24H29CIFN5O2, 474.2.

[0232] N-(3-chloro-4-fluorophenyl)-7-methoxy-6-((6-(piperazin-l-yl)hexyl)oxy)quinazolin-4- amine (29b): White semisolid, Yield 70%, ESMS (ESI) [M + H]+found, 488.5 calculated for C25H31CIFN5O2, 488.2.

[0233] N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(2-(2-(piperazin-l-yl)ethoxy)ethoxy)quinazolin-4-amine (29c): White semisolid, Yield 75%, ESMS (ESI) [M + H]+found, 476.4 calculated for C23H27CIFN5O3, 476.2.

[0234] N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(2-(2-(2-(piperazin-l-yl)ethoxy)ethoxy)ethoxy)quinazolin-4-amine(29d): White semisolid, Yield 65%, ESMS (ESI) [M + H]+found, 520.6 calculated for C25H31CIFN5O4, 520.2.

[0235] N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(2-(2-(2-(2-(piperazin-l-yl)ethoxy)ethoxy)ethoxy)ethoxy)quinazolin-4-amine (29e): White semisolid, Yield 70%, ESMS (ESI) [M + H]+found, 564.6 calculated for C27H35CIFN5O5, 564.2.PT / 2026 / 12022

[0236]

[0237] Scheme If. Synthesis of compound 30a-o as final compound.

[0238] General procedure for preparation of 30a-o: Compound 11 (1 equiv.) the requisite amine 15a-e, 19, 25, 29a-e (3 equiv.) were dissolved in dichloroethane. The reaction mixture was allowed to stir at room temperature for 20 minutes, then sodium triacetoxyborohydride (3 equiv.) was added portion-wise at 0 °C. Thereafter, the reaction mixture was stirred at room temperature overnight, and quenched with aqueous sodium bicarbonate. The aqueous phase was extracted with dichloromethane (3 x 20 ml). The combined organic layers were dried over Na2SO4and concentrated under reduced pressure to give crude material which was purified by column chromatography over silica gel with MeOH / DCM (7 -9%) to afford the final compound as an off-white solid (70-80% yield).

[0239]

[0240] Scheme 2. Synthesis of compound 11 as intermediate for preparation of general formula.

[0241] Procedures for Scheme 2.

[0242] Synthesis of compound 9, 29a-c are already mentioned in scheme la, le

[0243] Procedures for Preparation of N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3- (ethyl(tetrahydro-2H-pyran-4-yl)amino)-5-formyl-2-methylbenzamide (31): A mixture of 9 (100PT / 2026 / 12022

[0244] mg, 0.0210 mmol.) Potassium vinyltrifluoroborate (42 mg, 0.315 mmol), K2CO3(58 mg, 0.42 mmol), Pd(PPh3)4 (12 mg, 0.02) in a mixture ofDioxane(l ml), water (0.1 ml). The reaction mixture was purged for 30 minutes. Thereafter, the reaction mixture was heated at 100°C for 5h under N2 aatmosphere. After completion of the reaction, the reaction mixture was passed through a celite bead, and the aqueous layer was extracted with EtOAc (2 x 20 mL). The combined organic phases were dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue of compound 31 further proceeded to the next reaction without purification. ESMS (ESI) [M + H]+found, 424.6 calculated for C25H33ClFN3O3, 424.2.

[0245] N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methyl-5-vinylbenzamide(32) To a solution of 31 (55 mg, 0.13 mmol) in 1,4-dioxane (2 mL) and water (0.4 mL) at 0 °C, 2,6-lutidine (0.03 mL, 0.26 mmol), osmium tetroxide (0.05 mL, 2.5% in tert butanol), and sodium periodate (111 mg, 0.0518 mmol) was added. The reaction mixture was allowed to warm up to room temperature while stirring for 15 minutes. The reaction mixture was transferred to a separatory funnel containing water (5 mL). The aqueous layer was extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (5 mL), dried over Na2SO4 and concentrated under reduced pressure. The product was purified by column chromatography MeOH / DCM (5%) to afford 32 as an off-white solid (73% yield). 'H NMR (400MHZ, CDC13): 12.33 (brs, 1H), 9.87 (s, 1H), 7.62 (s, 1H), 7.53 (s, 1H), 7.23 (brs, 1H), 5.99(s, 1H), 4.52 (d, J=5.48 Hz, 2H), 3.95-3.92 (m, 2H), 3.32-3.26 (m, 2H), 3.08 (q, J=6.95 Hz, 2H), 3.01-2.94 (m, 1H), 2.39 (d, J= 6.46 Hz, 6H), 2.21 (s, 3H), 1.68-1.64 (m, 4H), 0.84 (t, J= 7.00 Hz, 3H);13C NMR (100 MHz, CDC13): 191.6, 168.9, 151.3, 150.3, 142.9, 142.2, 139.6, 134.0, 125.1, 124.0, 121.7, 110.4, 67.2, 58.4, 41.3, 36.1, 30.3, 29.7, 19.7, 18.7, 15.8, 12.7; ESMS (ESI) [M + H]+found, 426.5 calculated for C24H31N3O4, 426.2. Synthesis of 33a-h is similar as the general procedure for preparation of 30a-o.

[0246]

[0247] Scheme 3. Synthesis of compound 41a-i as final compound.PT / 2026 / 12022

[0248] Procedure for the syntheis of 41a-i

[0249] General Preparation of 36a-i: The precursor compound 34 (1 equiv.) and aniline derivatives 35a-i (lequiv.) were mixed in MeCN. Then the reaction mixture was heated at 80 °C overnight. The mixture was cooled to room temperature. The white solid was filtered to obtain the product 36a-i (90-99%). This product has proceeded to the next reaction without further purification.

[0250] 4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl acetate (36a): Yellow solid, Yield 90%, ESMS (ESI) [M + H]+found, 334.4 calculated for C19H15N3O3, 334.1.

[0251] 4-((3,4-dichlorophenyl)amino)-7-methoxyquinazolin-6-yl acetate (36b): Yellow solid, Yield 96%, ESMS (ESI) [M + H]+found, 378.2 calculated for C17H13CI2N3O3, 378.0.

[0252] 4-((3-chlorophenyl)amino)-7-methoxyquinazolin-6-yl acetate (36c): Yellow solid, Yield 98%, ESMS (ESI) [M + H]+found, 344.3 calculated for C17H14CIN3O3, 344.1.

[0253] 4-((4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl acetate (36d): Off white solid, Yield 99%, ESMS (ESI) [M + H]+found, 328.3 calculated for C17H14FN3O3, 328.1.

[0254] 4-((2,4-difluorophenyl)amino)-7-methoxyquinazolin-6-yl acetate (36e): Off white solid, Yield 96%, ESMS (ESI) [M + H]+found, 346.4 calculated for C17H13F2N3O3, 346.1.

[0255] 4-((3-bromophenyl)amino)-7-methoxyquinazolin-6-yl acetate (36f): Yellow solid, Yield 91%, ESMS (ESI) [M + H]+found, 388.3 calculated for C17H14BrN3O3, 388.0.

[0256] 7-methoxy-4-((3-(trifluoromethyl)phenyl)amino)quinazolin-6-yl acetate (36g): Off white solid, Yield 93%, ESMS (ESI) [M + H]+found, 378.4 calculated for C18H14F3N3O3, 378.1.

[0257] 4-((3-bromo-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl acetate (36h): Yellow solid, Yield 96%, ESMS (ESI) [M + 3] found, 408.3 calculated for C17H13BrFN3O3, 408.0.

[0258] 4-((3-chloro-2,4-difluorophenyl)amino)-7-methoxyquinazolin-6-yl acetate (36i): Off white solid, Yield 95%, ESMS (ESI) [M + H]+found, 380.4 calculated for C17H12CIF2N3O3, 380.1.

[0259] Preparation of compound 37a-iPT / 2026 / 12022

[0260] Then the white solid was dissolved in a mixture of the corresponding solid 36a-i (1 g, 2.77 mmol) and NH3·H2O (2 mL) in MeOH (40 mL). The reaction mixture was heated up to 75 °C for 30 minutes. The sediment was filtered under vacuum followed by washing the sediment with methanol. It was dried under a vacuum for 1 day to get the solid 37a-i (60-79%).

[0261] 4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-ol (37a): White solid, Yield 60%, ESMS (ESI) [M + H]+found, 292.3 calculated for C17H13N3O2, 292.1

[0262] 4-((3,4-dichlorophenyl)amino)-7-methoxyquinazolin-6-ol (37b): White solid, Yield 74%, ESMS (ESI) [M + H]+found, 336.3 calculated for C15H11CI2N3O2, 336.0

[0263] 4-((3-chlorophenyl)amino)-7-methoxyquinazolin-6-ol (37c): White solid, Yield 68%, ESMS (ESI) [M + H]+found, 302.3 calculated for C15H12CIN3O2, 302.1.

[0264] 4-((4-fluorophenyl)amino)-7-methoxyquinazolin-6-ol (37d): White solid, Yield 79%, ESMS (ESI) [M + H]+found, 286.4 calculated for C15H12FN3O2, 286.1.

[0265] 4-((2,4-difluorophenyl)amino)-7-methoxyquinazolin-6-ol (37e): White solid, Yield 73%, ESMS (ESI) [M + H]+found, 304.3 calculated for C15H11F2N3O2, 304.1.

[0266] 4-((3-bromophenyl)amino)-7-methoxyquinazolin-6-ol (37f): White solid, Yield 69%, ESMS (ESI) [M + H]+found, 346.3 calculated for C15H12BrN3O2, 346.0.

[0267] 7-methoxy-4-((3-(trifluoromethyl)phenyl)amino)quinazolin-6-ol (37g): White solid, solid, Yield 47%, ESMS (ESI) [M + H]+found, 336.3 calculated for C16H12F3N3O2, 336.1.

[0268] 4-((3-bromo-4-fluorophenyl)amino)-7-methoxyquinazolin-6-ol (37h): White solid, solid, Yield 74%, ESMS (ESI) [M + 3] found, 366.3 calculated for C15H11BrFN3O2, 366.0.

[0269] 4-((3-chloro-2,4-difluorophenyl)amino)-7-methoxyquinazolin-6-ol (37i): Off white solid, Yield 67%, ESMS (ESI) [M + H]+found, 338.4 calculated for C15H10ClF2N3O2, 338.1.

[0270] Procedure for the preparation 38a-i (40-71%) is as similar of general procedure of 27a-e.

[0271] 6-(2-(2-bromoethoxy)ethoxy)-N-(3-ethynylphenyl)-7-methoxyquinazolin-4-amine (38a): White semisolid, Yield 61%, 'H NMR (400MHZ, DMSO-d6): 9.47 (s, 1H), 8.51 (s, 1H), 7.99 (t, J=1.70 Hz, 1H), 7.91-7.89 (m, 1H), 7.86 (s, 1H), 7.40 (t, J=8.00 Hz, 1H), 7.22-7.20 (m, 2H), 4.32-4.29 (m, 2H),PT / 2026 / 12022

[0272] 4.19 (s, 1H), 3.94-3.91 (m, 5H), 3.88-3.85 (m, 2H), 3.66-3.63 (m, 2H);13C NMR (100 MHz, DMSO-d6): 156.7, 154.9, 153.1, 148.5, 147.2, 140.2, 129.4, 126.9, 125.2, 123.1, 122.2, 109.3, 107.6, 103.3, 83.9, 81.0, 71.0, 68.9, 68.8, 56.7, 32.7; ESMS (ESI) [M + 3] found, 444.4 calculated for C21H20BrN3O3, 442.1,

[0273] 6-(2-(2-bromoethoxy)ethoxy)-N-(3,4-dichlorophenyl)-7-methoxyquinazolin-4-amine (38b): White semisolid, Yield 71%, 'H NMR (400MHZ, DMSO-d6)): 9.55 (s, 1H), 8.54 (s, 1H), 8.25 (d, J=2.48 Hz, 1H), 7.89 (dd, J= 2.48, 8.86 Hz, 1H), 7.83 (s, 1H), 7.62 (d, J=8.86 Hz, 1H), 7.22 (s, 1H), 4.32-4.29 (m, 2H), 3.95-3.92 (m, 5H), 3.89-3.86 (m, 2H), 3.66 (t, J= 5.74 Hz, 2H);13C NMR (100 MHz, DMSO-d6): 156.3, 155.0, 158.0, 148.6, 147.5, 140.3, 131.1, 130.7, 124.8, 123.2, 122.2, 109.3, 107.7, 103.1, 71.1, 68.9, 68.8, 56.4, 32.7; ESMS (ESI) [M + H]+found, 486.4 calculated for C19H18BrCl2N3O3, 486.0.

[0274] 6-(2-(2-bromoethoxy)ethoxy)-N-(3-chlorophenyl)-7-methoxyquinazolin-4-amine (38c): White semisolid, Yield 67%, 'H NMR (400MHZ, DMSO-d6)): 9.52 (s, 1H), 8.54-8.53 (m, 1H), 8.04 (t,.7=2.01 Hz, 1H), 7.86 (s, 1H), 7.83 (s, 1H), 7.83-7.81 (m, 1H), 7.42 (t, J= 8.10 Hz, 1H), 7.22 (s, 1H), 7.16-7.14 (m, 1H), 4.32-4.29 (m, 2H), 3.95-3.92 (m, 5H), 3.89-3.86 (m, 2H), 3.67-3.64 (m, 2H);13C NMR (100 MHz, DMSO-d6): 156.5, 154.9, 153.2, 148.6, 147.5, 141.6, 133.2, 130.5, 123.2, 121.6, 120.6, 109.3, 107.8, 103.2, 71.0, 68.9, 68.8, 56.4, 32.7; ESMS (ESI) [M + 3] found 452.4 calculated for C19H19BrClN3O3, 452.0.

[0275] 6-(2-(2-bromoethoxy)ethoxy)-N-(4-fluorophenyl)-7-methoxyquinazolin-4-amine (38d): White semisolid, Yield 64%, 'H NMR (400MHZ, DMSO-d6)): 9.48 (brs, 1H), 8.44 (s, 1H), 7.85 (s, 1H), 7.80-7.77 (m, 2H), 7.26-7.20 (m, 3H), 4.31-4.29 (m, 2H), 3.95-3.92 (m, 5H), 3.89-3.86 (m, 2H), 3.67-3.64 (m, 2H);13C NMR (100 MHz, DMSO-de): 156.3, 155.0, 153.0, 148.6, 140.3, 131.1, 130.7, 124.8, 123.1, 122.0, 109.3, 107.7, 103.1, 71.1, 68.9, 68.8, 56.4, 32.7;19F NMR (376 MHz, DMSO-d6): - 119.23; ESMS (ESI) [M + 3] found 438.4 calculated for C19H19BrFN3O3, 438.0.

[0276] 6-(2-(2-bromoethoxy)ethoxy)-N-(2,4-difluorophenyl)-7-methoxyquinazolin-4-amine (38e): White semisolid, Yield 41%, 'H NMR (400MHZ, DMSO-d6)): 9.47 (brs, 1H), 8.35-8.32 (m, 1H), 7.84 (s, 1H), 7.59-7.53 (m, 1H), 7.40-7.35 (m, 1H), 7.20 (s, 1H), 7.18-7.13 (m, 1H), 4.29-4.27 (m, 2H), 3.95(s, 3H), 3.94-3.91 (m, 2H), 3.89-3.86 (m, 2H), 3.67-3.64 (m, 2H);13C NMR (100 MHz, DMSO-d6): 172.5, 157.9, 154.9, 153.4, 148.5, 146.8, 130.0, 111.8 (d, J= 18.44 Hz), 116.7, 108.9, 107.3, 105.3, 103.3, 79.6, 71.0, 68.9, 68.8, 56.4, 32.7; 19F NMR (376 MHz, DMSO-d6): -119.23; ESMS (ESI) [M + 3] found 456.4 calculated for C19H18BrF2N3O3, 456.4.

[0277] 6-(2-(2-bromoethoxy)ethoxy)-N-(3-bromophenyl)-7-methoxyquinazolin-4-amine (38f): White semisolid, Yield 70%, 'H NMR(400MHZ, DMSO-d6)): 9.51 (s, 1H), 8.53 (s, 1H), 8.15 (t, J=1.90 Hz,PT / 2026 / 12022

[0278] 1H), 7.90-7.88 (m, 1H), 7.86 (s, 1H), 7.36 (t, J= 8.09 Hz, 1H), 7.29-7.27 (m, 1H), 7.22 (s, 1H), 4.32-4.30 (m, 2H), 3.95-3.92 (m, 5H), 3.89-3.86 (m, 2H), 3.67-3.64 (m, 2H);13C NMR(100 MHz, DMSO-d6): 156.5, 154.9,153.1, 148.6, 147.4, 141.7, 130.8, 126.1, 124.5, 121.7, 121.0, 109.3, 107.8, 103.2, 71.0, 68.9, 68.8, 56.4, 32.7; ESMS (ESI) [M + 3] found 452.4 calculated for C19H19BrClN3O3, 452.0.

[0279] 6-(2-(2-bromoethoxy)ethoxy)-7-methoxy-N-(3-(trifluoromethyl)phenyl)quinazolin-4-amine (38g): White semisolid, Yield 58%, 'H NMR(400MHZ, DMSO-d6)): 9.51 (s, 1H), 8.53 (s, 1H), 8.15 (t, J=1.90 Hz, 1H), 7.90-7.88 (m, 1H), 7.86 (s, 1H), 7.36 (t, J= 8.09 Hz, 1H), 7.29-7.27 (m, 1H), 7.22 (s, 1H), 4.32-4.30 (m, 2H), 3.95-3.92 (m, 5H), 3.89-3.86 (m, 2H), 3.67-3.64 (m, 2H);13C NMR (100 MHz, DMSO-d6): 172.5, 156.6, 155.0, 153.0, 148.6, 147.4, 140.9, 130.1, 129.7 (d, J= 31.83 Hz), 125.8, 123.4, 119.8 (d, J= 3.54 Hz), 118.2 (d, J= 4.08 Hz), 109.3, 107.7, 103.2, 71.06, 68.9, 68.8, 56.4, 32.7;

[0280] ESMS (ESI) [M + 3] found 488.4 calculated for C19H19BrF3N3O3, 488.1

[0281] N-(3-bromo-4-fluorophenyl)-6-(2-(2-bromoethoxy)ethoxy)-7-methoxyquinazolin-4-amine (38h):

[0282] White semisolid, Yield 54%, 'H NMR (400MHZ, DMSO-d6): 9.52 (s. 1H), 8.51 (s, 1H), 8.21 (dd, J= 2.57, 6.35 Hz, 1H), 7.89-7.83 (m, 2H), 7.42 (t, J= 8.20 Hz, 1H), 7.22 (s, 1H), 4.31-4.29 (m, 2H), 3.95-3.92 (m, 5H), 3.89-3.86 (m, 2H), 3.67-3.64 (m, 2H);13C NMR (100 MHz, DMSO-d6): 172.5, 156.5, 155.9, 154.9, 153.5, 153.1, 148.6, 147.3, 137.4 (d, J= 3.52 Hz), 126.6, 123.5 (d, J= 6.79 Hz), 116.8 (d, J= 22.93 Hz), 109.2, 107.8 (d, J= 4.53 Hz), 103.2, 71.1, 68.9, 68.8, 56.4, 32.7; ESMS (ESI) [M + H]+found, 514.3 calculated for C19H18Br2FN3O3, 514.0.

[0283] 6-(2-(2-bromoethoxy)ethoxy)-N-(3-chloro-2,4-difluorophenyl)-7-methoxyquinazolin-4-amine (38i): White semisolid, Yield 40%, 'H NMR (400MHZ, DMSO-d6): 9.62 (s. 1H), 8.38 (s, 1H), 7.95-7.82 (m, 1H), 7.60-7.54 (m, 1H), 7.41-7.37 (m, 1H), 7.21 (s, 1H), 4.29-4.27 (m, 2H), 3.95(s, 3H), 3.93-3.91 (m, 5H), 3.88-3.85 (m, 2H), 3.66-3.63 (m, 2H);13C NMR (100 MHz, DMSO-d6): 154.4 (d, J= 20.88 Hz), 155.1, 154.8, 153.3, 148.6, 147.0, 127.4 (d, J= 8.05 Hz), 124.8 (d, J= 9.84 Hz), 112.2 (dd, J= 18.16, 4.83 Hz), 109.3, 108.9, 107.4, 103.3, 71.0, 68.9, 68.7, 56.4, 55.3, 32.6; ESMS (ESI) [M + H]+found, 488.4 calculated for C19H17BrClF2N3O3, 488.0.

[0284] The procedure for the preparation 39a-i (64-84%) is similar to the general procedure of 28a-e.

[0285] / e / 7-butyl4-(2-(2-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazine-l-carboxylate (39a): Pale yellow liquid, Yield 84%,XH NMR (400MHZ, DMSO-d6): 9.47 (s. 1H), 8.51 (s, 1H), 8.00-7.99 (m, 1H), 7.92-7.89 (m, 1H), 7.86 (s, 1H), 7.41 (t, J= 8.02 Hz, 1H), 7.23-7.20 (m, 2H), 4.31-4.28 (m, 2H), 4.20 (s, 1H), 3.95 (s, 3H), 3.86-3.84 (m, 2H), 3.65 (t, J= 5.73 Hz, 2H), 3.28-3.26 (m, 4H), 2.56-2.53 (m, 2H), 2.39-2.38 (m, 2H), 1.39 (s, 9H);13C NMR (100 MHz, DMSO-d6): 156.6, 154.9, 154.3, 148.6, 147.5, 140.3, 129.4, 126.8, 125.2,PT / 2026 / 12022

[0286] 123.0, 122.2, 109.3, 107.8, 103.1, 83.9, 81.0, 79.2, 68.9, 68.7, 57.5, 56.3, 53.3, 28.5; ESMS (ESI) [M + H]+found, 548.6 calculated for C30H37N5O5, 548.3.

[0287] / e / 7-butyl4-(2-(2-((4-((3,4-dichlorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazine-l-carboxylate (39b): Pale yellow liquid, Yield 68%,XH NMR (400MHZ, DMSO-d6): 9.57 (s. 1H), 8.55 (s, 1H), 8.25 (d, J= 2.51Hz, 1H), 7.89 (dd, J= 2.51Hz, 1H), 7.84 (s, 1H), 7.64 (d, J= 8.80 Hz, 1H), 7.23 (s, 1H), 4.30-4.28 (m, 2H), 3.95 (s, 3H), 3.86-3.85 (m, 2H), 3.65 (t, J= 5.66 Hz, 2H), 3.29-3.26 (m, 4H), 2.55-2.53 (m, 2H), 2.38 (brs, 4H), 1.38 (s, 9H);13C NMR (100 MHz, DMSO-d6): 156.3, 155.0, 154.3, 148.7, 147.6, 140.3, 131.1, 130.7,124.7, 123.1, 122.0, 109.4, 107.8, 103.0, 79.2, 68.9, 57.5, 56.4, 53.3, 28.5; ESMS (ESI) [M + H]+found, 592.6 calculated for C28H35Cl2N5O5, 592.2.

[0288] te / 7-butyl4-(2-(2-((4-((3-chlorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazine-l-carboxylate (39c): Pale yellow liquid, Yield 78%, 'H NMR (400MHZ, DMSO-d6): 9.50 (s. 1H), 8.52 (s, 1H), 8.25 (t, J= 2.05 Hz, 1H), 7.84 (s, 1H), 7.82-7.80 (m, 1H), 7.41 (t, J= 8.12 Hz, 1H), 7.21 (s, 1H), 7.15-7.13 (m, 1H), 4.30-4.27 (m, 2H), 3.94 (s, 3H), 3.85-3.83 (m, 2H), 3.64 (t, J= 5.73 Hz, 2H), 3.28-3.25 (m, 4H), 2.54-2.52 (m, 2H), 2.39-2.36 (m, 4H), 1.37 (s, 9H);13C NMR (100 MHz, DMSO-d6): 172.5, 156.5, 154.9, 154.3, 153.1, 148.6, 147.5, 141.6, 132.2, 130.5, 123.1, 121.6, 120.5, 109.3, 107.8, 103.1, 79.2, 68.9, 68.7, 57.5, 56.3, 53.3, 28.5; ESMS (ESI) [M + H]+found, 558.6 calculated for C28H35ClN5O5, 558.2.

[0289] rerr-butyl4-(2-(2-((4-((4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazine-l-carboxylate (39d): Pale yellow liquid, Yield 64%, 'H NMR (400MHZ, DMSO-d6)): 9.47 (brs, 1H), 8.44 (s, 1H), 7.85 (s, 1H), 7.80-7.76 (m, 2H), 7.26-7.21 (m, 2H), 7.19 (s, 1H), 4.29-4.27 (m, 2H), 3.94 (s, 3H), 3.86-3.84 (m, 2H), 3.67-3.64 (m, 2H), 3.30-3.29 (m, 4H), 2.62-2.55 (m, 2H), 2.45 (brs, 4H), 1.38 (s, 9H);13C NMR (100 MHz, DMSO-d6): 161.6, 159.5, 159.0, 153.2, 152.1, 140.9, 129.6 (d, J= 8.20 Hz), 120.2 (d, J= 22.17 Hz), 113.9, 112.5, 107.9, 84.03, 73.7, 73.4, 61.1, 57.9, 53.7, 33.3;19F NMR (376 MHz, DMSO-d6): -114.54; ESMS (ESI) [M + H]+found 542.6 calculated for C28H36FN5O5, 542.3.

[0290] ter / -butyl4-(2-(2-((4-((2,4-difluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazine-l-carboxylate (39e): Pale yellow liquid, Yield 79%, 'H NMR (400MHZ, DMSO-d6)): 9.44 (brs, 1H), 8.34 (s, 1H), 7.82 (s, 1H), 7.59-7.53 (m, 1H), 7.40-7.34 (m, 1H), 7.20 (s, 1H), 7.17-7.12 (m, 1H), 4.27-4.24 (m, 2H), 3.94 (s, 3H), 3.85-3.83 (m, 2H), 3.65-3.62 (m, 2H), 3.27 (brs, 4H), 2.53 (brs, 2H), 2.38 (brs, 4H), 1.38 (s, 9H);13C NMR (100 MHz, DMSO-d6):

[0291] 177.2, 162.5, 159.6, 159.0, 158.3, 153.2, 152.1, 134.7 (d, J= 11.74 Hz), 128.3 (dd, J= 13.26, 3.93 Hz), 116.5 (dd, J= 22.06, 3.96 Hz), 113.7, 109.7 (t, J= 26.56 Hz), 107.9, 83.9, 73.9, 73.3, 62.3, 61.0, 58.1,PT / 2026 / 12022

[0292] 33.3;19F NMR (376 MHz, DMSO-d6): -119.23; ESMS (ESI) [M + H]+found 560.7 calculated for C28H35F2N5O5, 560.3.

[0293] / e / 7-butyl4-(2-(2-((4-((3-bromophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazine-l-carboxylate (39f): Pale yellow liquid, Yield 72%,XH NMR (400MHZ, DMSO-d6): 9.46 (s. 1H), 8.43 (s, 1H), 7.83 (s, 1H), 7.79-7.76 (m, 2H), 7.24-7.20 (m, 1H), 7.18 (s, 1H), 4.28-4.26 (m, 2H), 3.93 (s, 3H), 3.85-3.83 (m, 2H), 3.64 (t, J= 5.59 Hz, 2H), 3.29-3.27 (m, 4H), 2.58-2.55 (m, 2H), 2.43-2.41 (m, 4H), 1.37 (s, 9H);13C NMR (100 MHz, DMSO-d6): 172.5, 159.9, 157.6, 156.8, 156.4, 154.9, 154.7, 154.2, 153.3, 148.6, 148.4, 147.5, 147.3, 141.8, 136.2, 136.1, 130.8, 126.0, 124.8, 124.7, 124.4, 121.6, 120.9, 115.6, 115.3, 109.3, 109.2, 107.8, 107.7, 103.2, 103.0, 79.2, 68.9, 68.8, 68.6, 57.4, 56.3, 56.3, 53.2, 28.5; ESMS (ESI) [M + H]+found, 602.6 calculated for C28H36BrN5O5, 602.2.

[0294] ter / -butyl4-(2-(2-((7-methoxy-4-((3-(trifluoromethyl)phenyl)amino)quinazolin-6-yl)oxy)ethoxy)ethyl)piperazine-l-carboxylate (39g): Pale yellow liquid, Yield 70%, 'H NMR (400MHZ, DMSO-d6): 9.65 (s. 1H), 8.54 (s, 1H), 8.24-8.22 (m, 2H), 7.87 (s, 1H), 7.63 (t, J=7.80 Hz, 2H), 7.44-7.43 (m, 1H), 7.24 (s, 1H), 4.32-4.30 (m, 2H), 3.96 (s, 3H), 3.87-3.85 (m, 2H), 3.65 (t, J= 5.69 Hz, 2H), 3.29-3.26 (m, 4H), 2.56-2.53 (m, 2H), 2.39 (brs, 4H), 1.38 (s, 9H);13C NMR (100 MHz, DMSO-d6): 177.2, 161.2, 159.7, 159.0, 153.4, 152.3, 145.7, 134.7 (d, J= 11.36 Hz), 130.4 (d, J= 38.85 Hz), 124.4, 122.9, 114.1, 112.5, 107.8, 83.9, 73.7, 73.6, 73.4, 62.3, 61.0, 58.0, 33.2;19F NMR (376 MHz, DMSO-d6): -56.39; ESMS (ESI) [M + H]+found, 592.7 calculated for C29H36F3N5O5, 592.3.

[0295] ter / -butyl4-(2-(2-((4-((3-bromo-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazine-l-carboxylate (39h): Pale yellow liquid, Yield 68%, 'H NMR (400MHZ, DMSO-d6): 9.51 (s. 1H), 8.51 (s, 1H), 8.21 (dd, J= 2.61 Hz, 6.40 Hz, 1H), 7.89-7.85 (m, 1H), 7.83 (s, 1H), 7.42 (t, J= 8.83 Hz, 1H), 7.22 (s, 1H), 4.29-4.27 (m, 2H), 3.95 (s, 3H), 3.86-3.83 (m, 2H), 3.65 (t, J= 5.72 Hz, 2H), 3.29-3.26 (m, 4H), 2.55-2.53 (m, 2H), 2.39 (brs, 4H), 1.38 (s, 9H);13C NMR (100 MHz, DMSO-d6): 177.3, 161.2, 159.6, 159.0, 158.1 (d, J= 30.60 Hz), 153.3, 152.2, 142.3, 131.3, 128. l(d, J= 7.63 Hz), 121.5 (d, J= 24.35 Hz), 113.9, 112.4 (d, J= 24.35 Hz), 107.8, 83.9, 73.7, 73.4, 62.3, 61.1, 58.0, 53.8, 32.2;19F NMR (376 MHz, DMSO-d6): -110.75; ESMS (ESI) [M + H]+found, 620.6 calculated for C28H35BrFN5O5, 620.2.

[0296] ter / -butyl4-(2-(2-((4-((3-chloro-2,4-difluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazine-l-carboxylate (39i): Pale yellow liquid, Yield 83%, 'H NMR (400MHZ, DMSO-d6): 9.60 (s. 1H), 8.38-8.31 (m, 1H), 7.81 (s, 1H), 7.59-7.54(m, 1H), 7.42-7.37 (m, 1H), 7.22 (s, 1H), 4.27-4.25 (m, 2H), 3.95 (s, 3H), 3.85-3.83 (m, 2H), 3.64 (t, J= 5.65 Hz, 2H), 2.53 (brs, 2H), 2.38 (brs, 4H), 1.38 (s, 9H);13C NMR (100 MHz, DMSO-d6): 162.2, 159.7, 159.0, 158.2(d,PT / 2026 / 12022

[0297] J= 7.13 Hz), 153.3, 152.2, 132.2(d, J= 7.00 Hz), 129.7, 117.1 (d, J= 21.25 Hz), 113.7, 112.4, 107.9, 83.9, 73.6, 73.3, 62.3, 61.1, 58.1, 33.2;19F NMR (376 MHz, DMSO-d6): -111.6, 112.4; ESMS (ESI) [M + H]+found, 594.6 calculated for C28H34CIF2N5O5, 594.2.

[0298] The procedure for the preparation 40a-i (61-89%) is similar to the general procedure of 15a-b.

[0299] N-(3-ethynylphenyl)-7-methoxy-6-(2-(2-(piperazin-l-yl)ethoxy)ethoxy)quinazolin-4-amine (40a):

[0300] White semisolid, Yield 61%, ESMS (ESI) [M + H]+found, 448.6 calculated for C25H29N5O3, 448.2.

[0301] N-(3,4-dichlorophenyl)-7-methoxy-6-(2-(2-(piperazin-l-yl)ethoxy)ethoxy)quinazolin-4-amine (40b): White semisolid, Yield 75%, ESMS (ESI) [M + H]+found, 492.5 calculated for C23H27CI2N5O3, 492.2.

[0302] N-(3-chlorophenyl)-7-methoxy-6-(2-(2-(piperazin-l-yl)ethoxy)ethoxy)quinazolin-4-amine (40c):

[0303] Off white semisolid Yield 77%, ESMS (ESI) [M + H]+found, 458.5 calculated for C23H28CIN5O3, 458.2 N-(4-fluorophenyl)-7-methoxy-6-(2-(2-(piperazin-l-yl)ethoxy)ethoxy)quinazolin-4-amine (40d):

[0304] White semisolid, Yield 86%, ESMS (ESI) [M + H]+found, 442.5 calculated for C23H28FN5O3, 442.2.

[0305] N-(2,4-difluorophenyl)-7-methoxy-6-(2-(2-(piperazin-l-yl)ethoxy)ethoxy)quinazolin-4-amine (40e): White semisolid, Yield 80%, ESMS (ESI) [M + H]+found, 460.5 calculated for C23H27F2N5O3, 460.2.

[0306] N-(3-bromophenyl)-7-methoxy-6-(2-(2-(piperazin-l-yl)ethoxy)ethoxy)quinazolin-4-amine (40f):

[0307] White semisolid, Yield 74%, ESMS (ESI) [M + H]+found, 502.5 calculated for C23H28BrNsO3, 502.1.

[0308] 7-methoxy-6-(2-(2-(piperazin-l-yl)ethoxy)ethoxy)-N-(3-(trifluoromethyl)phenyl)quinazolin-4-amine (40g): White semisolid, Yield 76%, ESMS (ESI) [M + H]+found, 492.6 calculated for C24H28F3N5O3, 492.2.

[0309] N-(3-bromo-4-fluorophenyl)-7-methoxy-6-(2-(2-(piperazin-l-yl)ethoxy)ethoxy)quinazolin-4-amine (40h): White semisolid, Yield 86%, ESMS (ESI) [M + H]+found, 520.5 calculated for C23H27BrFN5O3, 520.1.

[0310] N-(3-chloro-2,4-difluorophenyl)-7-methoxy-6-(2-(2-(piperazin-l-yl)ethoxy)ethoxy)quinazolin-4-amine (40i): White semisolid, Yield 89%, ESMS (ESI) [M + H]+found, 494.5 calculated for C23H26ClF2N5O3, 494.2.

[0311] Synthesis of 41a-i is similar to the general procedure for preparation of 30a-o

[0312] Series 1

[0313] {4'-((4-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-PT / 2026 / 12022

[0314] pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide}( S-023-0983): Isolated as light yellow solid (yield 80 %, mp 133°C). 'H NMR (400MHZ, DMSO-d6):8 11.46 (s, 1H), 9.56 (s, 1H), 8.50 (s, 1H), 8.32 (s, 1H), 8.20-8.17 (m, 1H), 8.13-8.11 (m, 1H), 7.81-7.79 (m, 1H), 7.58-7.56 (m, 2H), 7.47-7.42 (m, 1H), 7.39-7.34 (m, 3H), 7.23 (d, J= 1.51 Hz, 1H), 7.20 (s, 2H), 5.86 (s, 1H), 4.30 (d,.7=4,90 Hz, 2H), 4.20-4.17 (2H, m), 3.94 (s, 3H), 3.83 (d, J= 9.51 Hz, 2H), 3.48 (s, 2H), 3.27-3.22 (m, 2H), 3.11-2.99 (m, 8H), 2.24 (s, 3H), 2.21 (s, 3H), 2.11 (s, 3H), 1.67 (d, J=10.91 Hz, 2H), 1.57-1.48 (m, 2H), 0.85 (t, J= 6.96Hz, 3H);13C NMR (100MHz, DMSO-d6): 169.5, 163.5, 156.4, 155.0, 153.1, 152.3, 149.3, 148.8, 147.5, 143.3, 140.1, 137.5 (d, J= 17.041 Hz),, 133.1, 130.0, 129.9, 126.9, 124.0, 122.8 (d, J= 6.06 Hz), 116.9 (d, J= 22.05 Hz), 107.8, 79.6, 67.6, 66.8, 62.2, 58.3, 56.4, 53.4, 53.1, 52.6, 35.4, 30.8, 19.4, 18.7, 15.0, 13.2;19F NMR (376MHz, DMSO-d6): -123.32; HRMS (ESI) [M + H]+found, 931.4430 calculated for C52H60ClFN8O5, 931.4432; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 17.483 min, purity = 98.78%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nM.

[0315] {4'-((4-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide} (S-023-0986, 30b): Isolated as pale yellow solid (yield 78 %, mp 168°C). 'H NMR (400MHZ, DMSO-d6): S 11.46 (s, 1H), 9.54 (s, 1H), 8.50 (s, 1H), 8.19 (t,.7=4,90 Hz, 1H), 8.12 (dd, J= 2.62 Hz, 6.86 Hz, 1H), 7.84-7.79 (m, 2H), 7.57 (d, J= 8.17 Hz, 2H), 7.44 (d, J= 9.09 Hz, 1H), 7.40-7.35 (m, 3H), 7.23 (d, J= 1.42 Hz, 1H), 7.20 (s, 1H), 5.85 (s, 1H), 4.30 (d, J= 4.90 Hz, 2H), 4.24 (t, J= 5.97Hz, 2H), 3.93 (s, 3H), 3.83 (d, J= 10.44 Hz, 2H), 3.48 (s, 2H), 3.28-3.22 (m, 2H), 3.11-2.99 (m, 3H), 2.83-2.80 (m, 2H), 2.57 ( brs, 4H), 2.42 (brs, 4H), 2.2 5(s, 3H), 2.21 (s, 3H), 2.10 (s, 3H), 1.67 (d, J=10.79 Hz, 3H), 1.57-1.48 (m, 2H), 0.83 (t, J= 6.89 Hz, 3H);13C NMR (100MHz, DMSO-d6): 169.5, 163.5, 156.5, 155.0, 153.1, 152.4, 150.0, 149.3, 148.7, 147.5, 143.2, 140.1, 139.0, 138.0, 137.5 (d, J= 21.27 Hz), 133.1, 129.9, 126.8, 124.0, 122.8 (d, J= 6.71 Hz), 122.1, 121.3, 119.2 (d, J= 18.36 Hz), 117.0 (d, J= 21.75 Hz), 109.2, 107.8, 103.1, 67.2, 66.8, 62.6, 58.3, 57.0, 56.4, 53.8, 53.1, 49.1, 35.4, 32.0, 30.8, 19.4, 18.6, 15.0, 13.1;19F NMR (376MHz, DMSO-d6): -123.29; HRMS (ESI): [M + H]+found, 917.4397 calculated for C51H58ClFN8O5, 917.4275; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 17.261 min, purity = 95.10%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nM.

[0316] {4'-((4-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperi din-1-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide} (S-023-0984, 30c): Isolated as whitePT / 2026 / 12022

[0317] solid (yield 65 %, mp 178°C). 'H NMR (400MHZ, DMSO-d6): 5 11.47 (s, 1H), 9.54 (s, 1H), 8.49 (s, 1H), 8.20-8.18 (m, 1H), 8.12-8.10 (m, 1H), 7.88 (s, 1H), 7.81-7.77 (m, 2H), 7.59 (d, J=8.13 Hz, 2H), 7.45 (d, J= 9.08 Hz, 1H), 7.40 (d, J= 8.17 Hz, 3H), 7.24-7.22 ( m, 2H), 5.86 (s, 1H), 4.61-4.60 (m, 1H), 4.30 (d, J= 4.85 Hz, 2H), 3.94 (s, 3H), 3.83 (d, J= 10.68 Hz, 2H), 3.56 (s, 2H), 3.28-3,23(m, 2H), 3.12-3.00 (m, 3H), 2.79-2.76 (m, 2H), 2.34-2.30 (m, 2H), 2.25 (s, 3H), 2.21 (s, 3H), 2.10 (s, 3H), 2.05-2.03 (m, 2H), 1.77-1.65 (m, 4H), 1.57-1.48 (m, 2H), 0.85 (t, J= 7.01 Hz, 3H);13C NMR (100MHz, DMSO-d6): 169.5, 163.5, 156.6, 156.0, 153.2, 152.5, 150.0, 149.3, 147.6, 147.0, 143.2, 140.1, 139.0, 138.0, 137.5, 137.2 (d, J= 3.29 Hz), 133.1, 129.9, 126.9, 124.2, 123.3, 123.2 (d, J= 6.68 Hz), 122.1, 121.3, 119.3 (d, J= 18.37 Hz), 117.1 (d, J=21.77 Hz), 109.2, 108.2, 107.8, 105.9, 74.4, 66.8, 63.3, 62.1, 58.3, 56.4, 50.6, 49.1, 41.6, 35.4, 31.1, 30.8, 19.4, 18.6, 15.0, 13.2;19F NMR (376MHz, DMSO-d6): -123.12; HRMS (ESI) [M + H]+found, 888.4030 calculated for C50H55ClFN7O5, 888.4010; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 17.661 min, purity = 98.25%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nM.

[0318] {4'-((4-(((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)methyl)piperi din-1-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-023-0985, 30d): Isolated as white solid (yield 68 %, mp 143°C). 'H NMR (400MHZ, DMSO-d6): 8 11.46 (s, 1H), 9.53 (s, 1H), 8.49 (s, 1H), 8.19 (t, J=4.88 Hz 1H), 8.11 (dd, J= 2.59 Hz, 6.87 Hz, 1H), 7.82-7.79 (m, 2H), 7.58 (d, J=8.09 Hz, 2H), 7.44 (d, J= 9.12 Hz, 1H), 7.40-7.36 (m, 3H), 7.23(d, J=1.15 Hz, 1H), 7.20 (s, 1H), 5.85 (s, 1H), 4.30 (d, J= 4.91 Hz, 2H), 4.01-3.99 (m, 2H), 3.94 (s, 3H), 3.82 (d, J= 10.51 Hz, 2H), 3.50 (s, 2H), 3.28-3.22 (m, 2H), 3.11-2.99 (m, 3H), 2.90 (d, J= 10.29 Hz, 2H), 2.25 (s, 3H), 2.21 (s, 3H), 2.10 (s, 3H), 2.05-1.99 (m, 2H), 1.84 (d, J=\ 1.09 Hz, 3H), 1.66 (d, J=\ 1.20 Hz, 2H), 1.56-1.47 (m, 2H), 1.57-1.47 (m, 2H), 1.43-1.37 (m, 2H, 0.83 (t, J= 7.01 Hz, 3H);13C NMR (100MHz, DMSO-d6): 169.5, 163.5, 156.5, 155.0, 153.1, 150.0, 149.3, 148.9, 147.4, 143.2, 140.1, 138.9, 137.4 (d,.7=2.54 Hz), 133.1, 129.9, 126.8, 124.0, 123.3, 122.9, 122.8, 122.1, 121.2, 119.2 (d, J= 18.31 Hz), 117.0 (d, J=21.64 Hz),, 109.2, 107.8, 102.8, 79.6, 73.8, 66.8, 62.6, 58.3, 56.4, 53.3, 41.6, 36.0, 35.4, 30.8, 29.4, 29.3, 19.4, 18.7, 15.0, 13.2;19F NMR (376MHz, DMSO-d6): -123.29; HRMS (ESI) [M + H]+found, 902.41827 calculated for C51H57ClFN7O5, 902.4167; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 17.545 min, purity = 97.10%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nM.

[0319] {4'-((3-(((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)methyl)piperi din-1-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-023-0987, 30e): Isolated as white solid (yield 67 %, mp 160°C). 'H NMR (400MHZ, DMSO-d6): 5 11.47 (s, 1H), 9.52 (s, 1H), 8.49(s,PT / 2026 / 12022

[0320] 1H), 8.20-8.18 (m, 1H), 8.12 (dd, J= 2.60 Hz, 6.84 Hz, 1H), 7.83-7.79 (m, 2H), 7.56 (d, J=8.13 Hz, 2H), 7.44 (d, J= 9.09 Hz, 1H), 7.41-7.36 (m, 3H), 7.23 (d, J= 1.30 Hz, 1H), 7.18 (s, 1H), 5.85 (s, 1H), 4.30 (d,.7= 4.85 Hz, 2H), 4.02 (d, J= 6.04 Hz, 2H), 3.86-3.81 (m, 5H), 3.52 (s, 3H), 3.28-3.22 (m, 2H), 3.11-2.96 (m, 4H), 2.76-2.73 (m, 1H), 2.25 (s, 3H), 2.21 (s, 3H), 2.16-2.13 (m, 1H), 2.10 (s, 3H), 2.07- 1.92 (m,, 3H), 1.86-1.84 (m, 1H), 1.68-1.65 (m, 3H), 1.58-1.48 (m, 3H), 0.84 (t, J= 6.92 Hz, 3H);13C NMR (100MHz, DMSO-d6): 169.5, 163.5, 156.5, 155.0, 153.1, 150.0, 149.3, 148.8, 147.4, 143.2, 140.1, 139.0, 137.4 (d, J= 25.46 Hz), 133.1, 129.8, 126.8, 124.0, 123.3, 122.8 (d, J= 6.66 Hz), 122.1, 121.3, 119.2 (d, J= 18.34 Hz), 116.9 (d, J= 21.64 Hz), 109.2, 107.8, 107.7, 103.1, 72.1, 66.8, 62.7, 58.3, 57.0, 56.3, 54.2, 41.7, 36.4, 35.4, 30.8, 27.5, 19.4, 18.6, 15.0, 13.1;19F NMR (376MHz, DMSO-d6): -123.28; HRMS (ESI): [M + H]+found, 902.4185 calculated for C51H57ClFN7O5, 902.4167; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5 pm); retention time = 17.745 min, purity = 97.26%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nM.

[0321] 4'-((3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azeti din-1-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide(S-024-0560, 30f): Isolated as white solid (yield 25 %, mp 170°C). 'H NMR (400MHZ, CDCk & CD3OD): S 8.54 (s, 1H), 7.92-7.90 (m, 1H), 7.62-7.61 (m, 1H), 7.53-7.51 (m, 2H), 7.40 (brs, 1H), 7.35-7.34 (m, 3H), 7.28-7.27 (m, 1H), 7.22-7.14 (m, 3H), 6.00 (s, 1H), 4.51 (s, 2H), 4.04-4.03 (m, 5H), 3.97-3.94 (m, 2H), 3.84-3.81 (m, 2H), 3.41-3.32 (m, 5H), 3.13-3.03 (m, 3H), 2.42 (s, 3H), 2.32 (s, 3H), 2.23 (s, 3H), 2.06-2.00 (m, 2H), 1.72-1.69 (m, 2H), 0.89 (m, 3H);13C NMR (125MHz, CDCk & CD3OD): 166.5, 164.6, 153.3, 151.7, 147.1, 146.4, 142.3, 137.9, 135.8, 133.3, 129.2, 127.1, 124.6, 124.0, 122.5, 120.8 (d, J= 30.50 Hz), 116.3 (d, J= 19.03 Hz), 110.1, 109.1, 107.2, 102.4, 67.2, 62.7, 60.6, 58.3, 56.2, 41.7, 35.6, 30.4, 30.2, 29.3, 19.5, 18.4, 14.5, 13.9, 12.6;19F NMR (376MHz, CDCI3 & CD3OD): -76.32; HRMS (ESI) [M + H]+found, 860.3708 calculated for C48H51ClFN7O5, 860.3697; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 13.713 min, purity = 95.82%; eluent A (H2O+ 0.1% Formic acid): eluent B (Acetonitrile), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0322] 4'-((4-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethyl)piperi din-1-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-024-0562, 30g): Isolated as white solid (yield 23 %, mp 125°C). 'H NMR (400MHZ, DMSO-d6): 5 11.47 (brs, 1H), 9.66 (s, 1H), 8.49 (s, 1H), 8.20-8.14 (m, 2H), 7.88 (s, 1H), 7.85-7.81 (m, 1H), 7.56 (d, J= 8.17 Hz, 2H), 7.44 (d,.7= 9.07 Hz, 1H), 7.40-7.39 (m, 1H), 7.35 (d, J= 9.07 Hz, 2H), 7.22-7.21 (m, 1H), 7.19 (s, 1H), 5.85 (s, 1H), 4.29 (d, J= 5.08 Hz, 2H), 4.18 (t, J= 6.40 Hz, 2H), 3.93 (s, 3H), 3.84-3.81 (m, 2H), 3.46 (s, 2H), 3.27-P 172026 / 12022

[0323] 3.22 (m, 2H), 3.11-3.06 (m, 2H), 3.04-2.99 (m, 2H), 2.84-2.81 (m, 2H), 2.24 (s, 3H), 2.20 (s, 3H), 2.10 (s, 3H), 1.97-1.91 (m, 2H), 1.82-1.72 (m, 4H), 1.67-1.65 (m, 2H), 1.56-1.48 (m, 3H), 1.28-1.25 (m, 2H), 0.83 (m, J= 7.00 Hz, 3H);13C NMR (125MHz, DMSO-d6): 169.6, 163.5, 156.5, 155.0, 153.1, 150.1, 149.4, 148.9, 147.4, 143.2, 140.1, 138.9, 138.4, 137.4 (d, J= 26.06 Hz), 133.1, 129.8, 126.8, 124.0, 123.3, 122.9 (d, J= 7.15 Hz), 122.1, 121.3, 116.9 (d, J= 21.58 Hz), 109.3, 107.8 (d, J= 23.36 Hz), 103.1, 67.3, 66.8, 62.6, 58.3, 56.4, 53.7, 41.7, 35.8, 35.4, 32.8, 32.4, 30.8, 29.4, 19.4, 18.6, 15.0, 14.4, 13.2;19F NMR (376MHz, DMSO-d6): -123.37; HRMS (ESI) [M + H]+found, 916.4307 calculated for C52H59ClFN7O5, 916.4323; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 14.107 min, purity = 98.44 %; eluent A (H2O+ 0.1% Formic acid): eluent B (Acetonitrile), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0324] 4'-((4-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)piperidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide(S-024-0564, 30h): Isolated as white solid (yield 17 %, mp 75°C). 'H NMR (400MHZ, DMSO-d6): 5 11.5 (brs, 1H), 9.53 (s, 1H), 8.49 (s, 1H), 8.18 (t, J= 4.94 Hz, 1H). 8.18 (dd, J= 2.62, 6.86 Hz, 1H), 7.82-7.78 (m, 2H), 7.59-7.57 (m, 2H), 7.46-7.37 (m, 4H), 7.23-7.20 (m, 2H), 5.85 (s, 1H), 4.30 (m, 2H), 4.15-4.11 (m, 2H), 3.93 (s, 3H), 3.84-3.81 (m, 2H), 3.28-3.22 (m, 3H), 3.17-3.16 (m, 1H), 3.11-3.06 (m, 2H), 3.04-2.99 (m, 1H), 2.89 (s, 2H), 2.24 (s, 3H), 2.21 (s, 3H), 2.10 (s, 3H), 1.86-1.82 (m, 2H), 1.72-1.65 (m, 4H), 1.57-1.46 (m, 3H), 1.42-1.33 (m, 4H), 1.32-1.25 (m, 1H), 1.18-1.11 (m, 1H), 0.83 (t, J= 6.80 Hz, 3H);13C NMR (125MHz, DMSO-d6): 169.6, 163.5, 156.5, 155.0, 153.1, 150.0, 149.4, 148.8, 147.4, 143.2, 140.1, 137.4( d, J= 13.51 Hz),, 126.9, 123.9, 122.7 (d, J= 6.71 Hz), 121.3, 117.1, 109.3, 107.8, 103.0, 69.5, 66.8, 58.3, 56.3, 41.6, 35.4, 29.5, 26.3, 19.4, 18.7, 15.03, 13.2;19F NMR (376MHz, DMSO-d6): -121.45; HRMS (ESI) [M + H]+found, 930.4487 calculated for C53H61ClFN7O5, 930.4480; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 14.389 min, purity = 99.15%; eluent A (H2O+ 0.1% Formic acid): eluent B (Acetonitrile), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0325] 4'-((3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pyrrolidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide(S-024-0566, 30i): Isolated as white solid (yield 20 %, mp 80°C). 'H NMR (400MHZ, DMSO-d6): 5 11.5 (brs, 1H), 9.57-9.54 (m, 1H), 8.52-8.49 (m, 1H), 8.17 (t, J= 5.00 Hz, 1H), 8.11-8.06 (m, 1H), 7.78-7.66 (m, 3H), 7.60 (brs, 1H), 7.47-7.40 (m, 3H), 7.23-7.22 (m, 2H), 5.85 (s, 1H), 5.16 (brs, 1H), 4.29 (d, J= 4.93 Hz, 2H), 3.94 (s, 3H), 3.84-3.81 (m, 1H), 3.27-3.21 (m, 2H), 3.10-2.98 (m, 3H), 2.24 (s, 3H), 2.20 (s, 3H), 2.10 (s, 3H), 1.67-1.64 (m, 2H), 1.55-1.47 (m, 4H), 1.35-1.26 (m, 7H), 0.84-0.81 (m, 3H);13C NMR (125MHz, DMSO-P 172026 / 12022

[0326] d6): 174.0, 169.6, 163.5, 156.5, 155.3, 152.9, 150.0, 143.3, 140.2, 137.1, 133.3, 132.1 (d, J= 14.90 Hz), 127.1, 124.3, 123.4(d, J= 6.83 Hz), 121.3, 119.3 (d, J= 18.56 Hz), 117.0 (d, J= 20.71 Hz), 109.3, 66.8, 58.4, 56.4, 52.8, 35.4, 31.8, 30.9, 22.6, 19.4, 18.7, 15.0, 14.4, 13.2;19F NMR (376MHz, CDCh): -121.65; HRMS (ESI) [M + H]+found, 874.3851 calculated for C49H53CIFN7O5, 874.3854; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5 m); retention time = 13.655 min, purity = 95.46%; eluent A (H2O+ 0.1% Formic acid): eluent B (Acetonitrile), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 300.0 nm.

[0327] {4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl 4-((3'-(((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)carbamoyl)-5'-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4'-methyl-[l,l'-biphenyl]-4-yl)methyl)piperazine-l-carboxylate}( S-023-0982, 30j): Isolated as white solid (yield 70 %, mp 196 °C). 'H NMR (400MHZ, DMSO-d6):5 11.49 (s, 1H), 9.69 (s, 1H), 8.60 (s, 1H), 8.30 (s, 1H), 8.23-8.19 (m, 2H), 7.86-7.82 (m, 1H), 7.63-7.61 (m, 2H), 7.45-7.40 (m, 4H), 7.33 (s, 1H), 7.25 (d, J=1.39Hz, 1H), 5.86 (s, 1H), 4.31 (d, J=4.86 Hz, 2H), 3.93 (s, 3H), 3.84 (d, J= 10.58 Hz, 2H), 3.68 (brs, 2H), 3.60 (s, 2H), 3.49 (brs, 2H), 3.26 (t, J= 10.80Hz, 21.95Hz, 2H), 3.12-3.01(m, 3H), 2.49 (m, 4H), 2.26 (s, 3H), 2.22 (s, 3H), 2.11 (s, 3H), 1.69-1.66 (m, 2H), 1.58-1.49 (m, 2H), 0.85 (t, J= 6.87Hz, 3H);13C NMR (100MHz, DMSO-d6): 169.5, 163.5, 157.2, 156.6, 154.9, 152.9, 152.4, 150.4, 149.9, 149.4, 143.2, 140.4, 140.1, 139.2, 137.5, 137.3 (d, J= 17.07 Hz), 133.1, 130.0, 126.9, 123.5, 123.4, 122.4, 122.3 (d, J= 6.97 Hz), 121.3, 119.3, 119.2, 117.1, 116.8 (d, J= 19.01 Hz), 109.0, 108.6, 107.8, 66.8, 62.0, 58.3, 56.8, 52.6, 41.6, 35.4, 30.8, 19.4, 18.6, 15.0, 13.2);19F NMR (376MHz, DMSO-d6): -123.11; HRMS (ESI) [M + H]+found, 917.3918 calculated for C50H54ClFN8O6. 917.391;.

[0328] HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 18.964 min, purity = 96.76%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nM.

[0329] {4'-((4-(2-((4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)amino)-2-oxoethylidene)piperidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-023-0989, 30k): Isolated as Light yellow solid (yield 55 %, mp 173°C). 'H NMR (400MHZ, DMSO-d6): 8 11.44 (s, 1H), 10.30 (s, 1H), 9.92 (s, 1H), 8.71 (d, J= 1.52 Hz, 1H), 8.53 (s, 1H), 8.17 (t,.7=4,90 Hz. 1H), 8.11 (dd, J= 2.57 Hz, 6.84 Hz, 1H), 7.84 (dd, J= 1.99 Hz, 1H), 7.81-7.75 (m, 2H), 7.56 (d, J=8.16 Hz, 2H), 7.44-7.39(m, 1H), 7.37-7.35(m, 3H), 7.21(d, J= 1.37 Hz, 1H), 5.84 (s, 1H), 5.58 (brs, 1H), 4.28 (d, J= 4.88 Hz, 2H), 3.81 (d, J= 10.41 Hz, 2H), 3.55 (s, 2H), 3.26-3.20 (m, 2H), 3.16 (d, J= 4.78 Hz, 1H), 3.08-2.97 (m, 4H), 2.91 (s, 2H), 2.54-2.52 (m, 2H), 2.23 (s, 3H), 2.19 (s, 3H), 2.17-2.14 (m, 2H), 2.10 (s, 3H), 1.65 (d, J= 11.16 Hz, 2H), 1.55-1.46 (m, 2H), 0.82 (t, J= 7.03 Hz, 3H);13C NMR (100MHz, DMSO-d6): 169.5, 163.5, 157.8, 153.4, 150.0, 149.3, 147.0, 143.2, 140.1, 139.0, 138.2, 137.5, 137.4,P 172026 / 12022

[0330] 137.2 (d, J= 3.74 Hz), 133.1, 131.3, 129.8, 128.9, 127.6, 126.9, 124.3, 123.3, 123.1 (d, J= 6.02 Hz), 122.1, 121.3, 119.2 (d, J= 22.41 Hz), 116.9 (d, J= 21.77 Hz), 115.8, 112.1, 107.8, 66.8, 61.8, 58.3, 52.7, 49.8, 45.0, 41.6, 35.4, 30.8, 29.6, 29.4, 19.4, 18.6, 15.0, 13.2;19F NMR (376MHz, DMSO-d6): -122.91;

[0331] HRMS (ESI): [M + H]+found, 897.40491 calculated for C51H54ClFN8O4, 897.4013; HPLC Analysis:

[0332] Column, C-18 (4.6 x 250 mm x 5pm); retention time = 16.105 min, purity = 98.10%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 300.0 nM.

[0333] {4'-((4-(5-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pentyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide} (S-023-0995, 301): Isolated as white solid (yield 70 %, mp 137°C).JH NMR (400MHZ, CDCl3): 8 12.08 (brs, 1H), 8.78 (brs, 1H), 8.61 (s, 1H), 7.91 (dd, J=:2.46 Hz, 6.57 Hz, 1H), 7.68-7.64 (m, lH), 7.57 (s, 1H), 7.41 (d, J=8.05 Hz, 2H), 7.31-7.28 (m, 3H), 7.30 (s, 2H), 7.21 (s, 1H), 7.08 (t, J=8.78 Hz, 1H), 5.90 (s, 1H), 4.54 (d, J= 5.71 Hz, 2H), 4.11-4.09 (m, 2H), 3.95-3.92 (m, 5H), 3.50-3.48 (s, 2H), 3.32-3.27 (m, 2H), 3.10-3.05 (m, 2H), 3.00-2.96 (m, 4H), 2.69 (brs, 4H), 2.61-2.53 (m, 6H), 2.37 (s, 3H), 2.34 (s, 3H), 2.12 (m, 3H), 1.90-1.83 (m, 2H), 1.69-1.64 (m, 5H), 1.50-1.45 (m, 3H), 0.89-0.88 (m, 3H);13C NMR (100MHz, CDCI3): 170.2, 165.1, 156.6, 155.0, 153.3, 150.7, 149.6, 148.7, 147.3, 142.7, 139.5, 139.3, 139.1, 138.2, 136.6, 133.5, 129.6, 126.8, 124.2, 122.0, 120.9, 119 (d, J= 22 Hz), 116.3 (d, J= 21 Hz), 109.9, 109.4, 107.6, 102.2, 68.7, 67.3, 62.2, 58.5, 57.6, 56.1, 52.9, 51.6, 41.7, 31.9, 29.5, 29.4, 28.0, 24.9, 23.1, 22.7, 19.7, 18.6, 14.8, 14.1, 12.8;19F NMR (376MHz, CDCk): -121.35; HRMS (ESI) [M + H]+found, 959.47809 calculated for C54H64CIFN8O5, 959.4745; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 15.825 min, purity = 99.76%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 330.0 nm.

[0334] {4'-((4-(6-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)hexyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-023-0990, 30m): Isolated as white solid (yield 60 %, mp 156°C). 'H NMR (400MHZ, CDCk): 8 12.06 (s, 1H), 8.62 (s, 1H), 8.23 (brs, 1H), 7.82-7.81 (m, 1H), 7.58-7.55(m,lH), 7.40-7.28 (m, 7H), 7.22 (d,.7=2,42 Hz, 2H), 7.10-7.05(m, 1H), 5.88 (s, 1H), 4.55 (d, J= 5.34 Hz, 2H), 4.07-4.04 (m,2H), 3.96-3.61 (m, 5H), 3.50 (s, 2H), 3.30-3.25(m, 2H), 3.07-3.05 (m, 2H), 2.99-2.95 (m, 1H), 2.48( brs, 4H), 2.35 (s, 3H), 2.32 (s, 3H), 2.08 (s, 3H), 1.88-1.85 (m, 3H), 1.97-1.59 (m, 5H), 1.50-1.42 (m, 5H), 1.36-1.35 (m, 5H), 0.86 (t, J= 7.00 Hz, 3H);13C NMR (100MHz, CDCI3): 170.3, 165.2, 156.6, 155.1, 153.3, 150.7, 149.6, 149.0, 147.3, 142.7, 139.5, 139.1, 138.2, 136.7, 133.4, 129.6, 129.8, 124.8, 124.2, 124.1, 122.0, 121.8 (t, J= 6 Hz), 120.8, 116.3 (d, J= 18 Hz), 114.1, 109.9, 109.4, 107.5, 101.9, 69.2, 67.3, 62.3, 58.5, 58.1, 56.2, 52.9, 51.9,P 172026 / 12022

[0335] 41.7, 36.3, 31.9, 30.5. 30.3, 29.4, 28.6, 26.7, 25.8, 25.4, 22.7, 19.7, 18.6, 14.8, 14.1, 12.8;19F NMR (376MHz, CDC13): -121.39; HRMS (ESI): [M + H]+found, 973.4919 calculated for C55H66C1FN8O5, 973.4901; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 25.326 min, purity = 96.26%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 330.0 nm.

[0336] {4'-((4-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide} (S-023-0988, 30n): Isolated as white solid (yield 85 %, mp 110°C). 'H NMR (400MHZ, DMSO-d6): 8 11.45 (s, 1H), 9.55 (s, 1H), 8.50 (s, 1H), 8.18 (t,,7=4.94 Hz 1H), 8.13 (dd, J= 2.68 Hz, 6.86 Hz, 1H), 7.84( s, 1H), 7.83-7.79 (m, 1H), 7.55 (d, J=8.20 Hz, 2H), 7.43 (t, J= 9.12 Hz, 1H), 7.39 (d, J= 1.15 Hz, 1H), 7.32 (d, J= 8.14 Hz, 2H), 7.22(d, J= 1.60Hz, 1H), 7.19 (s, 1H), 5.84 (s, 1H), 4.30 (m, 4H), 3.91 (s, 3H), 3.84-3.81 (m, 4H), 3.61 (t, J= 5.77 Hz, 2H), 3.42 (s, 2H), 3.27-3.17 (m, 4H), 3.11-2.98 (m, 3H), 2.45-2.33(m, 8H), 2.24(s, 3H), 2.20 (s, 3H), 2.10 (s, 3H), 1.65 (d, J= 10.74 Hz, 2H), 1.56-1.47 (m, 2H), 0.82 (t, J= 7.05 Hz, 3H);13C NMR (100MHz, DMSO-d6): 174.3, 168.2, 161.2, 159.7, 157.9, 157.1, 154.7, 154.1, 153.3, 152.2, 147.9, 144.8, 143.7, 142.6, 142.2, 142.0(d, J= 3.58 Hz), 137.8, 134.6, 131.6, 128.6, 128.1, 127.4 (d, J= 6.93 Hz), 126.8, 126.0, 124.0 (d, J= 18.44 Hz), 121.7 (d, J= 21.57 Hz), 114.0, 112.6, 107.9, 73.7, 73.5, 71.5, 67.0, 63.1, 62.4, 61.0, 58.4, 57.9, 53.8, 46.4, 40.1, 35.5, 24.2, 23.4, 19.8, 17.9;19F NMR (376MHz, DMSO-d6): -118.58; HRMS (ESI): [M + H]+found, 961.4568 calculated for C53H62CIFN8O6, 961.4538; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 17.963 min, purity = 95.71%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B(MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nM.

[0337] {4'-((4-(2-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide} (S-023-0992, 30o): Isolated as white solid (yield 80 %, mp 100 °C). 'H NMR (400MHZ, CDCI3): 5 11.94 (brs, 1H), 9.02 (brs, 1H), 8.56 (s, 1H), 7.98-7.96 (m, 1H), 7.79 (s, 1H), 7.73-7.69 (m, 1H), 7.34 (d, J=8.07 Hz, 2H), 7.28 (m, 2H), 7.23 (m, 1H), 7.11-7.05 (m, 4H), 5.90 (s, 1H), 4.54 (d, J= 5.64 Hz, 2H), 4.43-4.41 (m, 2H), 3.94-3.92 (m, 4H), 3.85 (s, 2H), 3.75-3.73 (m, 2H), 3.65-3.63 (m, 2H), 3.59 (m, 2H), 3.33-3,26(m, 4H), 3.07 (q, J-6.84 Hz, 13.93Hz, 2H), 3.01-2.96 (m, 1H), 2.60-2.53 (m, 8H), 2.38 (s, 3H), 2.33 (s, 3H), 2.14 (s, 3H), 1.69-1.63 (m, 4H), 0.87-0.86 (m, 3H);

[0338] 13C NMR (100MHz, CDCI3): 170.2, 165.0, 156.7, 153.5, 150.7, 149.5, 148.3, 142.6, 139.5, 139.3, 139.1, 138.1, 137.0 (d, 7= 4.0 Hz), 133.5, 129.6, 126.7, 124.8, 124.6, 124.0, 122.3 (d, J= 34 Hz), 120.9, 116.2 (d., / =22Hz). 114.1, 109.9, 109.2, 107.4, 103.8, 70.6, 69.9, 69.5, 68.8, 67.3, 62.2, 58.5, 57.8, 56.0,P 172026 / 12022

[0339] 53.2, 51.9, 41.7, 33.8, 31.9, 30.3, 29.5, 29.4, 29.2, 22.7, 19.7, 18.7, 14.8, 14.1, 12.9;19F NMR (376MHz, CDCl3): -121.67; HRMS (ESI) [M + H]+found, 1005.48224 calculated for C55H66ClFN8O7, 1005.4800; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5 pm); retention time = 25.671 min, purity = 99.79 %; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 280. Onm.

[0340] Series 2

[0341] 5-((3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide (S-024-0561, 33a): Isolated as off white solid (yield 96 %, mp 190 °C). 'H NMR (400MHZ, CDCI3): 3 13.85 (brs, 1H), 9.50 (s, 1H), 8.63 (s, 1H), 7.91-7.89 (m, 1H), 7.49 (s, 1H), 7.26-7.17 (m, 2H), 7.03 (s, 1H), 5.95 (s, 1H), 4.51 (brs, 2H), 3.97 (s, 5H), 3.80 (d, J= 10.98 Hz, 2H), 3.17-3.03 (m, 6H), 2.93-2.84 (m, 5H), 2.65-2.60 (m, 1H), 2.29 (s, 3H), 2.26 (s, 3H), 2.22 (s, 3H), 1.53-1.47 (m, 2H), 0.69 (t, J= 6.80 Hz, 3H);13C NMR (125MHz, CDCI3): 171.4, 165.4, 156.9, 154.6, 153.5 (d, J= 12.05 Hz), 150.3 (d, J= 17.41 Hz), 147.6, 146.6, 143.3, 137.8, 136.3, 134.4, 126.0, 124.4, 122.7(d, J= 12.37 Hz), 122.3(d, J= 5.62 Hz), 120.5, 116.4 (d, J= 22.07 Hz), 110.1, 109.4, 107.9, 102.2, 67.8, 67.0, 63.0, 59.9, 59.0, 56.2, 41.3, 37.3, 30.4, 29.7, 19.2, 18.8, 15.4, 12.9;19F NMR (376MHz, CDCI3): -121.70; HRMS (ESI) [M + H]+found, 784.3395 calculated for C42H47CIFN7O5, 784.3384;

[0342] HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 13.713 min, purity = 98.74%; eluent A (H2O+ 0.1% Formic acid): eluent B (Acetonitrile), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0343] 5-((4-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethyl)piperidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide(EG-30 / 33b): Isolated as off white solid (yield 90 %, mp 140 °C). 'H NMR (400MHZ, CDCk): 5 12.69 (brs, 1H), 9.77 (brs, 1H), 8.62 (s, 1H), 7.84-7.83 (m, 2H), 7.56 (brs, 1H), 7.50-7.48 (m, 1H), 7.17 (s, 1H), 7.10 (s, 1H), 7.04-6.99 (m, 2H), 5.95 (s, 1H), 4.53-4.51 (m, 2H), 3.93-3.84 (m, 6H), 3.48 (s, 1H), 3.29-3.23 (m, 2H), 3.01-2.94 (m, 2H), 2.92-2.87 (m, 1H), 2.80 (brs, 2H), 2.38 (s, 3H), 2.32 (s, 3H), 2.21 (s, 3H), 1.93-1.91 (m, 2H), 1.42-1.38 (m, 2H), 1.33-1.28 (m, 2H), 1.23-1.13 (m, 3H), 0.77 (m, J= 6.95 Hz, 3H);13C NMR (125MHz, CDCk): 170.5, 157.1, 154.9, 153.5, 149.4, 148.9, 147.1, 142.9, 135.9, 127.1, 124.7, 123.5, 122.4 (d, J= 5.90 Hz), 120.4(d, J= 18.26 Hz), 116.2 (d, J= 21.82 Hz), 110.9, 110.3, 170.6, 109.6, 107.0, 102.6, 67.3, 66.6, 56.5, 56.1, 52.9, 41.6, 36.5, 30.5, 29.7, 19.6, 18.7, 15.2, 12.8;19F NMR(376MHz, CDCk): -121.45; HRMS (ESI) [M + H]+found, 840.4011 calculated for C46H55CIFN7O5, 840.4010; HPLC Analysis: Column, C-18 (4.6 x 250PT / 2026 / 12022

[0344] mm x 5 pm); retention time = 14.319 min, purity = 98.12%; eluent A (H2O+ 0.1% Formic acid): eluent B (Acetonitrile), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0345] 5-((4-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)piperi din-1-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide(S-024-0565, 33c): Isolated as light yellow solid (yield 30 %, mp 91 °C). 'H NMR (400MHZ, CDCI3): 8 12.9 (brs, 1H), 9.29 (s, 1H), 8.62 (s, 1H), 8.18 (dd J= 2.60, 6.60 Hz, 1H). 7.74 (brs, 1H), 7.70 (s, 1H), 7.64-7.60 (m, 1H), 7.19 (s, 1H), 7.11 (s, 1H), 5.94 (s, 1H), 4.30 (d, J= 5.44 Hz, 2H), 3.91-3.89 (m, 5H), 3.85-3.82 (m, 2H), 3.69 (s, 1H), 3.41 (s, 2H), 3.28-3.21 (m, 2H), 3.02-2.95 (m, 2H), 2.92-2.85 (m, 1H), 2.78 (d, J= 10.18 Hz, 2H), 2.31 (s, 3H), 2.27 (s, 3H), 2.20 (s, 3H), 1.90-1.86 (m, 2H), 1.74-1.64 (m, 2H), 1.60-1.56 (m, 4H), 1.48-1.44 (m, 2H), 1.10-1.05 (m, 4H), 0.77 (t, J= 6.96 Hz, 3H);13C NMR (125MHz, CDC13): 170.3, 154.9, 153.4, 149.1 (d, J= 30.19 Hz), 147.2, 143.0, 136.0, 127.0, 124.2, 121.9 (d, J=6.28 Hz), 121.6, 116.2(d, J= 20.87 Hz), 110.2, 109.5, 107.3, 102.3, 69.6, 67.3, 63.6, 58.4, 56.1, 53.5, 41.7, 36.5, 32.5, 31.7, 30.5, 26.4, 19.5, 18.6, 15.1, 12.7;

[0346] 19F NMR (376MHz, CDCI3): -121.79; HRMS (ESI) [M + H]+found, 854.4166 calculated for C47H57CIFN7O5, 854.4167; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 14.475 min,

[0347] purity = 99.08%; eluent A (H2O+ 0.1% Formic acid): eluent B (Acetonitrile), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0348] 5-((3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pyrrolidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide (S-024-0567, 33d): Isolated as light brown solid (yield 54 %, mp 91 °C). 'H NMR (400MHZ, CDCI3): 8 13.0 (brs, 1H), 9.60 (s, 1H), 8.60 (s, 1H), 7.91-7.65 (m, 4H), 7.16-6.98 (m, 4H), 5.91 (m, 1H), 4.58 (s, 2H), 4.26-4.24 (s, 1H), 3.93-3.88 (m, 5H), 3.37 (brs, 2H), 3.21-3.18 (m, 3H), 2.94-2.84 (m, 3H), 2.91-2.55 (m, 3H), 2.32 (s, 3H), 2.25 (s, 3H), 2.18 (s, 3H), 2.04-2.00 (m, 1H), 1.81(brs, 1H), 1.73-1.71 (m, 1H), 1.58-1.53 (m, 4H), 0.71(brs, 3H);13C NMR (125MHz, CDCI3): 170.8, 165.3, 156.8, 153.5, 149.7, 147.0 (d, J= 5.69 Hz), 142.9, 138.0, 135.9, 126.6, 124.4 (d, J= 4.01 Hz), 122.9, 122.3 (d, J=12.84 Hz), 116.2 (d, J= 21.93 Hz), 110.2, 109.5, 107.5, 67.2, 59.9, 58.5, 56.1, 52.1, 41.7, 31.9, 30.6, 29.7, 29.4, 22.7, 19.3, 18.7, 15.1, 14.1, 12.7;19F NMR (376MHz, CDCI3): -121.72; HRMS (ESI) [M + H]+found, 798.3541 calculated for C43H49CIFN7O5, 798.3541.; HPLC Analysis. Column, C-18 (4.6 x 250 mm x 5pm); retention time = 13.779 min, purity = 97.46%; eluent A (H2O+ 0.1% Formic acid): eluent B (Acetonitrile), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.PT / 2026 / 12022

[0349] 5-((2-(((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)methyl)morpholino)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide(S-024-0563, 33e): Isolated as brown solid (yield 55 %, mp 113°C). 'H NMR (400MHZ, CDC13): 5 12.79 (brs, 1H), 9.43-9.36 (m, 1H), 8.62-8.61 (m, 1H), 7.96-7.91 (m, 1H), 7.77-7.68 (m, 2H), 7.55-7.51 (m, 1H), 7.12-7.05 (m, 4H), 5.97 (s, 1H), 4.60-4.52 (m, 2H), 3.89-3.87 (m, 2H), 3.82 (s, 3H), 3.77-3.74 (m, 1H), 3.71-3.51 (m, 4H), 3.38-3.33 (m, 1H), 3.27-3.17 (m, 3H), 3.00-2.95 (m, 2H), 2.87-2.84 (m, 1H), 2.52-2.49 (m, 1H), 2.41-2.40 (m, 3H), 2.31-2.30 (m, 3H), 2.26-2.25 (m, 3H), 2.06-1.90 (m, 2H), 1.83 (brs, 1H), 1.58-1.53 (m, 4H), 0.76 (t, J= 6.90 Hz, 3H);13C NMR(125MHz, CDC13): 170.5, 156.8, 154.9, 153.6, 150.8 (d, J= 9.84 Hz), 148.6, 142.9, 138.0, 136.1, 126.7 (d, J= 7.20 Hz), 124.0 (d, J= 6.58 Hz), 123.4, 122.3, 121.7 (d, J= 8.34 Hz), 116.2(d, 7= 28.38 Hz), 110.1, 109.2, 107.3, 102.5, 73.6, 70.5, 67.2, 66.5, 62.4, 58.5, 56.0, 54.5, 41.8, 36.9, 33.8, 31.9, 19.6, 18.7, 15.1, 12.7;19F NMR (376MHz, CDC13): -121.72; HRMS (ESI) [M + H]+found, 828.3646 calculated for C44H51CIFN7O6, 828.3646; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 13.907 min, purity = 98.41%; eluent A (H2O+ 0.1% Formic acid): eluent B (Acetonitrile), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0350] {5-((4-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide} (S-023-0991, 33f):

[0351] Isolated as light brown solid (yield 82 %, mp 80°C); 'H NMR (400MHZ, CDC13): 5 11.62 (s, 1H), 8.81 (brs, 1H), 8.60 (s, 1H), 7.89 (dd, J= 2.50 Hz, 6.55, 1H), 7.68-7.63 (m, 2H), 7.25-7.22 (m, 2H), 7.07 (t, 7=8.79Hz, 1H), 6.99-6.97 (m, 2H), 5.92 (s, 1H), 4.50 (d, J= 5.75 Hz, 2H), 4.31 (t, J= 4.96 Hz, 2H), 3.93-3.90 (m, 5H), 3.83 (t, 7=4.85Hz, 2H), 3.68-3.65 (m, 2H), 3.48 (s, 2H), 3.30-3.26 (m, 2H), 3.03-2.85 (m, 3H), 2.59-2.57 (m, 3H), 2.50 (brs, 4H), 2.36 (s, 3H), 2.29 (s, 3H), 2.24 (brs, 4H), 2.19 (s, 3H), 1.63-1.56 (m, 4H), 0.80 (t, J= 7.10 Hz, 3H);13C NMR (100MHz, CDC13): 107.4, 156.7, 155.1, 153.5, 153.2, 150.8, 149.0, 148.4, 142.4, 138.4, 135.0, 133.2, 126.2, 124.8, 124.1, 122.8, 122.2, 121.9 (d, 7= 6.99 Hz), 116.2 (d, J= 21.75 Hz), 114.1, 110.0, 109.3, 107.7, 103.7, 69.3, 68.9, 68.4, 67.3, 62.1, 58.3, 57.6, 56.1, 53.2, 52.2, 41.6, 36.2, 31.9, 30.5, 30.3, 29.4, 22.7, 19.6, 18.8, 14.8, 14.1, 12.7;19F NMR (376MHz, CDC13): -121.70; HRMS (ESI) [M + H]+found, 885.42444 calculated for C47H58ClFN8O6, 885.4225; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 23.416 min, purity = 96.17%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 280.0 nm.

[0352] {5-((4-(2-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-P 172026 / 12022

[0353] 3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide} (S-023-0993, 33g):

[0354] Isolated as off white solid (yield 78 %, mp 76°C). 'H NMR (400MHZ, CDCh): 8 11.40 (s, 1H), 8.96 (s, 1H), 8.55(s, 1H), 7.91 (dd, J= 2.39 Hz, 6.54Hz, 1H), 7.73 (s, 1H), 7.69-7.67 (m, 1H), 7.16-7.13 ( m, 2H), 7.06 (t, J= 8.80 Hz), 6.98-6.90 (m, 2H), 5.90 (s, 1H), 4.48 ( d, J=5.56 Hz, 2H), 4.40-4.37 (m, 2H), 3.93-3.90 (m, 5H), 3.73-3.72 (m, 2H), 3.63-3.62 (m, 2H), 3.53 (t, J= 4.78 Hz, 2H), 3.47 (s, 1H), 3.30-3.24 (m, 2H), 3.19 (s, 2H), 3.01-2.94 (m, 2H), 2.91-2.84 (m, 1H), 2.49-2.48 (m, 3H), 2.39 (brs, 8H), 2.35 (s. 3H), 2.26 (s, 3H), 2.18 (s, 3H), 1.60-1.56 (m, 4H), 0.77 (t, J= 7.0 Hz, 3H);13C NMR(100MHz, CDC13): 170.3,164.9, 156.8, 155.0, 153.5, 150.8, 148.9, 148.3, 147.5, 142.5, 138.4, 136.4, 135.2, 133.0, 126.2, 124.0,122.9, 122.1, 122.0, 121.9 (d, J= 6.56 Hz), 120.4 (d, 7=18.50 Hz), 116.1 (d, J=21.56 Hz), 109.8, 109.5, 107.5, 103.8, 70.5, 70.3, 70.0, 69.5, 68.6, 68.0, 67.3, 62.3, 58.3, 57.7, 56.1, 53.2, 52.4, 41.5, 36.0, 30.5, 30.3, 19.6, 18.7, 14.7, 12.7;19F NMR (376MHz, CDCI3): -121.79; HRMS (ESI) [M + H]+found, 929.45093 calculated for C49H62ClFN8O7, 929.4487; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 24.306 min, purity = 99.66 %; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 330.0 nm.

[0355] {5-((4-(2-(2-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethoxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide} (S-023-0994, 33h): Isolated as light brown solid (yield 66 %, mp 84°C). 'H NMR (400MHZ, CDCI3): 8 11.76 (s, 1H), 9.19 (s, 1H), 8.57 (s, 1H), 7.94 (dd, J= 2.6 Hz, 6.54Hz, 1H), 7.88 (s, 1H), 7.78-7.74 (m, 1H), 7.18 (s, 1H), 7.15 ( t, J= 5.68 Hz, 1H), 7.07 (t, J= 8.80Hz), 6.90 (d, J= 4.30 Hz, 2H), 5.88 (s, 1H), 3.84 ( d,.7=5.75 Hz, 2H), 4.41-4.38 (m, 2H), 3.94 (s, 3H), 3.91-3.89 (m,2H),3.73-3.72 (t, J= 5.10 Hz, 2H), 3.68-3.67 (m, 2H), 3.63-3.59 (m,4H), 3.57-3.55 (m, 2H), 3.51-3.49 (m, 2H), 3.30-3.23 (m, 2H), 3.17 (s, 2H), 2.99-2.94 (m, 2H), 2.90-2.87 (m, 1H), 2.77 (brs, 4H), 2.46 (t, J=5.15Hz, 2H), 2.37 (brs.

[0356] 4H), 2.32 (s, 3H), 2.25 (s, 3H), 2.16 (s, 3H), 1.60-1.54 (m, 4H), 0.76 (t, J= 7.0 Hz, 3H);13C NMR (100MHz, CDCI3): 170.3, 164.9, 156.8, 155.0, 153.5, 150.7, 148.9, 148.3, 147.5, 142.5, 138.4, 136.4, 135.2, 133.0, 126.2, 124.0, 122.9, 122.1, 121.9 (d, J= 6.61 Hz), 120.4 (d, J= 18.04 Hz), 116.1 (d, J= 21.31 Hz), 109.8, 109.5, 107.5, 103.8, 70.5, 70.3, 70.0, 69.5, 68.6, 68.0, 67.3, 62.3, 58.3, 57.7, 56.1, 53.2, 52.4, 41.5, 36.0, 30.5, 19.6, 18.7, 14.7, 12.7;19F NMR (376MHz, CDCI3): -122.07; HRMS (ESI) [M + H]+found, 973.4770 calculated for C51H66C1FN8O8, 973.4749; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 24.490 min, purity = 92.37 %; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.P 172026 / 12022

[0357] N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methyl-5-((4-methylpiperazin-l-yl)methyl)benzamide (S-024-0568, 33i): Isolated as white solid (yield 30 %, mp 120°C). 'H NMR (400MHZ, DMSO-d6): 8 11.45 (brs, 1H), 8.00 (t, J= 4.80 Hz, 1H), 7.09 (s, 1H), 6.85 (s, 1H), 5.86 (s, 1H), 4.26 (d, J= 4.94 Hz, 1H), 3.81 (d, J= 10.53 Hz, 1H), 3.39 (s, 2H), 3.25-3.20 (m, 2H), 3.03-2.97 (m, 2H), 2.95-2.90 (m, 1H), 2.33 (brs, 8H), 2.19 (s, 3H), 2.17 (s, 3H), 2.15 (s, 3H), 2.11 (s, 3H), 1.60 (d, J= 11.02 Hz, 2H), 1.53-1.47 (m, 2H), 0.77 (t, J= 6.91 Hz, 3H);13C NMR(125MHz, DMSO-d6): 169.8, 163.5, 149.9, 148.4, 143.2, 139.5, 135.5, 132.1, 125.4, 123.3, 122.1, 107.9, 66.8, 61.9, 58.2, 55.1, 52.7, 46.0, 41.6, 35.3, 30.7, 19.4, 18.7, 14.9, 12.9;

[0358] HRMS (ESI) [M + H]+found, 510.3343 calculated for C29H43N5O3, 510.3439. HPLC Analysis:

[0359] Column, C-18 (4.6 x 250 mm x 5pm); retention time = 4.12 min, purity = 95.76 %; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 40 min; flow rate, 1 mL / min, and detection at 300.0 nm.

[0360] Series 3

[0361] {N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-5-((4-(2-(2-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-2-methylbenzamide} (S-023-0996, 41a): Isolated as white solid (yield 80 %, mp 128°C). 'H NMR (400MHZ, CDC13): 8 11.81 (s, 1H, 7-NH), 8.62 (s, 1H, 40-qunazolline CH), 7.87 (brs, 1H), 7.79 (d, J= 8.19 Hz, 1H), 7.61 (s, 1H, 44, 33-ArCH), 7.28-7.27 (m, 2H), 7.23-7.19 (m, 3H, 46, 13-ArH), 6.99 (d, J=\ 1.37 Hz, 1H), 5.91 (s, 1H, 5-CH), 4.50 (d, J= 5.76 Hz, 2H, 2-CH2), 4.29 (t, J= 5.0 Hz, 2H, 5I-CH2), 3.93-3.90 (m, 6H, 50-OCH3, 62-alkyne-CH, 27 / 29-CH2), 3.84-3.81 (m, 2H, 52-CFb), 3.65 (t, J=5.2 Hz, 2H, 6I-CH2), 3.31-3.25 (m, 4H, 27 / 29, 6O-CH2), 3.03-2.97 (m, 2H, 23-CH2), 2.94-2.91 (m, 1H, 22-CH), 2.58-2.55 (m, 4H, 54, 58-piperazine-CH2), 2.47 (brs, 4H, 55, 57-piperazine-CH2), 2.35 (s, 5H, 10-CH3.25-CH2), 2.28 (s, 3H, 20-CH3), 2.18 (s, 3H, II-CH3), 1.63-1.58 (m, 4H, 26, 3O-CH2), 0.80 (t, J= 7.0 Hz, 3H, 24-CH3);13C NMR (100MHz, CDC13): 170.4 (18-CONH), 165.0 (38-quinazolline aromatic quaternary C), 156.7 (8-ArC), 155.0 (32-ArC), 153.6 (40-quinazolline aromatic CH), 150.7 (12, 4-ArC), 148.9 (14-ArC), 148.4, 147.7, 142.5 (6-ArC), 139.3, 138.4 (16-ArC), 135.2, 133.1 (15-ArC), 128.8, 127.5 (13-ArCH), 126.2, 125.3, 122.9, 122.6, 122.2 (3-ArC), 109.9 (5-CH), 109.4, 107.7 (17-ArCH), 103.3 (33-ArCH), 83.6 (49-ArC), 69.4 (52-CH2), 68.9 (51-CH2), 68.6 (6I-CH2), 67.3 (50-OCH3, 27 / 29-CH2), 62.1 (6O-CH2), 58.3 (22-CH), 57.6 (54, 58-pipcrazinc-CFF). 56.1 (62-alkyne-CH), 53.3 (55, 57-piperazine-CH2), 52.4 (25-CH2), 41.6 (23-CH2), 36.2 (2-CH2), 30.5 (26, 30-CH2), 19.6 (IO-CH3), 18.8 (II-CH3), 14.8 (20-ArCH3), 12.7 ( 24-CH3); IR (CH2CI2): 3776, 3295, 2931, 2852, 1772, 1631, 1516, 1433, 1388, 1243, 1144, 1073, 1017, 939, 758 cm-1. HRMS (ESI) [M + H]+found, 857.4731 calculated for C49H60N8O6, 857.4709. HPLC Analysis:

[0362] Column, C-18 (4.6 x 250 mm x 5pm); retention time = 12.759 min, purity = 97.16%; eluent A (H2O+PT / 2026 / 12022

[0363] 0.1% Formic acid): eluent B (Acetonitrile), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0364] {5-((4-(2-(2-((4-((3,4-dichlorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide} (S-023-0997, 41b):

[0365] Isolated as light brown solid (yield 84 %, mp 95°C ).XH NMR (400MHZ, CDC13): 8 11.7 (brs, 1H), 8.86 (brs, 1H), 8.55 (s, 1H), 7.92 (d, J= 2.29 Hz, 1H), 7.66-7.63 (m, 2H), 7.19 (s, 2H), 7.15 (s, 1H), 6.92 (d, J=8.28 Hz,lH), 5.85 (s, 1H), 4.43 (d, J= 5.80 Hz, 2H), 4.25-4.22 (m, 2H), 3.86-3.83 (m, 5H), 3.76 (t, J= 4.88Hz, 2H), 3.60 (d, J= 4.88 Hz, 2H), 3.22-3.18 (m, 4H), 2.95-2.83 (m, 4H), 2.56-2.54 (m, 2H), 2.48 (brs, 4H), 2.31-2.28 (m, 7H), 2.20 (s, 3H), 2.12 (s, 3H), 1.54-1.50 (m, 4H), 0.72 (t, J= 6.90 Hz, 3H);13C NMR (100MHz, CDC13): 169.4, 163.9, 154.2, 152.3, 149.8, 148.0, 147.5, 146.7, 141.4, 138.3, 138.1, 137.4, 132.2, 131.2, 129.1, 125.4, 125.2, 122.4, 122.3, 121.8, 121.2, 120.2, 113.0, 109.0, 108.5, 106.7, 102.6, 68.3, 67.9, 66.3, 60.9,57.3, 56.5, 55.1, 52.1, 51.0, 40.6, 30.9, 30.6, 29.5, 28.7, 21.7, 18.6, 17.8, 13.8, 13.1, 11.7; HRMS (ESI) [M + H]+found, 901.3955 calculated for C47H58C12N8O6, 901.3929; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 15.444 min, purity = 98.06%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0366] {5-((4-(2-(2-((4-((3-chlorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide} (S-023-0998, 41c): Isolated as white solid (yield 78 %, 99°C). 'H NMR (400MHZ, CDC13): 8 11.89 (brs, 1H), 8.77 (brs, 1H), 8.62 (s, 1H), 7.84 (t, J= 1.86 Hz, 1H), 7.69-7.65 (m, 2H), 7.25-7.24 (m, 1H), 7.2 l(d, J= 8.81 Hz, 2H), 7.04-7.02 (m,lH), 6.98 (d, J= 10.60 Hz, 2H), 5.91( brs, 1H), 4.50 (d, J= 5.77Hz, 2H), 4.30-4.27 (m, 2H), 3.92-3.90 (m, 5H), 3.84-3.81 (m, 2H), 3.66-3.63 (m, 2H), 3.31-3.25 (m, 4H), 3.02-2.96 (s, 2H), 2.94-2.89 (m, 1H), 2.56 (t, J==5.19 Hz, 2H), 2.47 (brs, 4H), 2.34 (s, 6H), 2.28 (s, 3H), 2.19 (s, 3H), 1.63-1.58 (m, 4H), 0.79 (t, J-= 6.95 Hz, 3H);!3C NMR(100MHz, CDC13): 170.4, 165.0, 156.6, 155.1, 153.5, 150.8, 149.0, 148.4, 147.6, 142.5, 140.6, 138.4, 135.1, 134.2, 133.1, 129.7, 126.3, 123.6, 122.9, 122.2, 121.8, 119.9, 110.0, 109.5, 107.7, 103.4, 69.4, 68.9, 68.5, 67.3, 62.1, 58.3, 57.6, 56.1, 53.2, 52.3, 41.6, 36.1, 31.9, 30.5, 19.6, 18.7, 14.8, 12.7; HRMS (ESI) [M + H]+found, 867.4338 calculated for C47H59ClN8O6, 867.4319;

[0367] HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 13.974 min, purity = 98.60%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.PT / 2026 / 12022

[0368] {N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-5-((4-(2-(2-((4-((4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-2-methylbenzamide} (S-023-0999, 41d): Isolated as white solid (yield 75 %, mp 130°C).1H NMR (400MHZ, CDC13): δ 11.90 (s, 1H), 8.62-8.56 (m, 2H), 7.63-7.60 (m, 3H), 7.22-7.19 (m, 2H), 7.02-6.95 (m, 4H), 5.90 (s, 1H), 4.48 (d, J= 4.46 Hz, 2H), 4.26 (s, 2H), 3.90 (s, 5H), 3.8 l(s, 2H), 3.63 (s, 2H), 3.28 (s, 4H), 3.00-2.98(m, 2H), 2.92 (brs, 1H), 2.81(brs, 4H), 2.55(s, 2H), 2.47 (brs, 4H), 2.33 (s, 3H), 2.27 (s, 3H), 2.17 (s, 3H), 1.60 (s, 4H), 0.80-0.79 (m 3H);

[0369] 13C NMR (100MHz, CDC13): 170.4, 165.0, 158.1, 157.0, 155.0, 153.7, 150.8, 149.0, 148.3, 147.5, 142.5, 138.5, 138.5, 135.1, 133.1, 126.2, 124.3 (d, J= 7.84 Hz), 122.8, 122.2, 115.4 (d, J= 22.40 Hz), 109.9, 109.2, 107.7, 103.5, 69.3, 68.9, 68.5, 67.3, 62.1, 58.3, 57.6, 56.1, 53.3, 52.4, 41.6, 36.1, 30.5, 29.7, 19.6, 18.7, 14.8, 12.7;19F NMR (376MHz, CDC13): -118.37; HRMS (ESI) [M + H]+found, 851.4649 calculated for C47H59FN8O6, 851.4614; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 12.901 min, purity = 96.40%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0370] {5-((4-(2-(2-((4-((2,4-difluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide} (S-023-1000, 41e):

[0371] Isolated as white solid (yield 67 %, mp 94°C).

[0372]

[0373] NMR (400MHZ, CDC13): 8 11.71 (brs, 1H), 8.58 (s, 1H), 8.10-8.04 (m, 1H), 7.94 (brs, 1H), 7.41 (s, 1H), 7.24 (m, 1H), 7.16 (t, J=5.68 Hz, 1H), 7.02 (s, 1H), 6.96 (s, 1H), 6.93-6.87 (m, 2H), 5.91 (s, 1H), 4.49 (d, J= 5.77 Hz, 2H), 4.31-4.28 (m, 2H), 3.95-3.90 (m, 5H), 3.87-3.85 (m, 2H), 3.68-3.65 (m, 2H), 3.32-3.25 (m, 4H), 3.03-2.98 (m, 2H), 2.96-2.90 (m, 1H), 2.57 (t, J= 5.30 Hz, 2H), 2.47 (brs, 8H), 2.35 (s, 3H), 2.26 (s, 3H), 2.18 (s, 3H), 1.62-1.58 (m, 4H), 0.80 (t, = 6.93 Hz, 3H);13C NMR (100MHz, CDC13): 170.3, 164.9, 156.7, 155.3, 153.5, 150.7, 148.9 (d,.7= 16.94 Hz),, 147.6, 142.4, 138.5, 135.2, 133.1, 126.2 (t, J= 6.78 Hz), 122.9, 122.3, 111.2 (d, J= 25.09 Hz), 109.9, 109.2, 107.8, 104.0, 102.4; 69.4, 68.9, 67.3, 62.3, 58.3, 57.6, 56.2, 53.4, 52.6, 41.6, 36.1, 30.5, 19.6, 18.8, 14.7, 12.7;19F NMR (376MHz, CDC13): -114.4 (d,2JF= 5.13 Hz), -121.53;

[0374] HRMS (ESI) [M + H]+found, 869.4545 calculated for C47H58F2N8O6, 869.4520; HPLC Analysis:

[0375] Column, C-18 (4.6 x 250 mm x 5pm); retention time = 12.961 min, purity = 96.08%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0376] {5-((4-(2-(2-((4-((3-bromophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide} (S-023-1001, 41f): Isolated as white solid (yield 83 %, mpPT / 2026 / 12022

[0377] 85°C). 'H NMR (400MHZ, CDC13): 8 11.67 (brs, 1H), 8.73 (brs, 1H), 8.63 (s, 1H), 7.99-7.97 (m, 1H), 7.76-7.75 (m, 1H), 7.66 (s, 1H), 7.22-7.20 (m, 2H), 7.18-7.16 (m, 2H), 7.00 (s, 1H), 6.97 (s, 1H), 5.92 (s, 1H), 4.50 (d, J= 5.81 Hz, 2H), 4.32-4.29 (m, 2H), 3.94-3.91 (m, 5H), 3.84-3.82 (m, 2H), 3.68-3.66 (m, 2H), 3.30-3.25 (m, 4H), 3.03-2.91 (m, 2H), 2.95-2.91(m, 1H), 2.69 (brs, 4H), 2.61-2.60 (m, 2H), 2.52 (brs, 4H), 2.36 (s, 3H), 2.28 (s, 3H), 2.19 (s, 3H) 1.62-1.58 (m, 4H), 0.80 (t, J= 6.95 Hz, 3H);13C NMR (100MHz, CDCl3): 170.4, 164.9, 156.6, 155.2, 153.5, 150.8, 149.0, 148.5, 147.7, 142.4, 140.7, 138.5, 133.2, 130.0, 126.5, 126.2, 126.2, 124.6, 122.9, 122.3, 120.4, 114.1, 110.0, 109.5, 107.7, 103.6, 69.4, 68.9, 68.3, 67.3, 62.0, 58.3, 57.6, 56.1, 53.2, 52.2, 41.6, 36.1, 31.9, 31.6, 30.5, 30.3, 29.4, 19.6, 18.8, 14.1, 12.7; HRMS (ESI) [M + H]+found, 911.3833 calculated for C47H59BrN8O6, 911.3814;

[0378] HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5 pm); retention time = 13.969 min, purity = 97.60%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0379] {N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-5-((4-(2-(2-((7-methoxy-4-((3-(trifluoromethyl)phenyl)amino)quinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-2-methylbenzamide} (S-023-1002, 41g): Isolated as white solid (yield 86 %, mp 100°C).1H NMR (400MHZ, CDC13): δ 11.94 (brs, 1H), 8.59 (s, 1H), 8.22 (brs, 1H), 7.99-7.93 ( in, 1H), 7.50 (s, 1H), 7.26 (s, 2H), 7.18 (t, =5.48 Hz,lH), 7.03-6.97 (m, 4H), 5.92 (s, 1H), 4.50 (d,

[0380] 5.59 Hz, 2H), 4.32-4.29 (m, 2H), 3.96-3.90 (m, 5H), 3.88-3.85 (m, 2H), 3.69- 3.66 (m, 2H), 3.33-3.25 (m, 4H), 3.04-2.98 (m, 2H), 2.96-2.92(m, 1H), 2.70 (brs, 4H), 2.58 (t, =5.13 Hz, 2H), 2.49 (brs, 4H), 2.36 (s, 3H), 2.27 (s, 3H), 2.19(s, 3H) 1.62-1.59 (m, 4H), 0.80 (t, J= 6.90 Hz, 3H);13C NMR (125MHz, CDC13): 170.3, 165.0, 156.7, 155.4, 153.4, 150.7, 148.9 (d, J= 13.21 Hz), 147.7, 142.5, 138.5, 135.2, 133.1, 126.2, 124.3, 123.5 (d, J== 7.22 Hz), 122.8, 122.2, 111.2 (d,

[0381] 19.93 Hz), 109.9, 109.2, 107.8, 102.5, 69.3, 68.9, 68.8, 67.3, 62.2, 58.3, 57.6, 56.2, 53.4, 52.5, 41.6, 36.1, 30.5, 19.6, 18.7, 14.7, 12.7;19F NMR (376MHz, CDC13): -122.85, -117.94; HRMS (ESI) [M + H]+found, 901.4616 calculated for C48H59F3N8O6, 901.4582; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 14.769 min, purity = 97.17%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0382] {5-((4-(2-(2-((4-((3-bromo-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide} (S-023-1003, 41h):

[0383] Isolated as white solid (yield 82 %, mp 162°C). 'H NMR (400MHZ, CDC13): 8 11.71 (brs, 1H), 8.85 (brs, 1H), 8.59 (s, 1H), 8.00 (dd, J= 2.37, 6.06 Hz, 1H), 7.72-7.67 (m, 2H), 7.24-7.18 (m, 2H), 7.07-7.03 (m, 1H), 6.97 (d, J=8.18 Hz, 2H), 5.91 (s, 1H), 4.49 (d, J= 5.58 Hz, 2H), 4.30-4.28 (m, 2H), 3.92-PT / 2026 / 12022

[0384] 3.90 (m, 5H), 3.84-3.81 (m, 2H), 3.67-3.64 (m, 2H), 3.29-3.24 (m, 4H), 3.02-2.97 (m, 2H), 2.93-2.88 (m, 1H), 2.80 (brs, 4H), 2.59 (m, 4H), 2.34 (s, 3H), 2.27 (s, 3H), 2.18 (s, 3H), 1.61-1.57 (m, 4H), 0.78 (t, J= 6.96 Hz, 3H);13C NMR (100MHz, CDC13): 170.4, 164.9, 156.7, 155.1, 154.2, 153.5, 150.9, 149.0, 148.5, 147.6, 142.5, 138.4, 136.3, 135.0, 133.2, 126.9, 126.3, 122.8 (d, J= 10.93 Hz), 122.2, 116.0 (d,.7=23.34 Hz), 110.0, 109.3, 108.5 (d, J= 21.57 Hz), 107.7, 103.6, 69.4, 68.9, 68.3, 67.3, 62.0, 58.3, 57.5, 56.1, 53.2, 52.1, 41.6, 36.2, 33.8, 31.9, 30.5, 29.4, 22.7, 19.6, 18.8, 14.8, 14.1, 12.7;19F NMR (376MHz, CDC13): -113.72; HRMS (ESI) [M + H]+found, 929.3736 calculated for C47H58BrFN8O6, 929.3719; HPLC Analysis: Column, C-18 (4.6 x 250 mm x 5pm); retention time = 14.343 min, purity = 98.28%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0385] {5-((4-(2-(2-((4-((3-chloro-2,4-difluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide} (S-023-1004, 41i):

[0386] Isolated as white solid (yield 75 %, mp 115°C). 'H NMR (400MHZ, CDCI3): 5 11.89 (brs, 1H), 8.83 (brs, 1H), 8.62 (s, 1H), 8.06-8.04 (m, 1H), 7.65 (s, 1H), 7.44-7.40 (m, 1H), 7.31 (d, J= 7.71 Hz, 1H), 7.20 (s, 1H), 6.96 (d,.7=13.03 Hz, 2H), 5.90 (s, 1H), 4.49 (d, J= 5.83 Hz, 2H), 4.29-4.27 (m, 2H), 3.90-3.89 (m, 5H), 3.83-3.81 (m, 2H), 3.64-3.62 (m, 2H), 3.30-3.23 (m, 4H), 3.01-2.96 (m, 2H), 2.93-2.89 (m, 1H), 2.55-2.43 (m, 10H), 2.33 (s, 3H), 2.26 (s, 3H), 2.18 (s, 3H), 1.62-1.56 (m, 4H), 0.77 (t, J= 7.00 Hz, 3H);13C NMR (125MHz, CDCI3): 170.4, 165.0, 156.6, 122.1, 153.5, 150.7 (d, J= 10.42 Hz), 149.0, 148.5, 147.7, 142.5, 140.0, 138.4, 135.2 (d, J= 15.32 Hz), 133.1, 129.2, 126.2, 129.2, 126.2, 125.0, 122.8, 122.1, 120.0, 109.9, 109.4, 107.7, 103.3, 69.4, 68.9, 68.6, 67.3, 62.01, 58.3, 57.7, 56.1, 53.3, 52.4, 41.6, 36.2, 30.5, 19.6, 18.7, 14.7, 12.6;19F NMR (376MHz, CDCI3): -62.47; HRMS (ESI) [M + H]+found, 903.4159 calculated for C47H57ClF2N8O6, 903.4130; HPLC Analysis. Column, C-18 (4.6 x 250 mm x 5pm); retention time = 13.964 min, purity = 97.68%; eluent A (H2O+ 0.1% Formic acid+ 5% Acetonitrile): eluent B (MeOH), gradient method; run time, 30 min; flow rate, 1 mL / min, and detection at 254.0 nm.

[0387] ANTICANCER ACTIVITY:

[0388] Materials and methods used in biology

[0389] Reagents: Tazemetostat (EPZ-6438) and Gefitinib were sourced from MedChem Express. Dimethyl Sulfoxide (DMSO) and bovine serum albumin (BSA) were obtained from Sigma-Aldrich. The anti- -Actin antibody (cat# A3854, 1: 10,000) was also purchased from Sigma -Aldrich. Antibodies for EZH2 (cat# 5246S), H3K27me3 (cat# 9733S), P-EGFR (cat# 3777S), and EGFR (cat# 4267S) were acquiredPT / 2026 / 12022

[0390] from Cell Signaling Technology (CST) and diluted at 1: 1000 for Western blot studies where applicable. PVDF membrane, enhanced chemiluminescence solution (Bio-Rad Clarity Western ECL Substrate) and stripping buffer were procured from Bio-Rad. The BCA protein estimation kit, RIPA cell lysis buffer, blocking buffer, Super Signal West Femto chemiluminescent substrates, FBS-US Origin, RPMI-1640 media, and Anti-Anti were obtained from Thermo Fisher Scientific. All chemicals and antibodies were sourced from Sigma or Thermo Fisher Scientific unless stated otherwise.

[0391] Cell Line Procurement and Culture: Various basal-like TNBC human cell lines (HCC1806, CRL-2335; MDA-MB-468, HTB-132; MDA-MB-231, CRM-HTB-26) and normal, non-cancerous monkey kidney epithelial cell line, Vero (CCL-81) were acquired from the American Type Culture Collection (ATCC), USA. Mycoplasma-free early passage cells were thawed from liquid nitrogen vapor stocks and checked for a stable phenotype under a microscope before use. Human cell lines were authenticated by STR profding. All experiments were conducted within the early passages (<10) of individual cell lines. Cells were grown as monolayers in recommended media supplemented with 10% FBS and lx Anti-Anti (containing 100 pg / ml streptomycin, 100 unit / ml penicillin, and 0.25 pg / ml amphotericin B) at 37 °C with 5% CO2 in a humidified environment. Cell counting was performed using trypan blue staining and a haemocytometer.

[0392] Western Blotting: Cells were lysed in RIPA buffer containing phosphatase and protease inhibitor cocktail and incubated at -80 °C overnight, followed by sonication. The lysates were centrifuged, and the supernatant was collected. Protein concentrations were determined using the BCA kit. Equal amounts of protein were separated by SDS-PAGE and transferred to a PVDF membrane. Membranes were blocked with non-fat dry milk or BSA, incubated with primary antibodies overnight at 4 °C, and then with secondary antibodies at room temperature. Immunoreactivity was detected using enhanced chemiluminescence solution and scanned by a gel documentation system (Bio-Rad chemidoc XRS plus). The final immunoblot images were then subjected to densitometric quantification using Image J software and % inhibition of the target protein was calculated.

[0393] Cytotoxicity Assay: A standard SRB colorimetric assay was used to assess cellular toxicity1. MDA-MB-231 and MDA-MB-468 cell lines were employed to evaluate the anti -cancer efficacy of the compounds of interest (NCEs) and Vero cell line was used to assess the safety window of these NCEs in a non-cancerous background. Cells of each cell line were seeded in 96-well plates in 5% RPMI, with the cell number varying depending on their doubling time, and incubated overnight to allow adherence. The following day, cells were treated with either the compound of interest or vehicle. After 72 hours, cells were fixed with 10% ice-cold TCA, stained with SRB, and the absorbance was measured at 510 nm on a microplate reader (Epoch Microplate Reader, Biotek, USA). The cytotoxic effects ofPT / 2026 / 12022

[0394] compounds were calculated using the formula [100-(Absorbance of compound -treated cells / Absorbance of untreated cells)] x 100 in MS excel.

[0395] Wound healing assay: The wound healing assay involved seeding 500,000 cells (HCC1806) per well into 6-well plates and allowing them to incubate overnight to form a confluent monolayer. A scratch was then made using a 200 pL tip to generate a straight-line scratch in the monolayer. After washing the cells with PBS, they were subjected to treatment with respective compounds or drugs. At different time points, images were taken to check for the wound healed after treatments for determining the cell migration inhibitory potential of the compounds.

[0396] Cellular thermal shift assay (CETSA): The CETSA procedure followed a previously documented protocol. DLD-1 cells were cultured in separate 150mm dishes until reaching approximately 1 million cells per mL in 10 mL of medium. Compounds of interest or drugs were added to the respective dishes at a final concentration of 10 pM. After a 2-hour incubation at 37 °C with the specified treatments, cells were harvested via trypsinization followed by centrifugation. The resulting cell pellets were resuspended in 1 mL of PBS supplemented with protease inhibitor, 1M MgCl2and Benzonase. Each treatment group was divided into 5 PCR tubes, with approximately 100 pL of cell suspension containing around 1 million cells per tube. The cells in each tube were then heated to predetermined temperatures ranging from 42-50 °C for 5 min using a thermal cycler, followed by a 3 -minute incubation at room temperature before snap-freezing the samples in liquid nitrogen. Complete cell lysis was achieved through 3 cycles of freeze-thaw-vortex. The resulting lysates were clarified by centrifugation, and equal amounts (10 pL) of cell lysate from each sample were subjected to electrophoresis and immunoblotting.

[0397] The band intensities of EZH2, EGFR, and -Actin (serving as a loading control) were assessed to validate target binding.

[0398] Rationale for Study Design: TCGA dataset mining revealed that both EZH2 and EGFR are overexpressed in TNBC cohort compared to non-TNBC (Fig. la & b). These findings prompted us to design a small molecule inhibitor capable of targeting both EZH2 and EGFR, offering a viable treatment strategy to abrogate the multifactorial progression of cancer. Thus, we planned to develop novel 2-Pyridone -based Quinazoline compounds as dual EZH2 and EGFR inhibitors.

[0399] Table-1. Dual target (EZH2 and EGFR) inhibition and cellular cytotoxicity at 10 pM dose of Comparator Drug

[0400]

[0401] PT / 2026 / 12022

[0402]

[0403] Table-2. Dual target (EZH2 and EGFR) inhibition and cellular cytotoxicity at 10 pM dose of F-I synthesized compounds

[0404]

[0405] PT / 2026 / 12022

[0406]

[0407] Table-3. Dual target (EZH2 and EGFR) inhibition and cellular cytotoxicity at 10 pM dose of F-II synthesized compounds

[0408]

[0409] Table-4. Dual target (EZH2 and EGFR) inhibition and cellular cytotoxicity at 10 pM dose of F-III synthesized compoundsPT / 2026 / 12022

[0410]

[0411] Table-5. Selectivity of Hit Molecule vs. Comparator Drug.

[0412]

[0413] Hit Identification Study: From the overall study, we have identified three hit molecules [S-023-0996 (41a), S-023-1001 (41f), and S-023-1003 (41h)] based on their dual-target inhibition (EZH2 and EGFR) and anti-proliferative potential against TNBC cells (MDA-MB-468 and MDA-MB-231), along with their lower cytotoxicity in non -cancerous cells (Vero). Among these three, after dose reduction, both S-023-0996 (41a) and S-023-1001 (41f) maintained effective dual-target inhibition, comparable to the comparator drugs (Tazemetostat and Gefitinib) (Table 5). However, S-023-1003 (41h) lost its potency after reducing the dose from 2.5 pM to 1 pM (Table 5). To identify the mostPT / 2026 / 12022

[0414] potent compound, we further assessed the anti -migratory potential of these three hit molecules using a wound healing assay.

[0415] Inhibition of migration and invasion of TNBC cells: Cell migration and invasion are key drivers of cancer progression, often leading to fatal outcomes for patients. EZH2 contributes to the proliferation and migration of breast cancer cells through STAT3 methylation2, while EGFR silencing in TNBC cells inhibits proliferation and promotes apoptosis by suppressing STAT33. This study evaluated the anti-migratory effects of compounds S-023-0996 (41a), S-023-1001 (41f) and S-023-1003 (41h) in the HCC-1806 cell line compared to a DMSO control (Fig. 2A). Among these, compound S-023-0996 (41a) demonstrated superior anti-migratory activity up to 24 hours. Thereafter, we sought to assess the anti -invasive potential of the most potent hit molecule. The transwell chamber invasion assay in MDA-MB-231 cells demonstrated inhibition of TNBC cell invasion by S-023-0996 (41a), at 10 pM concentration (Fig. 2B). Thus, we have selected compound S-023-0996 (41a) as our lead molecule for its effient dual target inhibition and anti -migratory as well as anti -invasive potential.

[0416] Inhibition of Migration and Invasion of TNBC Cells: Cell migration and invasion are key drivers of cancer progression, often resulting in poor clinical outcomes. EZH2 contributes to the proliferation and migration of breast cancer cells through STAT3 methylation2, while EGFR silencing in TNBC cells inhibits proliferation and promotes apoptosis by suppressing STAT33. This study evaluated the anti-migratory effects of compounds S-023-0996 (41a), S-023-1001 (41f), and S-023-1003 (41h) in the HCC-1806 cell line compared to the DMSO control (Fig. 2A). Among these, S-023-0996 (41a) demonstrated superior anti -migratory activity for up to 24 hours. Subsequently, we assessed the anti-invasive potential of the most potent hit molecule. The transwell chamber invasion assay in MDA-MB-231 cells revealed that S-023-0996 (41a) at a concentration of 10 pM inhibited TNBC cell invasion (Fig. 2B). Hence, S-023-0996 (41a) was selected as the lead molecule due to its efficient dual -target inhibition and robust anti -migratory and anti -invasive potential.

[0417] Structure-Activity Relationship Study:

[0418] To enhance the effectiveness of the initial compound, it was devised to synthesize a library comprising 33 compounds of dual EZH2 and EGFR inhibitors, which were then crafted, prepared, and assessed for their potential against Triple Negative Breast Cancer (TNBC). Analysis of the Structure -Activity Relationship (SAR) in Table 2 unveiled that S-023-0988 (30n), featuring a piperazine linked with a small polyethylene glycol unit, demonstrated moderate activity within the A series compounds. However, it became evident that the potency was compromised with the implementation of a smaller linker.PT / 2026 / 12022

[0419] In pursuit of bolstering efficacy, the synthesis of series B compounds, is delineated in Table 3. Here, structural modifications primarily targeted the A phenyl ring with subsequent removal of the B phenyl ring. Throughout this series, the focus remained oyn optimizing the linker, utilizing a piperazine linked with a small polyethylene glycol unit. The culminating modifications, as delineated in Table 4, showcased that meta substitution with alkyne, -Cl, -Br, and -CF3 were well accommodated.

[0420]

[0421] Fig 3. Structure-activity relationship (SAR) of synthesized compounds

[0422] Binding Confirmation through CETSA: The Cellular Thermal Shift Assay (CETSA) is an approach to determine the binding affinity of molecules and their target proteins4. Binding of small molecules to intracellular proteins enhances their thermal stability5. Thus, CETSA was employed to determine the binding affinity of S-023-0996 (41a) with its target proteins by assessing the thermal stability of these proteins. As shown in Fig. 3A and B, the stability of the EZH2 protein in S-023-0996 (41a)-treated cells was higher than that in DMSO-treated cells. Similarly, the thermal stability of EGFR protein was also enhanced in S-023-0996-(41a) treated cells (Fig. 3A and C). These findings confirm that S-023-0996 (41a) binds potently to both EZH2 and EGFR, enhancing their thermal stability.

[0423] Table-6. Antiproliferative activities (IC50 in pM) of S-023-0996 (41a) and Comparator drug against cancerous and non-cancerous cell lines

[0424]

[0425] Anti-proliferative Activity: The cytotoxicity of S-023-0996 (41a), our lead dual EGFR and EZH2 inhibitor, was assessed in MDA-MB-231, MDA-MB-468, 4T-1, Pfeiffer, and Vero cells. S-023-0996 (41a) inhibited cell growth in vitro in TNBC cell lines (MDA-MB-231, MDA-MB-468, 4T-1) and inPT / 2026 / 12022

[0426] the EZH2 inhibitor-sensitive Pfeiffer cell line, with IC50 values of 2.69 pM, 2.95 pM, 2.50 pM, and 2.8 pM, respectively. In Vero cells, S-023-0996 demonstrated significantly lower cytotoxicity compared to the comparator drugs, with an IC50 value greater than 100 pM (Table 6). In contrast, the comparator drug EPZ6438 did not affect the proliferation of cancerous or non -cancerous cells, except for Pfeiffer cells (IC50 0.7 pM), as this cell line is sensitive to EZH2 inhibitors. Conversely, Gefitinib induced cytotoxicity in all TNBC cells but also caused significant toxicity in non-cancerous Vero cells (IC50 1.54 pM). Thus, S-023-0996 (41a) demonstrated selective cytotoxicity in TNBC / cancerous cells while being significantly safer for non-cancerous cells.

[0427] Stability Study: In vitro stability studies demonstrated that S-023-0996 remains stable in simulated body fluids and plasma samples (Table 7 and Fig. 4A and B), indicating its suitability for further pharmacokinetic profiling in in vivo studies.

[0428] Table-7. Stability of S-023-0996 (41a) in different simulated body fluids and plasma samples.

[0429]

[0430] Table-8. Pharmacokinetic parameters of S-023-0996 (41a) and its absolute bioavailability.

[0431]

[0432] Pharmacokinetic Study: Given the stability of S-023-0996 (41a) in plasma samples in vitro and its potent activity against breast cancer, we evaluated its absolute bioavailability in BALB / c mice. Fig. 4CPT / 2026 / 12022

[0433] illustrates the mean plasma concentration-time profile for female BALB / c mice after subcutaneous and intravenous administration. Table 8 presents the pharmacokinetic parameters estimated using Phoenix WinNonlin (version 8.1, CertaraInc.). The absolute bioavailability of S-023-0996 (41a) was determined to be 19.81% (Table 8). These pharmacokinetic parameters indicate that S-023-0996 (41a) has favorable in vivo exposure, making it a promising candidate for further studies.

[0434] In vivo Efficacy Studies: Given its favorable in vivo exposure via the subcutaneous route, we sought to examine the efficacy of S-023-0996 (41a) in a preclinical model of TNBC. For this, 4T-1 Luc cells were orthotopically inoculated into the right mammary fat pad of female nude mice. Subcutaneous administration of S-023-0996 (41a) (100 mg / kg) every other day resulted in a significant reduction in the primary tumor burden (60% tumor growth inhibition) in the treated group compared to the control group (Fig. 5C and D). Additionally, in vivo bioluminescence imaging of whole mice, as well as ex vivo imaging of the harvested lungs from control and S-023-0996(41a)-treated tumor-bearing mice, demonstrated that administration S-023-0996 (41a) effectively dampens TNBC metastasis (Fig.5A and B)

[0435] To improve anti-cancer activity, various 2-Pyridone-based new Quinazoline compounds were synthesized. Based on in vitro results and SAR investigations of thirty three compounds, S-023-0996 (41a) emerged as the most promising candidate, exhibiting potent activity against both EZH2 and EGFR. The lead molecule demonstrated selective cytotoxic activity against TNBC cells (MDA-MB-468, MDA-MB-231, and 4T-1), while sparing non-cancerous cells. It also exhibited robust inhibitory impact on TNBC cell migration and invasion. Pharmacokinetic studies revealed that S-023-0996 (41a) is stable in simulated body fluids and plasma samples, with an absolute bioavailability of 19.81% following subcutaneous administration. In vivo studies demonstrated 60% tumor growth inhibition (TGI) in 4T-1 orthotopic allograft mice models after administration of S-023-0996 (41a) (100 mg / kg), along with significant inhibition of metastasis. Overall, our data suggest that S-023-0996 (41a) effectively suppresses TNBC cell growth in vitro and in vivo, while also curtailing metastasis in preclinical models of TNBC.

Claims

PT / 2026 / 12022WE CLAIM1. A 2-Pyridone-based quinazoline compound of general formula I,wherein, R is a substituted phenyl, wherein the substituent is selected from the group consisting of Cl, F, Br, -CF3, and alkyne;Zis H or OMe;A is a substituted or unsubstituted phenyl or biphenyl group; andL is a linker of one or more Oxygen containing aliphatic chain with a N containing heterocyclic group, comprising an ester or unsaturated amide or combination thereof.

2. The compound as claimed in claim 1, wherein the N containing heterocyclic group is selected form the group consisting of piperazine, piperidine, pyrrolidine, and azetidine.

3. The compound as claimed in claim 1, wherein the substituent at the ortho position of phenyl of R is F, substituent at the meta position of phenyl of R is Br, CF3, Cl or alkyne or the substituent at the para position of phenyl of R is Cl or F.

4. The compound as claimed in claim 1, wherein the compound is F-I,F Iwherein, Z is selected from H or OMe;L is a linker of one or more Oxygen containing aliphatic chain with a N containing heterocyclic group, comprising an ester or unsaturated amide or combination thereof, wherein the heterocyclic group is selected from the group consisting of piperazine, piperidine, pyrrolidine, and azetidine.

5. The compound as claimed in claim 1, wherein the compound is F-II,PT / 2026 / 12022FIIL is a linker of one or more Oxygen containing aliphatic chain with a N containing heterocyclic group, comprising an ester or unsaturated amide or combination thereof, wherein the heterocyclic group is selected from the group consisting of piperazine, piperidine, pyrrolidine, and azetidine.

6. The compound as claimed in claim 1, wherein the compound is F-III,wherein, R is a substituted phenyl, wherein the substituent is selected from the group consisting of Cl, F, Br, -CF3, and alkyne;A is a substituted or unsubstituted phenyl or biphenyl group.

7. The compound as claimed in claim 1, wherein the compound is a dual-target EZH2 (Enhancer of zeste homolog 2) and EGFR (Epidermal growth factor receptor) inhibitor for treatment of cancer.

8. The compound as claimed in claim 1, wherein the compound selectively induce cytotoxicity in cancer cells while sparing non -cancerous cells.

9. The compound as claimed in claim 1, wherein the compound is selected form the group consisting of:4'-((4-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-023-0983, 30a):4'-((4-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-023-0986, 30b):4'-((4-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-l-yl)methyl)-N- ((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-023-0984, 30c):PT / 2026 / 120224'-((4-(((4-((3 -chloro-4-fluorophenyl)amino)-7 -methoxyquinazolin-6-yl)oxy)methyl)piperidin- 1 -yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3-carboxamide (S-023-0985, 30d):4'-((3 -(((4-((3 -chloro-4-fluorophenyl)amino)-7 -methoxyquinazolin-6-yl)oxy)methyl)piperidin- 1 -yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,r-biphenyl]-3-carboxamide (S-023-0987, 30e):4'-((3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-l-yl)methyl)-N- ((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-024-0560, 30f):4'-((4-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethyl)piperidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,r-biphenyl]-3-carboxamide (S-024-0562, 30g):4'-((4-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)piperidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,r-biphenyl]-3-carboxamide (S-024-0564, 30h):4'-((3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pyrrolidin-l-yl)methyl)-N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,l'-biphenyl]-3-carboxamide (S-024-0566 30i):4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl4-((3'-(((4,6-dimethyl-2-oxo-l,2-dihydropyri din-3 -yl)methyl)carbamoyl)-5'-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4'-methyl-[ 1,1'-biphenyl]-4-yl)methyl)piperazine-l-carboxylate (S-023-0982, 30j):4'-((4-(2-((4-((3-chloro-4-fluorophenyl)amino)quinazolin-6-yl)amino)-2-oxoethylidene)piperidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,r-biphenyl]-3-carboxamide(S-023-0989, 30k):{4'-((4-(5-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pentyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,r-biphenyl]-3-carboxamide (S-023-0995, 301):4'-((4-(6-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)hexyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[l,r-biphenyl]-3-carboxamide(S-023-0990, 30m):4'-((4-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)- 5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[ 1, 1 '-biphenyl] -3 -carboxamide(S-023-0988, 30n):4'-((4-(2-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethoxy)ethyl)piperazin- 1 -yl)methyl)-N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3 -PT / 2026 / 12022yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-[1,1'-biphenyl]-3-carboxamide(S-023-0992, 30o):5-((3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)azetidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide (S-024-0561, 33a):5-((4-(2-((4-((3 -chloro-4-fluorophenyl)amino)-7 -methoxyquinazolin-6-yl)oxy)ethyl)piperidin- 1 -yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methylbenzamide (EG-30, 33b):5-((4-(3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)propyl)piperidin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methylbenzamide (S-024-0565, 33c):5-((3-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)pyrrolidin-l-yl)methyl)- N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)- 2 -methylbenzamide (S-024-0567, 33d):5-((2-(((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)methyl)morpholino)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methylbenzamide (S-024-0563, 33e):5-((4-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)- 3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methylbenzamide (S-023-0991, 33f):5-((4-(2-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethoxy)ethyl)piperazin- 1 -yl)methyl)-N-((4,6-dimethyl-2-oxo- 1,2-dihydropyridin-3 -yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methylbenzamide (S-023-0993, 33g):5-((4-(2-(2-(2-(2-((4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethoxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2 -methylbenzamide (S-023-0994, 33h):N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methyl-5-((4-methylpiperazin-l-yl)methyl)benzamide (S-024-0568, 33i):N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)- 5-((4-(2-(2-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yi)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-2-methylbenzamide(S-023-0996, 41a):5-((4-(2-(2-((4-((3,4-dichlorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l- yl)methyl)-N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide(S-023-0997, 41b):PT / 2026 / 120225-((4-(2-(2-((4-((3-chlorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-1-yl)methyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide(S-023-0998, 41c):N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)- 5-((4-(2-(2-((4-((4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-1-yl)methyl)-2-methylbenzamide(S-023-0999, 41d):5-((4-(2-(2-((4-((2,4-difluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4- yl)amino)-2-methylbenzamide(S-023-1000, 41e):5-((4-(2-(2-((4-((3-bromophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2 -oxo-1, 2-dihydropyridin-3-yl)methyl)-3-(etliyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide(S-023-1001, 41f):N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-5-((4-(2-(2-((7-methoxy-4-((3-(trifluoromethyl)phenyl)amino)quinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-1-yl)methyl)-2-methylbenzamide(S-023-1002, 41g):5-((4-(2-(2-((4-((3-bromo-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-1-yl)methyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide(S-023-1003, 41h): and5-((4-(2-(2-((4-((3-chloro-2,4-difluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)ethoxy)ethyl)piperazin-l-yl)methyl)-N-((4,6-dimethyl-2-oxo-l,2-dihydropyridin-3-yl)methyl)-3-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-2-methylbenzamide(S-023-1004, 41i).

10. The present invention provides a process for the preparation of the compound of general formula I, comprising the steps of:a. Suzuki coupling of intermediate 9 with 4- formyl phenyl boronic acid to prepare compound 11;b. reacting compound 11 with amine of formula A by reductive amination process to obtain compound F-I compounds in the presence of sodium tri acetoxy borohydride;PT / 2026 / 12022alternativelyc. Suzuki Molarder coupling of compound 9 with Potassium vinyltrifluoroborate in presence of Pd(PPh3)4 to prepare compound 32 andd. reacting compound 32 with amine B by reductive amination process to obtain the compound F-IIin the presence of sodium tri acetoxy borohydridee. alternatively reacting with compound 32 with amine C in the presence of sodium tri acetoxy borohydride to obtain F-III